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Dry powder inhalation aerosol is usually formed by blending lactose carrier with micronized 
drug particles using an order mix. In this thesis, blends of either Salbutamol Sulphate (SS), 
Beclomethasone Dipropionate (BDP) or Fluticasone Propionate (FP) and coarse lactose 
particles were employed to investigate the effects of lactose morphological features on drug 
delivery by dry powder aerosols in-vitro or ex-vivo using recorded patients’ inhalation profiles. 
Two lactose carriers were used in this study namely Lactohale and engineered lactose. 
Engineered lactose was prepared by a novel crystallisation technique from solid state using 
spray dried amorphous lactose prepared from lactose solution alone (10% w/v) or in the 
presence of additives (1% w/v) such as Polyvinyl Pyrrolidone (PVP K90) or sodium chloride 
(NaCl).  A 10 g of amorphous spray dried particles (< 5 µm) were introduced to a boiled 
ethanolic solution (100 mL) under stirring for 10 seconds or 30 seconds to form crystalline 
spherical porous hollow particles at least 10-fold larger in size compared to spray dried 
particles. The increase in size was possibly due to a combination of factors; crystal growth and 
the ethanol vapour pressure increase inside the hollow volume facilitating particles inflation 
causing an increase in the hollow volume of the particles. This method of crystallisation is 
predictable in forming spherical particles irrespective of the additive. The particles contacted 
with ethanol for 30 seconds (PSDL30) were more crystalline and rougher than those exposed 
for 10 seconds (PSDL10) to ethanolic solution.  The same process was successfully applied to 
lactose spray dried from a suspension to form large spherical particles with rougher surface 
compared to those spray dried from solution.  The engineered lactose particles were rougher 
than Lactohale lactose and were found to mix rapidly to stabilize the DPI formulations against 
segregation when compared to smooth Lactohale as confirmed by drug content uniformity and 
tribo-electrification study. Drug deposition in-vitro was dependent on the physico-chemical 
properties of drug particles. For SS, high drug deposition was obtained when smooth lactose 
was used, thus the fine particle dose (FPD) was higher for Lactohale followed by PSDL10 and 
finally PSDL30 suggesting that drug deposition increased with surface smoothness. A different 
trend was observed with hydrophobic drugs such as BDP and FP. A nano-surface roughness 
was favourable for both hydrophobic drugs BDP and FP and the order of FPD was PSDL10 > 
Lactohale > PSDL30. A balanced drug roughness is needed for hydrophobic drugs to improve 
drug content uniformity and to facilitate drug detachment during aerosolisation. Ex-vivo study 
using four patient profiles having the same inhaled volume (Vin) and acceleration (ACIM) at 
the start of the inhalation manoeuvre but having different maximum inhalation flow (MIF) 
were used to study the aerodynamic dose emission characteristics of SS with lactohale and 
engineered lactose carrier produced from spray dried lactose formed from spray dried 
suspension of lactose, which is commercially available (PSDL com). PSDL com had the 
highest roughness in comparison to all carriers highlighted above and showed low FPD at all 
MIFs in comparison to Lactohale. This study confirmed again that smooth carrier such as 
Lactohale provides better drug deposition for hydrophilic drugs such as SS. In conclusion, the 
drug deposition study showed that there is no ideal carrier for all drugs with different physico-
chemical properties such as hydrophilicity. To improve drug deposition from DPIs, hydrophilic 
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drugs are better formulated with a smooth carrier and hydrophobic drugs require a moderate 
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Pulmonary drug delivery is the preferred mode of drug delivery for numerous conditions such 
as asthma and chronic obstructive pulmonary disease (COPD). An advantage of pulmonary 
drug delivery is the direct targeting of the drug to the lungs, which is why it has become one 
of the preferred routes to administer large molecules that are subject to first-pass metabolism 
in the liver. Pulmonary drug delivery also requires a relatively low drug dose to produce the 
desired effect and offers a rapid onset with minimal side effects (Byron and Patton., 1994) 
 
Drug delivery to the lungs is not only applicable for pulmonary diseases but can also be used 
to treat cancer; diabetes; cystic fibrosis that can also affect the liver, pancreas and kidney; 
osteoporosis and thrombosis (Brocklebank et al., 2002; Chougule et al., 2006; Haynes et al., 
2003; Laube et al., 2011; Thomas et al., 1991; Hickey et al., 2004; Kawashima et al., 2005; 
Yang et al., 2004). Islam et al. evaluated the potential to use pulmonary drug delivery for the 
management of some neurological diseases such as Parkinson and Alzheimer’s disorders 
(Islam & Rahman, 2008). 
 
Several devices are available to target the delivery of drugs to the lungs. There are three main 
types of inhalers present in the market for that purpose, which are nebulizers, metered-dose 
inhalers (MDIs) and dry powder inhalers (DPIs). The difference between these devices lies in 
their mechanisms of delivering the drug into the lungs (Groneberg et al., 2003) 
Most DPIs are breath-actuated devices (Brocklebank et al., 2001). They do not require 
coordination between actuation and inhalation, which makes them easy to use for the patient. 
As opposed to other inhalers, DPIs do not use liquid propellants. They are patient friendly, 
environmentally friendly and portable (not requiring the use of spacers) (Bunnag et al., 2007; 
Siddiqui & Plosker, 2005).  
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DPI formulations are made of drug particles blended with a suitable large carrier such as 
lactose.  The main advantage of adding carrier particles to the formulation is to increase the 
bulk of the formulation improving the reproducibility of dose delivery. It also aids in reducing 
the cohesiveness of the micronized drug particle and improves the flow properties of the drug-
carrier formulation (Prime, 1997). The drug particles usually adhere onto the surface of lactose 
(Hersey, 1974). In order to achieve an efficient delivery of the aerosol into the lungs from DPI 
formulations,  adhesive forces between the drug and carrier have to be overcome,  resulting in 
dispersion of the particles and deposition of the drug particles in the deep regions of the lungs 
Islam et al., 2004b). Three inter-related parameters play a significant role in efficient delivery 
of drug via the pulmonary route: the design of the device, the powder formulation and the 
inhalation manoeuvers of the patient (Chougule et al., 2007; Frijlink and de Boer, 2005). 
 
Most DPI formulations available on the market are only able to deliver about 20-30% of the 
total dose to the lungs (Smith and Parry-Billings, 2003; Steckel and Müller, 1997). This low 
efficacy is caused by the complicated physiology of the respiratory tract, the physico-chemical 
properties of the components in the powder formulation and the inhalation device. There can 
be inefficient separation of the drug from the carrier because the micronized drug particles, 
which are adhered onto the surface of the carrier, produce agglomerates. To deliver the drug 
efficiently, the drug has to be dispersed from these agglomerates  Islam et al., 2004b). 
Commercially available inhalation grade lactose is irregular in shape and has asperities in its 
surface, which affects separation of drug from carrier during aerosolisation. Controlling the 
particle size, shape and surface roughness of the carrier particles is important in order to 
achieve an efficient drug detachment from the carrier particles (French et al., 1996; Steckel & 
Müller, 1997; Zeng et al., 2000). 
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Many studies have investigated factors that impact the delivery of drugs into the lungs. These 
studies mainly focused on improving dispersion of the pharmaceutical active ingredient (API) 
by optimizing the physico-chemical properties of the lactose carrier such as particle size 
(Larhrib et al., 1999), shape and surface texture (Kawashima et al., 1998b; Zeng et al., 2000), 
and mixing different grades of lactose (Bergström et al., 2000; Steckel & Müller, 1997). Some 
studies demonstrated that modifying the carrier surfaces improved the dispersibility of the drug 
from the surface of lactose. Many approaches have been used to achieve this result: one of the 
techniques used was to coat the surface of the lactose carrier by physically blending it with fine 
lactose particles, magnesium stearate or L-leucine (Grosvenor & Staniforth, 1996; Staniforth 
et al., 1999;  Staniforth, 1997; Staniforth, 1995).  
Common techniques used to modify the shape of the carrier particles include spray drying 
(Chew et al., 2005), encapsulation (Yue et al., 2004) and mechanofusion (Begat et al., 2005). 
It is well known that particles with curved surfaces, small asperities and low surface energy 
tend to reduce the contact area between particles (Katainen et al., 2006; Li et al., 2006; 
Podczeck, 1999). 
Particles with irregular shapes, such as commercially available Lactohale®, have many contact 
points leading to more cohesive forces than spherical particles. Irregular particles tend to 
interlock, which can compromise powder flow properties. Spherical particles have fewer 
contact points, which usually results in improved powder fluidity and potentially can be 
suitable shape for carrier particles in DPI formulations. Spherical particles produced by spray 
drying have been shown to achieve a higher deposition of the drug, Prankulast Hydrate, with a 
fine particle fraction of 17.8% compared to irregular lactose, which only achieved FPF of 3.4-
14.7% (Kawashima et al., 1998a). 
Therefore, producing carrier particles with a specific shape and surface texture may have 
potential in improving the efficacy of drug delivery with DPIs  (Zeng et al., 2000). 
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1.2 Aims and objectives 
1.2.1 Aims 
The principal aim of this thesis is to investigate the potential of engineered particles (processed 
spray-dried Lactohale: PSDL) produced from solid-state crystallization as an alternative carrier 
to a-lactose monohydrate. A further aim was to investigate the influence of the carrier surface 
properties on their interaction with drug particles for the development of dry powder 
formulations and to target maximum drug delivery to the deepest regions of the lung. 
Furthermore, it was the purpose of this thesis to extend this crystallization process to produce 
lactose carrier particles coated with a ternary component in particles suitable for inhalation. In 
addition, triboelectrification studies were performed to study the magnitude of the interactions 
between drug and carrier particles.  
Another aim of this study was to investigate the effect of the inhalation manoeuver parameters 
such as maximum inhalation flow rate (MIF), inhaled volume (Vin) and the initial acceleration 
rate of inhalation manoeuver (ACIM) on the aerodynamic characteristics of the emitted dose 
of SS from Onbrez Breezhaler® using patient profiles. 
 
1.2.2 Objectives 
The objectives of this study were: 
ü To modify and validate a High-Performance Liquid Chromatography (HPLC) method 
for salbutamol sulphate based on the USP method  
ü To engineer a novel lactose carrier in the presence of an inflating agent in the 
crystallisation medium to produce large hollow spherical carrier particles for inhalation 
(PSDL) 
ü To investigate the mechanism by which PSDL particles are formed  
ü To characterize PSDL particles using various analytical techniques. 
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ü To assess the effect of a ternary component in DPI formulations (NaCl and PVP) and 
determine their effect on the dose emission characteristics of SS formulation from 
MacHaler®. 
ü To assess the difference in aerosolisation behavior between the Andersen Cascade 
Impactor (ACI) and the Next Generation Impactor (NGI)  
ü To assess the difference between the dose emission characteristics using two different 
impactors (ACI and NGI) at different MIF and Vin.  
ü To measure the drug content uniformity of SS, FP and BDP in  both Lactohale and 
PSDL formulations and investigate the effect of mixing time on the deposition 
performance of the DPI formulation. 
ü To evaluate the effect of MIF and Vin on the dose emission of SS emitted from a 
MacHaler® using two different MIFs and Vins with both lactohale and PSDL 
formulations. 
ü To use an ex-vivo method with inhalation profiles to assess the effects of the inhalation 
manoeuver parameter (MIF, Vin, ACIM) on the aerodynamic dose emission 
characteristics of SS from a low resistance device:  BreezeHaler®. 
1.3 Thesis structure 
This thesis consists of eight chapters: 
Chapter 1 is a general introduction on pulmonary drug delivery with a focus on DPIs and the 
factors affecting drug de-aggregation and deposition. It also outlines the importance of carrier 
parameters selection during particle engineering and formulation.  
Chapter 2 offers an overview of the respiratory system, the related pulmonary diseases, 
different types of inhalers used in the treatment of such diseases. The chapter will focus more 
on DPIs and their dose emission, it also outlines the factors that can affect drug de-aggregation 
and deposition into the lung. In addition, previous studies are reviewed to demonstrate the flow 
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dependency of DPIs, and recent modified pharmacopoeia methodology and patient inhalation 
characteristics are highlighted. 
Chapter 3 reviews the materials and equipment which were used during the experimental 
studies. It also describes the HPLC method development and validation for the quantification 
of salbutamol sulphate.  
Chapter 4 describes the solid-state crystallisation method used to produce PSDL particles. It 
also provides a detailed characterisation of the lactose carrier particles used in this study as 
well as the in-vitro dose emission performance of SS formulations with both Lactohale and 
PSDL carriers using two different MIFs (60 L/min and 90L/min) and different Vins (1L and 
2L) using both ACI and NGI.    
Chapter 5 presents an in-vitro comparison between SS formulations with PSDL and with 
PSDL formulated with a ternary component (NaCl and PVP). The impact of adding a ternary 
component in the DPI formulation was assessed. 
Chapter 6 discusses the effects of mixing time on the homogeneity and dispersion 
performance of DPI formulations as well as the impact of the carrier surface morphology. 
Furthermore, the impact of triboelectric forces on in-vitro drug deposition was studied. 
Chapter 7 explores the effect of inhalation profiles characteristics on the ex-vivo dose emission 
characteristics for two DPI formulations.  







































This chapter provides a review of the literature related to pulmonary drug delivery. It 
summaries the structure of the respiratory system and outlines the mechanisms of drug 
deposition in the lungs. It also emphasizes the importance of the carrier in DPI formulations. 
This chapter also introduces the aspects of drug delivery from DPI systems, which include the 
device and the formulation properties. This chapter highlights the importance of lactose 
particles’ surface characteristics, which can potentially affect drug delivery and outlines the 
ternary components used in DPI formulations discussing the use of engineered lactose particles 
as carriers for DPIs.  
 
 
2.1 Introduction to inhalation drug delivery 
The lung is considered as being ideal to deliver drugs systemically because it has a large surface 
area (about 100 m2), it is well-vascularized (5L/min of blood supply), the epithelium of the 
alveolar are thin (0.1-0.2µm), which allows good solute exchange (Rahimpour & Hamishehkar, 
2012), and also because inhalation generates a rapid systemic onset. 
The common advantages of pulmonary drug delivery are listed below (Chrystyn, 2006). 
• Low doses of drugs used (typical salbutamol inhaled dose is 200µg whereas salbutamol 
dose orally is 4mg) 
• High local targeting  
• Low systemic concentration, decreasing toxicity 
• Bypass first-pass metabolism 
• Effective and rapid onset of action 
• Low enzymatic activity as opposed to the liver, making the lungs suitable for protein 
and peptide delivery 
• High specific surface area 
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Drug deposition via the pulmonary route is primarily controlled by the aerodynamic diameter 
of the drug particles (Wolff & Dorato, 1993), where particles with an aerodynamic diameter in 
the range of 1-5 µm are expected to be deposited in the lung periphery. The performance of 
dry-powder products highly depends on the formulation, the inhaler device and on the patient. 
Dry powder mixtures are usually prepared by blending the micronized drug particles with 
larger carrier particles. The carrier characteristics play an important role on the aerosolization 
efficiency of the formulation; such characteristics include the particle size distribution, particle 
shape and surface properties. The main goal in the inhalation field is to achieve high and 
reproducible deposition in the lung. To do so, there is a need to select successfully the carrier 
particles and optimise processes carefully (Pilcer et al., 2012).  
 
2.2 Pulmonary Delivery 
2.2.1 Organization of the respiratory system 
The lung is the main organ of breathing in humans. A schematic representation of the 
respiratory system is illustrated in Figure 2.1. The respiratory system can be classified into two 
components: the upper respiratory tract and lower respiratory tract (Fig. 2.1). The former 
comprises the nasal cavity, nose, larynx and pharynx. The main functions of the upper 
respiratory tract are to filter and clear unwanted particles, warm and humidify the inhaled air. 
When air is inspired, it is heated from the normal atmospheric air conditions of 20 °C and 50 
% moisture to 37°C and 99% moisture (Waldron, 2007). The lower respiratory system consists 
of the trachea, bronchi, bronchioles and alveoli, which cool and dehumidifies the air being 










The respiratory tract is made of a conduction tract and a respiratory tract. According to 
Weibel’s tracheobronchial organization (Fig. 2.2), the first 16 branches (or generations) 
characterise the conductive airways and branches 17 to 23 represent the respiratory portion 
where most of gas exchanges between air and blood occurs (Weibel, 1963). 
The 23 divisions increase significantly the airways’ total cross-sectional area from the trachea 
to the alveoli (2.5 to 11800 cm2, respectively) which consequently produces a lower velocity 
of airflow in the small airways. The conducting airways are shaped like an inverted tree 





Figure 2.2 Structure of the Lungs showing the branching airways and their characteristics 
(Weibel, 1963) 
As they go deeper in the lungs, the branches and tubes are more abundant, get narrower in 
diameter and have a thinner bronchial epithelium; these features allow gas exchanges to happen 
efficiently as the distance that separates the blood in alveolar capillary and the air inside an 
alveolus is only 1µm. Because filtering of the incoming air occurs in the upper respiratory tract, 
by the time the air gets to the alveoli, most pathogens and foreign particles would have been 
cleared out (Martini & Nath, 2009). 
The principal role of the respiratory system is to offer a high surface area for gas exchanges 
between air and circulating blood through the respiratory passageways (Martini & Nath, 2009).  
On the other hand, the conducting tract consists of the area from the trachea and the terminal 
bronchioles down to branch 16. No gaseous exchange occurs in this zone due to the absence 
of alveoli. The conducting tract has two important functions; firstly, the inhaled air gets 
humidified and warmed, which will protect the alveoli by avoiding contact with dry cold air. 
Secondly, it allows air to be conducted down to the alveoli where gas exchange occurs.  The 
muscles are situated in the conducting region where inflammation of the airways typically 
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happens. However, inflammations are also expected to occur in the respiratory region (Thomas 
et al., 2009) hence, particles less than 5µm are necessary to target these sites.  
 
2.2.2 Brief overview of pulmonary diseases 
Respiratory disorders, such as asthma and COPD, are characterized by a reduced rate of air 
into the lungs causing inflammation (Welte, 2009). Airway obstruction can be reversible for 
asthmatic patients; however, the airway obstruction of COPD patients is not fully reversible 
(Yawn, 2009). Asthma most commonly starts during childhood and the clinical symptoms vary 
between constant wheezing, cough or shortness of breath. In some cases, asthmatic symptoms 
reduce after childhood (Jenkins et al., 1994). On the other hand, COPD does not occur in 
children and young adults. Its prevalence increases substantially after the age of 40. Generally, 
COPD is related to intensive smoking habits, exposure to inhaled toxins or irritants (Yawn, 
2009), Table 2.1 summarises the differences between asthma and COPD. Airway obstruction 
in asthma is associated with bronchial smooth muscle constriction and inflammation. In COPD, 
the airways obstruction results from cellular damage and mucus hypersecretion with more 
prominent inflammation (Decramer et al., 2005).  
The acute symptoms related to asthma are usually treated with bronchodilators (b2 
adrenoreceptor agonists which can be classified in two categories: short-acting (e.g. 
Salbutamol and Terbutaline) and long-acting (e.g. salmeterol), Xanthines (e.g. theophylline, 
theobromine and caffeine), Muscarinic receptor antagonist (e.g. ipratropium) and 
corticosteroids (such as fluticasone, budesonide and bechlomethasone) (Yawn, 2009). A day-
to-day variability is observed for COPD patients and the most common approach to reduce 
inflammation is to give them fast-acting bronchodilators and corticosteroids as combination 




Table 2.1 Summary of some differences between asthma and COPD disease. (Adapted from 



















































































2.3 Drug deposition mechanisms 
A pharmacological effect is observed only when inhaled drug particles are deposited at the site 
of action (Byron and Patton., 1994). The deposition of inhaled drug particles in the lungs is 
usually dependent on the aerodynamic particle size of the particles and is regulated by three 
physiological factors: inertial impaction, gravitational sedimentation and diffusion (via 
Brownian motion). 
 
Figure 2.3 Schematic of the three mechanisms responsible for inhaled particle deposition in 
the respiratory airways ( with permission from Hussain et al., 2011) 
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Inertial impaction is the primary mode of deposition of particles larger than 5µm, such as 
lactose carrier particles, in the oropharynx (Hinds, 1982). Such deposition primarily occurs 
when the gas airstream is rapid, changing direction (e.g. in the throat) or turbulent.  
 
Sedimentation occurs for smaller particles between 1 to 5 µm in the lower respiratory tract 
(i.e. bronchial tree and alveoli). Inertial impaction occurs less and gravity become the main 
force in the deposition mechanism. The sedimentation efficiency is a function of aerodynamic 
diameter and residence time and occurs at low air velocity in the respiratory tract and when the 
residence time is great (Hinds, 1999). To be able to reach the alveolus tissue, the particle 
aerodynamic diameter needs to be between 1 to 3 µm. 
 
Diffusion is the mode of deposition for particles below 0.5µm that cannot be deposited in the 
respiratory tract by sedimentation during normal breathing. These particles are subjected to 
diffusion forces (Brain and Blanchard, 1993; Zeng et al., 2000) but are mostly exhaled by the 
expiratory flow. The efficiency of diffusion and sedimentation is enhanced by high residence 
times that may be achieved by the patient when they are required to hold their breath (Hatch 
and Gross, 1964; Hinds, 1999). 
 
Drug particles may acquire an electrostatic charge during aerosolisation (Yeomans et al., 
1949). The charging of particles may have an effect on the deposition mechanisms either by 
attractive electrostatic forces between dissimilar charges on drug particles and the respiratory 
surface, or by repulsive forces between like-charged aerosol particles directing them towards 




2.4 Expression used in inhaled drug delivery 
2.4.1 Particle aerodynamic diameter 
The deposition of the particles in the different levels of the respiratory tract is based on the 
aerodynamic size distribution of the particles. The aerodynamic diameter (dae) is defined as the 
diameter of a spherical particle with a density of 1000 kg/m2 and same settling velocity as the 
irregular particle. It is usually used to express the particle size because it takes into account the 
particle dynamic behaviour in the airflow which is dependent on the size, shape and density of 
the particles and also is representative of the deposition mechanisms of the particles (i.e. inertial 
impaction and gravitational sedimentation (Hinds, 1999; Telko & Hickey, 2005) 
 
2.4.2 Mass median aerodynamic diameter  
To assess the in-vitro performance of a DPI formulation, the American and European 
pharmacopoeias have designated methods that are based on inertial impaction to evaluate the 
fraction of fine inhalable particles (EP, 2010).  
The mass median aerodynamic diameter (MMAD) corresponds to the particle diameter that 
has 50% of the aerosol mass being present above and 50% below it. MMAD is a crucial 
parameter as its control certifies reproducibility and indicates that the particles have been 
retained in the desired regions of the lungs. On the cumulative curve, MMAD is read at the 
50% point. In order to achieve the required particle size of the drugs delivered by DPIs, 
numerous processes are available. Drug particles size reduction can most commonly be 
achieved by micronisation (Thibert & Tawashi, 1999). Other techniques are also available: 
spray-drying (Li et al., 2005) or supercritical fluid technologies  (Chow et al., 2003). 
 
Most of the therapeutic aerosol formulations comprise a wide range of particle sizes, they are 
said to be polydisperse.  
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Geometric standard deviation (GSD) is a representation of the particle diameter variations 
within the aerosol and is calculated from the ratio of the particle diameter at the 84.1% point 
on the cumulative distribution to the MMAD. A GSD of 1 signifies that the aerosol is mono-
dispersed; when GSD is higher than 1.2 the aerosol is polydisperse.  
To achieve good drug distribution in the lungs, particles are required to have an aerodynamic 
diameter between 1 and 5 µm (Atkins, 2005). The aerosol droplet diameter should be less than 
3µm to be able to target the alveolar region. Particles larger than 5µm are deposited in the 
oropharynx while particles smaller than 1µm are exhaled during tidal breathing. 
 
 
2.4.3 Fine particle dose and fine particle fraction  
The fine particle dose (FPD) corresponds to the mass of drug particles that have a dae less than 
5 µm. Such particles are theoretically proven to deposit in the deepest regions of the lungs after 
inhalation. 
 The fine particle fraction (FPF) is the percentage of the fine particle dose related to either 
the total drug mass contained in the inhaler device (nominal dose) or the recovered drug 
(collected from all the parts of the impactor after inhalation). FPF can also be calculated as a 
function of the emitted dose instead of the total recovered dose (Rahimpour & Hamishehkar, 
2012) 
 
2.4.4 Total emitted dose  
The total emitted dose (TED) corresponds to the total mass of drug exiting the inhaler device 
after the patient inhales. This parameter allows a better understanding on the fluidisation 
properties of the powder through the device, whereas FPF and FPD express the ability of the 
powder blend to be fluidised and de-agglomerated so that the drug and carrier detach from each 
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other to allow the drug to be deposited in distal parts of the impactor. The dispersibility is 
worked out as the ratio of FPD to emitted dose (Rahimpour & Hamishehkar, 2012) 
2.5 Drug delivery from Dry powder inhalers 
2.5.1 DPI formulation 
‘Top-down’ methods have been used to engineer DPI formulations, where drug particles with 
large particle size are micronized to generate particles with a median geometric diameter of 1-
5µm (Telko & Hickey, 2005). The resulting fine drug particles are then mixed with large 
lactose monohydrate carrier particles (50-100µm) (Figure 2.4) to improve the flow properties 
of the powder blend (Dunbar et al, 2000).  
 
Figure 2.4a SEM images of a DPI formulation containing lactose carrier and salbutamol 
sulphate particles at x5000 and x10 000 magnifications 
Only 20-30% of the nominal dose is generally delivered to the lungs, this poor delivery 
efficiency is due to the strong adhesive and cohesive forces between drug and carrier particles. 
To allow dispersion of the particles, the adhesive forces between the particles need to be 
overcome. Hence, deposition of drug particles in the airways is highly dependent on the balance 
of the forces between components of DPI formulations (Young, et al., 2008). 
 
DPIs are a widely accepted dosage form used to deliver drugs via the inhalation route and are 
commonly used to treat respiratory diseases. The interactions between the DPI formulation and 
	





the inhalation device are responsible for successful delivery of the drug in the lungs. For the 
drug to be delivered in the deepest regions of the lung, drugs particles are required to be in the 
size range of 1 to 5 µm; this size is usually achieved by micronizing the drug particles. 
However, small drug particles are known to have poor flow properties and tend to be highly 
cohesive, which would compromise the dispersion of the particles in the airstream (Atkins, 
2005). Because of their cohesive nature, the drug particles tend to remain in the capsule and 
DPI device during dose emission, resulting in a poor and unreproducible dose emission (York 
et al.,1998) 
Thus, to improve flow dispersion, coarse particles within the size range of 50 µm to 100 µm 
are added to the formulation. These particles will act as a carrier onto which the drug particles 
will adhere during blending (Tian et al., 2004). Lactose is the most commonly used carrier 
because it is inert, safe to use, non-toxic, widely available, inexpensive and has 
physicochemical properties that are compatible with most active pharmaceutical ingredients 
APIs (Pilcer & Amighi, 2010; Steckel & Bolzen, 2004). Lactose has been extensively used as 
an excipient in solid dosage forms, and is available on the market in various grades with various 
physicochemical properties.  
DPI formulations, also called adhesive mixtures, usually require a few milligrams of the API, 
as most commercially available medications contain between 20 µg to 500 µg of drug for 
asthma therapy; lactose acts as a bulking agent to ease the handling and dosing processes during 
manufacturing. Typically, the drug-to-carrier ratio is 1:67.5 (Flament et al., 2004; Larhrib et 






2.5.2 Dry powder inhaler devices 
While metered dose inhalers (MDIs) are the most commonly used devices, the number of MDI 
products dropped due to the gradual removal of chlorofluorocarbons use and the limited 
availability of substitute products with hydrofluorocarbon propellants (Steckel & Bolzen, 
2004). 
DPIs entered the market in the 1950s to overcome the drawbacks associated with pMDIs, such 
as the use of CFC-propellants and poor patient coordination techniques (Roche et al., 2013; 
Chrystyn et al., 2006). DPIs are commonly used to treat asthma and lung infections and has 
some key features which make inhalation an attractive route of delivery: rapid onset of action, 
reduction of side effects, and direct target of drug to the site of action.  
There are different types of DPIs available: single-dose inhalers or multi-dose inhalers. A list 
of the DPIs available in the market is displayed below in Table 2.2.   
Table 2.2 Types of DPI devices available in the market (Chrystyn, 2007)
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Single-dose DPIs are usually required to be filled with capsules which are pierced by the patient 
prior to inhalation to allow the aerosolisation of the dose (Chrystyn, 2007). Breezhaler® 
(Novartis, Basel, Switzerland) is a single dose, capsule-based DPI that delivers both LABA 
indacaterol and anticholinergic glycopyrronium bromide for the treatment of COPD (Lavorini 
et al., 2017).  
 
 
Figure. 2.4b Schematic diagram of the Breezhaler (Berkenfeld et al., 2015) 
 
BreezHaler’s® mouthpiece and capsule chamber are built with acrylonitrile butadiene styrene, 
push buttons are made from methyl methacrylate acrylonitrile butadiene styrene. The needles 
located inside the capsule camber and springs (in the buttons) are made from stainless steel. 
Prior to inhalation manoeuvre, the patient has to open the device, insert the capsule in the 
capsule chamber (Figure. 2.4b) and pierce the gelatine capsule by pressing the buttons located 
on both sides of the inhaler. The piercing sound of the capsule is an indicator that the device is 
primed and during the inhalation manoeuver a whirring noise should indicate to the patient that 
the dose has been emitted from the capsule (Berkenfeld et al., 2015; Buhl & Banerji, 2012). 
Breezhaler® is a low resistance device with an airflow resistance of 0.017 kPa0.5 min/L and an 
inhalation flow of 111 L/min is typically required to achieve 4KPa (Dal Negro, 2015; Pavkov 
et al., 2010). 
44  
The majority of DPIs are said to be passive breath-actuated devices which rely on the 
inspiration of the patient in order to operate. The efficacy of inhaled drugs is dependent on the 
patient’s age, inhalation technique and disease severity. One of the major disadvantage of DPIs 
is the requirement for a moderate inspiratory flow to draw the formulation from the device, 
however some patients are unable to achieve such effort. Several studies demonstrated that the 
patient failure to achieve the threshold inspiratory flow resulted in incomplete dose de-
aggregation, thus poor drug deposition in the lungs (Palander et al., 2000). 
 
Nevertheless, recently introduced DPIs have been shown to require low inspiratory flow rate 
(approximately 30 L/min) and are able to produce higher FPF (>40% of the nominal dose) 
(Colthorpe et al., 2013). 
 
Since the velocity distribution of air inside the lungs depends on the tidal volume and breathing 
frequency parameters, the amount of drug delivered to the alveoli can be improved by 
increasing the inspiratory volume (Sbirlea-Apiou et al., 2007). At a constant flow rate, particle 
de-agglomeration can be favoured by increasing the time of breathings, i.e. increasing the 
inspiratory volume. It has been demonstrated that for DPI formulations to be deposited deep in 
the lungs, not only the peak flow rate was important, but also the flow- increase rate. Studies 
have shown that a high peak flow does not always result in high aerosol deposition if the initial 
flow-increase rate was not high enough to disperse the drug particles, thus resulting in drug 
particles not reaching the deep lung (De Boer et al., 2003; Martini & Nath, 2009). 
 
The flow rate and inhaled volume through the DPI is determined by the lung volume of the 
patient, the force that the patient can generate and the resistance of the device. 
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The design of DPIs results in an inhaler specific resistance to airflow. The specific resistance 
can be calculated by the following equation: 
     √𝛥𝑝=R.Q      Eq 2.1 
where 𝛥𝑝 is the square root of pressure drop; R is the specific resistance and Q is the 
inhalation flow. 
The main forces resulting in drug particles de-agglomeration is believed to be achieved by 
three key mechanisms within the device: particle interaction with shear flow and turbulence, 








Figure 2.5. Schematic diagram of the dose de-aggregation mechanism of DPI powders 
formulations. (a) drug-only formulation (b) carrier-drug formulation  
(Lavorini et al., 2017) 
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The de-aggregating forces increase as turbulence forces in the device increase (Voss et al., 
2002). The turbulence energy is represented by the pressure drop occurring inside the device, 
this energy is responsible for the disintegration of the formulation into the emitted dose 
containing the drug particles (Figure 2.5) (Chrystyn, 2003; Chrystyn, 2009). 
Thus, DPIs are designed in such a way that the device produces enough turbulence for particles 
to collide with other particles, resulting in drug detachment from the carrier surface. The 
interaction between the powder and the device is poorly understood as well as the effects of 
such interactions on powder dispersion. Recently, computational dynamic fluids have allowed 
a better knowledge on particle-device impaction and its effects and has demonstrated that the 
performance of DPIs can be enhanced by making small changes in the device design (Chan et 
al., 2006; Coates et al., 2004).  
Most DPIs are made of short tubes through which an airflow, consisting of a turbulent core 
surrounded by a laminar envelope, passes (Dunbar et al., 2000). The inspiratory effort of the 
patient along with the inhaler specific resistance yield a flow rate that allows formation of an 
aerosol and deposition of drug particles in the lung. Generally, devices with high-specific 
resistance generate high turbulent forces that lead to higher drug dispersibility and higher FPF 
as opposed to lower resistance devices (Srichana et al., 1998). However, high resistance 
devices require a high inspiratory force from the patient to reach the desired air flow. 
Consequently, a balance between the design of the inhaler device (resistance and turbulence), 
the inspiratory flow of the patient, as well as the drug formulation is required.  
 
2.6 Inter-particulate forces 
During inhalation, the drug particles usually detach from the surface of the carrier particles, 
this phenomenon occurs only when the energy of the inspired flow is sufficient to overcome 
the adhesion forces between the drug and carrier particles (Zeng et al.,  2000). The large lactose 
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carrier particles tend to impact in the upper airways, while the micron-sized drug particles are 
able penetrate into the lungs. The adhesion forces between drug and carrier particles should be 
such that the drug particles are not too strongly adhered to the surface of the carrier particles 
preventing dispersion and leading to the drug-carrier agglomerates depositing in the upper 
airways.  
 
Figure 2.6 Physical forces occurring between drug and carrier particles (Peng et al., 2016) 
 
 
The stability of the formulation, the good homogeneity of the mixture and good content 
uniformity depend on the optimal balance between the adhesive and cohesive forces between 
drug and carrier particles. Ideally, the right balance would provide a stable formulation with 
no powder segregation, yet allow easy separation of the particles during inhalation. The lactose 
particle size, quality of the lactose particles as well as the surface roughness have been 
described to have a major influence on the aerosol properties (Flament et al., 2004; Zeng et al., 
2000a; Zeng et al., 2000b). This is why selecting the right carrier is pivotal during formulation 
to enhance the performance of the DPI.  
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The interactions between particles (cohesion (drug-drug) and adhesion (drug-carrier)) are 
governed by physical forces such as van der Waals forces, capillary forces, electrostatic 
charges and mechanical interlocking (Telko & Hickey, 2005). Some other interactions are 
dominated by chemical forces such as acid-base interactions and hydrogen bonding (Fowkes, 
1964). The degree of magnitude of the physical forces differs depending on the particle size, 
surface properties, surface roughness, press-on forces during mixing and relative humidity 
(RH) (De Boer et al., 2003). 
 
Capillary forces occur due to the formation of a liquid bridge (concave-shaped meniscus) 
around the contact area of two adjacent particles (Figure 2.6)  (Butt & Kappl, 2009). The 
attractive force caused by the concave-shaped meniscus is cause by the surface tension of the 
liquid around the border of the meniscus which pull particles towards one another. Also, the 
difference in pressure between the inside of the meniscus and the outer pressure pulls the 
particles together (Butt & Kappl, 2009). Capillary forces can be involved in adhesion and 
cohesion and their magnitude depends on the physicochemical properties of the particles such 
as shape, size, RH and surface roughness (Butt & Kappl, 2009). 
 
Electrostatic charges arise when two particles with dissimilar surfaces get in contact with 
each other and then separate quickly. This result in a charge transfer between a donor and an 
acceptor (Figure 2.6). The collision is generally short or can happen as an intense friction 
between the particles and a charging phenomenon called triboelectrification as a result. Contact 
charges are categorized into three types: metal-metal, metal-insulator and insulator-insulator 
(Bailey, 1993; Matsusaka et al., 2010).  
Pharmaceutical drugs and excipients behave as insulators under ambient conditions.  The 
contact surface can either be metal (such as the mixer vessel) or insulating materials (device’s 
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plastic components and excipient or drug during mixing and aerosolisation). Metal surfaces 
(stainless steel) and the device components (polypropylene and acetal) effect the magnitude 
and the polarity of the charges. A study showed that the addition of fine lactose (less than 
10µm) to the coarse lactose particles resulted in a decrease in the magnitude of the 
triboelectrification charges during mixing process (Bennett et al., 1999). 
 
Triboelectrification charges which appear during mixing, handling and filling, can be a 
drawback to powder aerosol performance as they limit powder flowability during 
manufacturing processes by increasing the inter-particle adhesive and cohesive forces.  Studies 
have shown that the polarity and magnitude of triboelectric charges increase with increasing 
amorphous content in the sample as well as high particle size distribution of the carrier particles 
(Murtomaa et al., 2004; Murtomaa et al., 2002). Chow et al. (2008) studied the triboelectric 
forces arising during different stages of manufacturing and while aerosolizing the powder 
formulation through the inhaler using a coarse lactose (InhalacÒ 230). They observed that the 
initial negative charges were not significant and decreased with increasing RH. They noted that 
during the mixing process and during handling powder in gelatin capsules there was an increase 
in the triboelectric charges. They did not see any changes in the sign of the charge of the lactose 
particles, however they noticed that the charge became much higher during aerosolisation and 
the polarity of the charge changed. This was believed to be due to the contact between the 
lactose particles (insulator) and the plastic of the inhaler device (insulator) (Chow et al., 2008). 
In DPI formulations, the net charge on the drug particles could occur during drug detachment 
from the carrier particles or from the surface of the capsule and/or from the device. Studies 
showed that the aerosolisation of the DPI formulation is influenced by the grade of lactose 
(sieved or milled), the type of device and the type of capsule as they have an effect on the 
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polarity and magnitude of the electrostatic charges arising during in-vitro aerodynamic 
performance (Hickey et al., 2007; Telko et al., 2007). 
 
 
2.7 Influence of physical properties of carrier on the performance of DPIs 
2.7.1 a-Lactose monohydrate 
 
 
Figure 2.7: Structure of α-lactose monohydrate (C12H22O11H2O) 
 
 
Lactose is a disaccharide found in the milk of most mammals and is made of galactose and 
glucose. Lactose is extracted from the whey of cow’s milk (Chan et al., 2012). The production 
of lactose is achieved by several steps; the first step involves producing raw lactose which is 
obtained by de-proteinating the whey using heat or acid treatment, then the remaining super-
saturated solution is further cooled, dissolved, re-cooled and recrystallized. There are different 
grades of lactose available in the pharmaceutical market: below 93.5ºC a-lactose is produced, 
whereas above 93.5ºC b-lactose crystals are formed. Lactose can also exist as anhydrous 
lactose (containing 70-80% β-lactose anhydrous and 20-30% a-anhydrous lactose) (Kaialy et 
al., 2012). 
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Lactose is soluble in 2.04 parts of water at 50°C. a-lactose monohydrate is the most stable 
form due to its less hygroscopic properties, cheap cost, wide availability and high compatibility 
with drug substances. a-lactose particles shape can vary from pyramid, prism to tomahawk.  
 
All the grades differ in their physical characteristics and flow properties. The different physical 
forms of lactose have been demonstrated to affect the adhesive forces between the particles. 
For example, the crystalline form of lactose reduced the adhesion forces which resulted in a 
better dispersion with the drug being released more easily from the lactose surfaces. Lactose 
can be either processed by micronizing, spray-drying or sieving, resulting in different surface 
morphologies.  
 
Many researchers focus their work on modifying the surface characteristics of lactose by 
‘particle engineering’. The disadvantage of particle engineering is that the resulting modified 
lactose particles are characterized by a heterogeneous surface with non-homogenous energy 
distribution and morphology on the surface of the particles, leading to batch to batch variations 
which could compromise the performance of the formulations (Young et al., 2008). 
2.7.2 Particle size 
It is well accepted that particle size of the carrier has a great influence on the aerosolisation 
performance of the DPI formulation. Authors have published contradictory reports about the 
suitable size for carriers in DPIs. Some previous studies have reported that decreasing the 
particle size of the carrier increased the fraction of respirable drug delivered from a DPI (Gilani 
et al., 2004; Kaialy et al., 2012; Louey et al., 2003; Steckel & Müller, 1997), however this has 
a negative effect on drug content uniformity and resulted in a higher amount of drug deposited 
in the oropharyngeal region (Kaialy et al., 2012). It was suggested that smaller agglomerates 
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are subjected to more forceful shear in the turbulent airstream which resulted in better de-
agglomeration (Islama et al., 2012).  
However, Zeng et al., suggested that the addition of a coarse carrier in the formulation was due 
to the poor powder flow properties of small carriers  (Zeng et al., 2001a). 
Another study demonstrated that larger carrier particles have larger gaps on the surface than 
fine crystals ( De Boer et al., 2003). These discontinuities offered shelter to drug particles when 
press-on forces occurred during mixing ( De Boer et al., 2005), enhancing the drug deposition 
profiles after inhalation (Hamishehkar et al., 2010). The contradictory results could be due to 
the interdependence of physical characteristics of the particles. It is therefore very important to 
optimize the particle size to achieve efficient aerosolization. 
To achieve the optimum particle size of carrier particles, other physical properties need to be 
taken into consideration, such as their shape, surface roughness, density and geometric 
diameter (Sahane et al., 2012) 
 
2.7.3 Particle shape 
It is recognized that the attractive forces between drug and carrier particles depend on the shape 
of the particles, thus this will affect the aerosolisation and dispersibility of the drug (Crowder, 
et al., 2001; Kaialy et al., 2011; Mullins et al., 1992). Shape modification has been used to try 
to improve drug deposition.  
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Figure 2.8 Scanning electron microscopy images of different lactose shapes obtained from 
crystallization (Kho et al., 2013) 
 
When particles have different shapes, they are exposed to different drag forces and velocities 
during aerosolisation, which affects drug deposition (Kaialy & Nokhodchi, 2013). Most carrier 
particles generally used in DPI formulations have irregular shapes (image A from Figure 2.8). 
Several authors have shown that carriers with different shapes resulted in improved drug 
deposition, such shapes include elongated particles (image F from Figure 2.8) (Larhrib et al., 
2003; Zeng et al., 2000a), porous and wrinkled particles (images C and D from Figure 2.8) ( 
Chew et al., 2005) and needle-like particles (image E from Figure 2.8)  (Ikegami et al., 2002). 
An increase in the elongation ratio of the lactose carrier also resulted in a higher FPF of 
salbutamol sulphate (Zeng et al., 2000). More recent studies reported an increase in the 
dispersibility of budesonide particles when using pollen-shape like hydroxyapatite carrier 
particles. This is due to the reduction in the interactions between the drug and carrier particles 
(Hassan & Lau, 2010a, 2010b). Additionally, particle shape was found to exert an effect on the 
aerodynamic diameter of the agglomerates. Elongated particles have a lower aerodynamic 
diameter than spherical particles, therefore they have a longer time of flight and remain for a 
longer distance in the airstream, enhancing de-agglomeration (Islama et al., 2012). Needle 
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shape particles, which have a high elongation ratio, result in more efficient drug deposition in 
the small airways of the lungs (Larhrib et al., 2003; Yang et al., 2014), however such particles 
have limitations because they tend to have an adverse effect when processing and handling due 
to their poor flowability (Kaialy et al., 2011). 
 
2.7.4 Surface roughness 
 
The surface roughness of carrier particles has been found to have a profound impact on the 
adhesion forces between drug and carrier particles (Podczeck, 1999). To achieve an efficient 
drug delivery deep into the lung, drug particles need to be adhered to the carrier and detach 
from the surface of the carrier particles. The magnitude of the adhesion forces between drug 
and carrier particles depends on the particles geometry (Figure 2.9), is directly proportional to 
the surface energies and inversely proportional to the contact area between them (Adi et al., 
2008; Peng et al., 2016). 
 
Figure 2.9 Carrier particles differing in their surface roughness: (a) micrometer topography, 
(B) smooth and (C) nano-metered topography (with permission from Peng et al., 2016) 
 
Several attempts have been made by different research groups to modify the surface properties 
of the drug and carrier particles with the intent to improve aerosol performance (Peng et al., 
2016). Increasing surface roughness can be done by re-crystallisation, coating the carrier 
particles, mechanofusion or also by spray drying (or adding micronized particles with spray 
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dried particles) (El-Sabawi et al., 2006; Kumon et al., 2008; Parlati et al., 2009). On the other 
hand, smoothing the surface of carrier particles in DPIs can be achieved by crystallization 
processes whereby carrier particles were partially dissolved in an ethanol-water mixture and 
then filtered and dried (Dickhoff et al., 2006; Iida et al., 2003; Steckel et al., 2004). 
Smooth carrier particles can also be obtained by solution phase variable temperature 
dissolution, where an increase in the dissolution led to a decrease in the surface roughness of 
the particles (El-Sabawi et al., 2006). It has also been shown that applying direct shear stress 
to the bulk powder can smooth out carrier particles (Iida et al., 2004). However, numerous 
studies in the literature have contradictory findings with regards to the impact of smooth and 
rough carrier particles on drug detachment and dispersion.  
For example, a study showed that higher SS FPF was observed when lactose surface roughness 
was decreased (Timsina et al., 1994). 
Other authors published studies where they reduced the roughness of lactose carrier particles 
which led to a reduction in the surface area and consequently a reduction in the van der Waals 
adhesion forces (Zeng et al., 2000) 
(Iida et al., 2003). Similarly, Zeng et al. study showed that lactose crystals with higher surface 
smoothness resulted in higher respirable fraction of SS. A study by Heng et al. confirmed that 
less SS was detached from the surface of rougher lactose particles (Heng et al., 2000). A study 
by Larhrib et al. assessed the drug delivery efficiency of different batches of crystallised lactose 
with different morphologies. They found that smoother lactose delivered more SS as opposed 
to rougher surfaces (Larhrib et al., 2003). 
Comparably, Young et al. demonstrated that “smoothing” lactose particles led to an increase 
in the respirable fraction of BDP (Young et al., 2002). 
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On the other hand, some conflicting results have been found in the literature, showing that 
surface roughness can be beneficial in drug delivery of DPIs. For example, Adi et al. 
demonstrated a direct relationship between roughness, particle adhesion and deposition of 
drugs in-vitro. They observed that adhesion forces between particles was reduced as the degree 
of corrugation increased, which resulted in a higher FPF value, thus the roughness of particles 
can greatly affect the aerodynamic performance of DPIs (Adi et al., 2008).  
Some studies performed surface modification on the drug particles by increasing the surface 
roughness. This modification resulted in a decrease in the contact area between drug and carrier 
particles, which consequently reduced the van der Waals forces that were involved in the 
adhesion forces (Adi et al., 2008; Chew et al., 2005;  Kawashima et al., 1998b).  Chan et al. 
observed a more significant SS deposition with lactose carriers having higher surface 
roughness. They incorporated fine lactose particles on the surface of coarser lactose particles. 
The fine particles formed undulations that facilitated the detachment of SS from the carrier 
(Chan et al., 2003).  
 
The lactose carrier surface is represented by a non-homogenous energy distribution which is 
characterized by the presence of low energy sites as well as active sites of high energy. Active 
sites generally arise in amorphous regions (resulting from milling or spray-drying processes), 
in the presence of impurities (protein and fat present in lactose extracted from milk), in 
polar/non-polar regions and in morphological regions (peaks and troughs). Active sites are 
generally occupied by small particles, therefore when low-drug dose formulations are made 
the drug particles tend to saturate the active sites and compromise the aerosol performance. 
Drug particles also lodge in non-active sites where a lower adhesion forces occur. Young et 
al., (2005) studied the relationship between drug/lactose ratio and the influence of drug dose 
on aerosolisation performance. They found that when higher doses of salbutamol sulphate were 
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used (from 135 µg to 450 µg) a significant increase in the FPD occurred. A possible explanation 
was that when a higher drug dose was used, some of the SS particles acted as a ternary 
component and lodged in the active sites of the carrier, allowing the other drug particles to 
adhere to lower energy sites on the carrier surface (Young et al., 2005). 
 
On the other hand, Flament et al., found that FPF of tebutaline sulphate decrease with 
increasing surface roughness of lactose particles (Flament et al., 2004). It was suggested that 
due to the increase of contact points between the carrier and drug particles, the blend was 
stabilised but less deaggregation occurred during aerosolisation. These conflicting studies 
show that in order for DPIs to be efficient, a certain level of surface roughness needs to be 
achieved (Peng et al., 2016). This is why it has become a great challenge for researchers in the 
inhalation field to achieve high inhalable dose fraction delivery to the lung with high 
reproducibility. One of the main cause for great variability and poor deposition results is poor 
drug-carrier detachment (Zeng et al., 2000). 
 Thus, when developing DPI products, it is crucial to select carrier particle with suitable 
physicochemical properties to achieve efficient drug deposition deep in the lungs. 
 
Four interrelated factors control drug delivery to the lungs: firstly, the physicochemical 
properties of the DPI formulation (powder flow, particle size and morphological features, drug-
carrier interaction forces); the second factor is the DPI device (its performance, geometry, 
dosing method); another factor is that the patient should be trained to use the device properly 
and use correct inhalation technique and finally the last factor is the inspiratory flow and 
volume. All these parameters are essential and need to be taken into consideration when 
engineering new DPI formulations.  
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2.7.5 Lactose in ternary mixtures 
The addition of ternary components into DPI formulations was intended to reduce the cohesion 
between particles. Researchers believed that incorporating additives would weaken the bond 
between fine particles and thus reduce adhesion. Studies demonstrated an improvement in the 
efficiency of inhaled drugs when fine particles were added to the formulation (Staniforth et al., 
1998; Zeng et al., 1998). Islam et al. confirmed that when fine lactose particles were added to 
larger lactose particles or added as an excipient, they had a great impact on drug dispersion 
(Islam et al., 2004).  
 
Figure 2.10 Drug dispersion in (1) binary mixtures and (2,3) ternary mixtures (Pilcer et al., 
2012). 
 
Drug dispersion was improved when a ternary component, such as Magnesium Stearate (MgSt) 
and Leucine, was added to the formulation (French et al., 1996; Grosvenor & Staniforth, 1996; 
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Islam et al., 2004b). The ternary component reduced the cohesive forces between drug-drug 
particles. The same conclusion was reached when 10% of fine carrier particles (lactose, 
glucose, mannitol or sorbitol) were added in the formulation containing Salmeterol Xinafoate 
and coarse carriers. This study showed that the addition of fines improved the detachment of 
the drug particles from the surface of the carrier (Adi et al., 2007) as represented in Figure 
2.10(2) where fine lactose will lodge in the high energy areas on the lactose surface, forcing 
drug particles to adhere less to those active sites.  
The ‘active sites’ theory was first introduced by Hersey (Hersey, 1975) suggesting that the 
carrier surface is characterized by the presence of sites of high energy, thus these areas are 
more adhesive than others. (Pilcer et al., 2012). The ‘agglomeration theory’ (Figure 2.10 (3)) 
is believed to improve DPI performance by the presence of fine particles resulting from the 
formation of drug-fine agglomerates. The fines are more likely to bind to the carrier due to 
high drag forces, allowing the API particles to detach from the carrier particle surface ( Jones 
et al., 2008).  
 
However, a few studies have shown the opposite effect with the impact of fines in DPI 
formulations.  These studies stated that the concentration of added fine lactose particles has to 
be prudently measured so that the right dispersibility of the drug can be attained without 
decreasing the flow properties of the powder formulation (Zeng et al., 1998). The addition of 
lactose fines in the formulation is inclined to reduce the flow because fines can lodge into the 
empty spaces between larger particles and promote packing, thus resulting in a more densified 
powder, with fine particles having poor flow properties (Augsburger, 1974) due to several 
surface interactions (Hickey et al., 2007) and great cohesion between particles. Some recent 
studies demonstrated that the addition of fines in the DPI formulation caused a decrease in FPF 
(Hamishehkar et al., 2010; Steckel & Bolzen, 2004). 
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Furthermore, when micronised fine carrier particles are used, they usually have some 
amorphous content and may cause the formulation to be to thermodynamically unstable 
(Saleki-Gerhardt et al., 1994). 
In order to reduce the cohesion between drug particles, force controlled agents (FCA) can be 
added to formulations. The most common FCA is magnesium stearate (Staniforth et al., 1982; 
Staniforth, 1997), a lubricant used to modify the properties of DPI formulations, such as the 
ability of the formulation to pick up moisture and the interaction between particles. Magnesium 
stearate can be added in the formulation by mechanofusion, where the particles are dispersed 
around the lactose carrier, forming nano-structured layers around the carrier particles (Begat et 
al., 2009). 
The modifications of the lactose surface morphology allowed a reduction in the interaction 
forces between the drug and carrier particles in DPI formulations, allowing drug particles to  
be detached from the carrier more easily and improve aerosol generation.  
 
The particle engineering processes described above were quite successful and encouraging for 
the optimization of DPI formulations, however, the safe use of hydrophobic excipients such as 
Mg St is still not fully understood as the way they are cleared from the lungs is still unclear. 
 
2.8 Mixing process  
Mixing is an important step in DPI powder formulation as the aerosolisation performance of 
the formulation depends on the balance between the adhesion forces between particles but also 
the detachment and dispersion of drug particles from the surface of carrier particles upon 
actuation. Although mixing remains a major source of variability in manufacturing processes, 
as batch-to-batch variations still occur (but are limited by controlled blending parameters), 
mixing remains a key operation in the formulation of adhesive mixtures as the blending of drug 
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particles with carrier particles is a crucial step that determines the homogeneity of the blend 
and is the first stage towards achieving the requirements of the final product.  
The mixing of powder particles necessitates motion to be exerted on them. Hence, powder 
blenders induce motion by either rotating the container or by the aid of an impeller that moves 
within the powder. Powder mixing differs from fluid mixing as the latter is characterized by 
the diffusion of molecules from a high concentration area to a low concentration location. In 
the initial stages of the mixing process, drug particles are randomly allocated on the surface of 
carrier particles and they tend to locate and regroup on the carrier surface discontinuities as 




Figure 2.11 Schematic representation of drug distribution on the surface of a carrier particle 
during mixing (Kaialy, 2016) 
The distribution of drug particles depends on the concentration of drug: if the concentration is 
low, the distribution is less effective as drug particles lodge into the discontinuities and are 
exempt from the frictional and initial forces, thus they remain strongly attached to the carrier 
(De Boer et al., 2005)   
There are two types of blenders that have been utilised in the production of DPI formulations. 
These are tumbling blenders (e.g Turbula mixer, V-blender) and high-speed impeller mixers. 
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They differ in the range of energy inputs they have, which may play an important role on the 
mixing properties and adhesive properties of the drug to the carrier. 
Powder mixing is accomplished by different mechanisms, namely convective, diffusive and 
shear mixing. Although all three tend to happen during mixing processes, the one that 
predominates will depend on the type of blender used, the blending parameters, such as fill 
weight, speed and percentage loading, and also the flow properties of the carrier used in the 
formulation. Shear mixing was reported to be the only mechanism efficient in engendering 
enough stress needed to de-agglomerate cohesive drug particles (Figure 2.12).  
 
Figure 2.12 Schematic representation of a Picomix® and Turbula mixer (Hertel, 2016) 
 
High stresses are required to break up the drug agglomerates, thus allowing individual drug 
particles to be distributed on the surface of the carrier. During mixing, each component of the 
DPI formulation collides with each other and with the walls of the container. The powder flow 
in the blender may cause friction between the particles, such friction forces are accountable for 
de-agglomerating drug particles. It has been demonstrated in the literature that drug 
agglomerates can still subsist after mixing. However, these agglomerates were weaker than the 
initial ones. They have been shown to be broken up into single particles at a relatively low 
pressure drop of 4 kPa in an inhaler (De Boer et al., 2004) 
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2.9 Particle engineering for lactose particles 
2.9.1 Spray-drying 
Spray-drying (SD) is a well-used particle engineering technique because it is rapid, continuous, 
straightforward, easy to operate, cost-effective, reproducible and is available for large scale 
batches.   
SD consists of producing dry powders from a liquid feed by atomisation through an atomiser 
into hot air. The process involves four fundamental steps listed below (Master et al., 1998): 
Step 1: Feed solution is atomised into a spray  
Step 2: Drying of spray into drying medium (gas or air)  
Step 3: Formation of dry particles 
Step 4: Dried particles are separated from the air and collected. 
 
Figure 2.13 Diagram of the conventional spray drying equipment (with permission from 
(Sosnik & Seremeta, 2015). 
Figure 2.13 shows a diagram of a conventional spray drying process. The process starts by 
introducing the liquid feed through a nozzle into the chamber using a peristatic pump. There 
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are three types of nozzles, namely rotary atomiser, pressure nozzle or a two-fluid nozzle, and 
the atomisation takes place by centrifugal, pressure or kinetic energy, respectively (Lee et al., 
2011).  The feed can either be a solution, a suspension,  a colloidal dispersion, slurry, paste or 
emulsion (Gómez-Gaete et al., 2008; Rabbani & Seville, 2005). Following atomisation, the 
micro-droplets undergo fast solvent evaporation (Elversson et al., 2003; Fatnassi et al., 2014) 
forming dry particles.  
The separation of the dry particles from the drying gas occurs in the cyclone, where the dried 
particles are deposited in a glass collector at the bottom end of the spray-drier (Schoubben et 
al., 2010; Ståhl et al., 2002). The solid dry particles generated show relatively narrow size 
distribution at the micron scale and the percentage yield is usually quite low and not optimal 
(20-70%) (Lee et al., 2011; Rabbani & Seville, 2005; Liu et al., 2006). A great loss of particles 
occurs in the cyclone due to the low capacity of the cyclone to separate particles that are less 
than 2 µm, which end up passing into the exhaust air, and because a lot of product is usually 
adhered to the walls of the drying chamber (Sosnik & Seremeta, 2015). 
 
Several parameters can be adjusted to optimise the spray drying technique. The main adjustable 
parameters are listed in Table 2.3. The important drying parameters are inlet and outlet 
temperatures, the type of drying gas, the flow rate of the drying gas and residence time, all of 










It is important to note that particles generated by spray-drying from solutions are spherical, 
small (less than 10 µm) and predominantly amorphous; however, suspensions can be processed 
to preserve the crystalline state of the material. For example, the crystallinity of spray-dried 
lactose can be adjusted depending on the ethanol-to-water ratio in the liquid feed solution. 
Because lactose is practically insoluble in ethanol, spray drying a lactose suspension from pure 
ethanol will produce 100% crystalline spray-dried lactose particles, but spray-drying a lactose 
solution from pure water will generate 100% amorphous lactose particles (Harjunen et al., 
2002). It is interesting to note that commercial lactose (SuperTab®, DFE Pharma) generally 
used for direct compression is generated by spray-drying. SuperTab® particles are spherical, 
have a narrow size distribution and have an excellent flow and compactibility (DFE Pharma). 
Studies in the literature show that spray-dried lactose did not improve the inhalation efficiency 
of the DPI formulation containing pranlukast hydrate because the drug was strongly adhered 
to the surface of the smooth spray-dried lactose. However, it was found that spray-dried 
crystallised lactose, which had microscopical projections on its surfaces, had a higher fine 
particle fraction. The conclusion of this study was that a certain degree of roughness was 
needed to improve inhalation efficiency. As spray-dried lactose on its own is not optimal for 
efficient drug delivery in DPIs (Kawashima et al., 1998b). More recently, to improve the 
dispersibility of cohesive materials, additives such as amino acids (leucine and trileucine) were 
incorporated with the carrier particles to modify the inter-particulate forces (Vehring, 2008). 
Parameters	
Process	 	 	 	 Liquid	feed	 	 	 Equipment	
	
Flow	rate	of	feed	 	 	 Concentration		 	 Co-current	flow	
Flow	rate	of	drying	gas	 	 Viscosity	 	 	 counter-current	flow	
inlet	temperature	(gas/air)	 	 Density	 	 	 Mixed	flow	







Micronisation or milling is a well-established and widely used technique to produce particles 
in numerous marketed inhaler formulations. Such particles are firstly crystallised, then filtered, 
dried and finally micronised. Particle size reduction is a result of either pressure, friction, 
attrition, impact or shear (Kalman, 2000). Ball-milling and jet-milling are widely used to 
produce particles intended for inhalation. In the jet-milling technique, particle-particle and 
particle-wall collisions occur before the separation of larger particles from smaller particles by 
inertial impaction. This categorisation guarantees that the particle size required is eventually 
obtained.  
Unwanted changes in the physico-chemical properties of the material can occur due to intense 
milling. Such changes include the generation of amorphous domains at the surface, which 
compromise the stability of the material and the possibility of undergoing recrystallization, 
thus crystal growth on the amorphous regions; solid bridges can also be formed between 
particles. Milling is also known to induce electrostatic charging at the particle surface, thus 
making the material more cohesive and adhesive. Additionally, the micronisation process 
produces small, irregular lactose particles with highly flat surfaces which contributes to larger 
contact areas, promoting the adhesion between the particles and exhibiting poor flow properties 
(Mohammed et al., 2017). Despite micronisation being a convenient technique for size 
reduction, it offers only a limited opportunity to manipulate particle characteristics such as size 
distribution, shape and morphology. That is why it is necessary to develop other particle 
engineering methods capable of producing particles suitable for inhalation.  
 
2.9.3 Crystallisation of solids 
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Crystallisation methods have been extensively used in particle engineering to produce carrier 
particles with different size, shapes (Section 2.7.3) and surface textures (Section 2.7.4 and 
2.7.5).  
This section will cover the mechanism of crystallisation as it is important to understand how 
each step during crystallisation can influence the morphological properties of the crystallised 
material. 
Crystallisation processes are made of three important steps: 
Step 1: Supersaturation 
Step 2: Nucleation 
Step 3: Crystal growth. 
 
Supersaturation is the driving force of the crystallisation process because the second and third 
steps in crystallisation depend on the level of supersaturation in the solution (Davey and 
Garside, 2000). Supersaturated solutions are generally produced by cooling, evaporation, anti-
solvent addition or a mixture of these processes.  
 
Nucleation is defined by the development of small agglomerates in the supersaturated solution. 
Such agglomerates are formed by either bimolecular addition or can occur when molecules 
collide with each other (Mullin, 1993). Bimolecular addition is characterised by the coagulation 
of a molecule, with the lowest interaction energy amongst others in that particular zone, to 
another molecule which will act as a seed for others to bind to. Agglomerates form until a 
stable nucleus is formed. The formation of crystal nuclei is challenging because molecules have 
to coagulate but also fight dissolution (Kitaigorodsky & Ahmed, 1972). 
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Crystal growth is characterised by the increase in particle of size leading to a crystal state. 
The increase in particle size occurs by the formation of layers from loose particles that lodge 
themselves on the imperfections of the crystal’s surface.  
The mechanisms of nucleation and crystal growth are still a difficult phenomenon, however by 
optimising the crystallisation parameters, it is still possible to control some crystals features 
such as morphology and size, but this is quite limited, because several factors can affect the 
quality of the final crystals (e.g. induction time, cooling rate, level of supersaturation, type of 
solvent used, stirring rate, impurity levels) (Mullin, 1993; Storey, 1997; Raseneck and Muller, 
2002).  
 
2.10 Reasons for engineering new lactose carriers 
Most commercially available dry powder inhalers are only able to deliver about 20-30% of the 
dose to the lungs (Figure 2.14) 
 
Figure 2.14 In-vitro %FPF of label claim from different DPIs tested at 4kPa using a next 
generation impactor (DeBoer et al. (2016) 
 
The undelivered portion of the drug stays attached to the carrier surface (Steckel & Müller, 
1997). The possible explanations for this ineffective delivery have not been completely 
understood. One of the reason is known to be the morphology of the commercially available 
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inhalation grade lactose such as its irregular shape and rough surface which may affect drug 
dispersion. Another reason for inefficient delivery is attributed to the sensitivity of the DPI 
formulations to high temperatures and humidity. a-lactose monohydrate is not hygroscopic; 
however, moisture can get into DPI formulations and may affect the performance of the powder 
blend. Because of the difference in particle size between lactose carriers (< 100 µm) and drug 
particles (1-5 µm), any moisture entering the particles will enhance the cohesion between 
particles in the DPI formulation. Lactose is usually produced by particle size reduction 
techniques which usually produce amorphous regions on the processed material. These 
amorphous regions are usually associated with high free energy sites which require higher 
energy to detach drug particles from the carrier surfaces (Malcolmson & Embleton, 1998). 
 A study by Larhrib et al. demonstrated that different grades of lactose exhibited different 
delivery profiles of SS, this suggests that the grade of lactose has a profound effect on the 
delivery of the drug (Larhrib et al., 1999).  
All of the studies listed in this chapter suggest that modifications of the carrier particles are 




































This chapter gives an outline of the laboratory materials, apparatus and methods used in the 
study.  
 
3.1 General laboratory apparatus and materials 
 
Ø 4 decimal places analytical balance (ADAM, AAA 160 LE) 
Ø Ultrawave U300 benchtop bath (Scientific Laboratory Supplies, Ltd) 
Ø Sealing Parafilm™ (Fisher Scientific Ltd, UK) 
Ø 20 mL clear vials (Sigma Aldrich, UK) 
Ø Syringe filter 0.45µm pore size (Fisher Scientific Ltd, UK) 
Ø 5 mL plastic syringe (Fisher Scientific Ltd, UK) 
Ø Glass Pasteur pipettes (Fisher Scientific Ltd, UK) 
Ø Hot plate and magnetic stirrer (Cole-Parmer®, UK) 
 
3.2 Measurement of the aerodynamic characteristics of the emitted dose using the in-
vitro and ex-vivo methods 
3.2.1 Apparatus and Software’s 
Ø Andersen Cascade Impactor (ACI) (Copley Scientific Ltd, UK)  
Ø Next Generation Impactor (NGI) (Copley Scientific Ltd, UK) 
Ø Breath Simulator (BRS) 3000 (Copley Scientific, Ltd, UK)  
Ø Alberta Idealised Throat (AIT) (Copley Scientific Ltd, UK)  
Ø Mixing Inlet (Copley Scientific Ltd, UK)  
Ø Cyclohaler® and BreezHaler® Mouth Pieces (Copley Scientific Ltd, UK)  
Ø Critical flow controller, TPK 2000 (Copley Scientific Ltd, UK)   
Ø Vacuum Pump (HCP5 High capacity pump; Copley Scientific Ltd, UK)   
Ø Digital flow meter 2000 (Copley Scientific Ltd, UK)  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Ø Filter paper Grade 934-AH circle glass microfibre 47mm for DSU (Fisher Scientific 
Ltd, UK) 
Ø Filter paper Grade 934-AH circle glass microfibre 82 mm Whatman (Fisher 
 Scientific Ltd, UK)   
Ø Silicone spray (Pro-Power Silicone Lubricant, Premier Farnell plc, UK)   
Ø Copley Inhaler Testing Data Analysis Software (CITDAS) version 2.00 (Copley 
 Scientific Ltd, Nottingham, UK)   
 
3.2.2 Impactors set-up  
The use of impactors allows the API to be quantified and differentiated from the other 
components of the formulation as these devices capture the entire dose and measure the 
aerodynamic diameter, which is relevant to particle behavior during inhalation (Mark Copley, 
2008). 
The aerodynamic properties of SS with Lactohale® and PSDL have been determined using an 
Andersen cascade impactor (ACI) and the next generation impactor (NGI) with maximum 
inhalation flows of 60 and 90 L/min and inhaled volumes of 1 and/or 2L. 
The ACI configuration used for 60L/min was designed with collection stages -1A to 6 (Figure 
3.1) and the pre-separator appropriate for 60 L/min was used. Similarly, the ACI configuration 
used for 90 L/min was with stages -2A to 5 with the pre-separator suited for 90 L/min.   
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(a)    (b)  
Figure 3.1 (a) Andersen Cascade Impactor set up for DPIs (b) Mechanism of operation of 
the Andersen Cascade Impactor (Adapted from Copley Scientific, 2016) 
 
The next generation impactor (Copley Scientific Ltd, Nottingham, UK) comprises seven 
stages (Figure 3.2). The impactor was fitted with a pre-separator to prevent any powder 
boluses and larger carrier particles from overloading the collection plate of the first stage of 
the impactor. One of the differences between the NGI and the ACI is the arrangement of the 
different stages which are vertically organized for the ACI and horizontally set for the NGI. 
The airflow passes through the NGI in a “saw-tooth pattern” (Copley, 2008). Particles pass 
through a series of nozzles containing gradually reducing diameters. 
All the NGI testing was first carried out with an airflow of 60 L/min with a sampling time of 
1 second (corresponding to 1 L) and 2 seconds (corresponding to 2L). A secondary set of 
testing was carried out at 90 L/min for 0.7 seconds and 1.3 seconds corresponding to 1 L and 
2 L respectively. The inhaler device was connected to the throat using a rubber mouthpiece 
adapter. 20 ml of the HPLC mobile phase (described in section 3.3.3) was added to the pre-
separator and 10 ml was added to each collection cups.  The collection cups were coated with 
a sprayed layer of silicone to reduce the chances of particles hitting the cup and bouncing 
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back into the airstream. The required airflow was generated from a vacuum pump. After each 
experiment, the NGI was cleaned with water and methanol and was left to air dry.  
 
Figure 3.2 The Next Generation Impactor (with permission from Copley Scientific, 2014) 
 
The NGI was operated at 60 and 90 L/min, which are within the calibration range from 30 to 
100 L/min (Marple et al., 2003), with its appropriate pre-separator and the standard NGI 
collection cups (1 to 7). 
Both cascade impactors were equipped with a United States Pharmacopeia (USP) throat. The 
collection cups and collection stages for NGI and ACI, respectively, were each coated with 
silicone lubricant (Pro-Power premier Farnell plc, UK) and left to dry at room temperature 
before use. The coating was done to ensure good API recovery and assay by avoiding bias from 
particle bounce and re-entrainment in the impactors. 
The impactors were connected to a vacuum pump (HCP5, Copley Scientific Ltd, UK) via a 
TPK critical flow rate controller (Copley Scientific Ltd, UK).  The cascade impactors were 
assembled with their appropriate pre-separator containing 10 ml of water and a glass fiber 
GF50 (Whatman, UK) filter positioned in the last stage and a Micro-Orifice Collector (MOC) 
for ACI and NGI, respectively. 
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A total of 27.4 mg of SS/lactose carrier (1:67.5 w/w) mixture were filled into three size 3 hard 
gelatine capsules for each formulation. The capsules were entered into the dry powder 
inhalation device (MacHaler®) which was fitted to the mouthpiece and attached to the USP 
throat. The pump was then switched on and allowed to run for 1 and 2 secs at 60 L/min and 
0.7 and 1.3 sec at 90L/min, as the dose was being released from the device. The deposition test 
was repeated two more times in the same manner. The capsule shells were washed with 5ml of 
the washing solution. The inhaler device and the mouthpiece were washed with 10ml. 
Similarly, the inlet port was washed with 20 ml of the washing solution and the pre-separator 
with 25ml. All the stages/plates were washed separately with 10ml and finally the filter with 
10 ml.  Salbutamol sulphate was recovered from each component of the cascade impactor using 
a suitable solvent (Methanol) and then assayed by a validated high-performance liquid 
chromatography (HPLC) method described in section 3.3.3.  
In order to calculate the aerodynamic dose emission parameters, the Copley Inhaler Testing 
Data System Analysis Software (CITDAS Version 2.0, Copley Scientific Ltd, UK) was used. 
The American and European pharmacopoeias have described methods based on inertial 
impaction in order to evaluate the in-vitro performance of formulations by studying the fine 
particles (Pilcer et al., 2012). The efficiency of drug delivery in the lung is mainly dependent 
on the delivered dose. High fractions of emitted dose and fine particle fraction are required for 
an optimized performance. Statistical analysis using two-way analysis of variance (ANOVA) 
was used to compare the different parameters obtained (%FPF; FPD; MMAD; TED) from the 
different inhalation volumes and inhalation flow rates used for all the formulations. 
 
3.2.3 Inhalation profiles 
Patient’s inhalation profiles can be characterised by three important parameters which are the 
peak inspiratory flow rate (PIF), the inhalation volume, the initial acceleration rate.   
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One of the most important parameter for breath actuated DPIs to achieve sufficient dose de-
aggregation is the PIF. 
 
Figure 3.3 Schematic diagram displaying different COPD patients’ inhalation profiles (Red: 
low profile; Green: medium profile; blue: high profile) (Abadelah, 2017) 
 
 
3.2.4 Breath Simulator (BRS) 3000 
The BRS 2000 was originally intended for being used by nebulisers. The launch of the BRS 
into the market in 2012 allowed the use of higher inhalation flows up to 240 L/min with a 
maximum acceleration rate of 25 L/s2 and an inhalation volume capacity of up to 5 L (Copley 
Scientific, 2015). These new features allowed the BRS 3000 to be used in testing DPIs and 





3.3 High Performance Liquid Chromatography (HPLC) 
3.3.1 Materials 
3.3.1.1 General materials 
ü Amber HPLC vials (2mL) (Fisher Scientific Ltd, UK) 
ü Filter membranes, 0.45µm pore size (Sigma Aldrich Ltd, UK) 
ü Supelco® mobile phase filtration apparatus (Sigma Aldrich Ltd, UK) 
ü Ultra-purified water apparatus (Thermo Scientific Ltd, UK) 
ü Glass Pasteur pipettes (Fisher Scientific Ltd, UK) 
ü Volumetric flasks and beakers (Fisher Scientific Ltd, UK) 
3.3.1.2 Chemicals used for buffer preparation 
ü Hexanesulfonic acid (Sigma Aldrich Ltd, UK) 
ü Methanol, HPLC grade (Fisher Scientific Ltd, UK) 
ü Ultrapure water (Barnsted™ Nanopure ™, Thermo Scientific Ltd, UK) 
 
3.3.2 Introduction 
High performance liquid chromatography (HPLC) is a chromatographic technique highly used 
in the pharmaceutical field for the quantification of separate components of a mixture. It is both 
a qualitative and quantitative method in which the separation of components is dependent on 
the polarity of the compounds as well as the polarity of the aqueous phase and stationary phase. 
The separation is also driven by the affinity of the compound to the mobile and stationary 
phase, therefore the elution time will vary depending on their affinity (McPollin, 2009). 
Reversed-phase HPLC (RP-HPLC) is most commonly used, the stationary phase is usually 
made of non-polar alkyl hydrocarbons bound to silica. On the other hand, the mobile phase is 
polar, creating a strong attraction between the polar molecules and solvent when the mixture 
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passes through the column (McPolin, 2009b). A schematic diagram of a HPLC system is 
illustrated in Figure 3.4 below.  
The solvent constituting the mobile phase is water/buffer which is used in parallel with an 
organic solvent (miscible in water). The most commonly used solvents in HPLC are acetonitrile 
and methanol which are water miscible and easily accessible from suppliers in HPLC grade).  
 
 
Figure 3.4 Configuration of a typical HPLC system (McPolin, 2009) 
 
3.3.3 HPLC conditions 
The concentration of SS solution was measured by a Shimadzu system consisting of a 
Prominence liquid chromatograph (LC-20AT) pump (Shimadzu Ltd, UK), a Prominence 
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degasser (DGU-20A5) (Shimadzu Ltd, UK) and a Photodiode Array detector (SPD-M20A). 
The column used was Luna® C18 100A (250mm x 4.6 mm) with a pore size of 5µm 
(Phenomenex, UK). The mobile phase consisting of a mixture of 30% v/v methanol and 70% 
v/v hexanesulfonic acid. This buffer was chosen to achieve maximum separation and 
sensitivity. The buffer (10 mM of hexanesulfonate buffer) was prepared by dissolving 0.941 g 
of sodium hexanesulfonate and 10 ml of glacial acetic acid in 1L of ultra-pure water (18.2 Ω). 
The buffer was then filtered under vacuum using 0.45µm nylon filter. 
 
The mobile phase was filtered and degassed before use. The flow rate was 1mL/min. Samples 
were detected at 276nm using photodiode array detector. The data analysis was performed with 
Shimazu LC-solutions. All the calculations concerning the quantitative analysis were 
performed by measurement of peak areas. Results were expressed as the mean of three 
determinations. 
The preparation of standard solutions is described below:  
Eight standard solutions were prepared. Firstly, 10 mg of SS was dissolved in ultrapure water 
in a 10 mL volumetric flask to obtain solution A with concentration of 1 mg/mL. Solution B 
was made by withdrawing 1 mL of solution A and then topping up with water in a 10 mL 
volumetric flask. Its concentration was 100 µg/mL. Solutions C, D, E, F, G, H, I and J with 
concentrations 25 µg/mL, 20 µg/mL, 10 µg/mL, 5 µg/mL, 2.5 µg/mL, 1 µg/mL, 500 ng/mL 
and 250 ng/mL respectively were prepared using the same method using appropriate dilution 
factors.  
The accuracy of HPLC methods can be inferred from the analytical parameters used in assay 
validation such as linearity and precision. In order to establish the linear detection range for 
SS, standard stock solutions were analyzed to determine the linearity. 
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Calibration ranges of 250 ng/mL to 25 mg/mL (solutions C to J) were prepared. Triplicate 10 
µL injections were made for each standard solution to see the reproducibility of the detector 
response at each concentration level. 
 
3.3.4 HPLC system suitability and validation 
The suitability of the system is one of the parameters that must be checked to validate the 
HPLC method, according to the ICH guidelines (ICH, 2005). The system suitability test 
ensures that the HPLC system is performing as expected, including the mobile phases, pump, 
injector, column, detector, data processor and the operator (McPolin, 2009a).  
The system suitability parameters are listed below: 
- Void volume determination: 
The void volume of the column was determined by using thiourea. Using the same HPLC 
conditions as described above, Thiourea was assayed at λmax= 240 nm with the working 
concentration range of 1 to 25ug/ml. 
- Capacity factor (k’): 
The capacity factor of the column was calculated using the formula 
k’= (TrT0)/T0 
Where T0 being the initial retention time (solvent front), Tr being the retention time of the 
analyte (salbutamol sulphate in this study) 
 
- Tailing factor: 
Tailing factor was calculated by using the below formula 
T= W/2F 
Where W is the width of the peak, F is the flow rate (ml/min) 
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- Number of theoretical plates:  
Number of theoretical plates was calculated by using the below formula 
N= 5.54[Tr/W0.5]2 
Where Tr is the retention time of the analyte, W0.5 is half the peak width 
 
3.3.5 Linearity 
The linearity of the method is verified to establish a proportional relationship of response 
versus salbutamol concentration over the working range. The calibration curve was constructed 
and linearity was verified between inter and intra-day, all experiments were carried out in 
triplicate. 
The peak area of each drug was plotted against the concentration to obtain the calibration graph. 
The eight concentrations were subjected to regression analysis to calculate calibration equation 
and correlation coefficients (Fig.3.6). The equation of the regression line formula is: 
   y = 3157.2 + 132.54 
 
With correlation coefficient r2 = 0.99904. The regression analysis indicated that there was an 





Figure 3.6 Calibration curve of salbutamol sulphate 
 
 
The inter-day precision is defined as relative standard deviation (RSD) calculated from the 
values measured from three samples at SS concentrations of 0.25, 0.5, 1, 2.5, 5, 10, 20 and 25 
mg/mL, respectively, in three different days. The calculated inter-day precision (RSD) values 
ranged from 2.56 % to 6.6 % indicated that the HPLC method is accurate for measurement of 
SS concentrations.  
 
3.3.6 Precision 
The precision is the measure of degree of repeatability of an analytical method under normal 
operation and it is expressed in relative standard deviation. The relative standard deviation of 
obtained in an experiment should be less than 1%. For salbutamol sulphate the developed 
method shows high degree of precision with relative standard deviation below 1% (n=6). 
Statistical significance was evaluated using One-way Anova, there was no significant 
difference (P<0.05), found in both the method. From these results, the developed method shows 



















































-0.30 3.40 3.41 3.40 3.40 3.40 3.41 3.40 0.00 0.09 
0.00 3.70 3.70 3.71 3.71 3.71 3.70 3.70 0.00 0.04 
0.40 4.09 4.09 4.09 4.09 4.09 4.09 4.09 0.00 0.02 
0.70 4.40 4.40 4.40 4.40 4.40 4.40 4.40 0.00 0.01 
1.00 4.70 4.70 4.70 4.70 4.70 4.70 4.70 0.00 0.01 
1.30 5.00 5.00 5.00 5.00 5.00 5.00 5.00 0.00 0.00 
1.40 5.09 5.09 5.09 5.09 5.09 5.09 5.09 0.00 0.01 
 
3.3.7 Accuracy 
The accuracy describes the closeness between the true values by the proposed analytical 
method. The Accuracy of the developed method was studied by adding a known amount of 
drug (10 mg) to the placebo formulation (30 mg of lactose). Accuracy studies were performed 
in the range of 500 ng/ml to 25 µg/ml; all experiments were carried out in triplicate. For all 
concentrations, RSD were calculated and statistical significance was tested using one-way 
ANOVA.  
Accuracy of an analytical method is the closeness of test results obtained by the method to the 
true value. Accuracy is assessed by analysing the sample of known concentration and 
comparing it with measured true value. Seven different concentrations were used for accuracy 
test in a linear range. In both the methods recovery was found to be 99% with relative standard 
deviation below 1% confirms that the method is accurate and can be used to quantify analyte 
accurately within the specified range. Statistical significance was evaluated using One-way 










Table 3.2 Accuracy test Salbutamol Sulphate 
Number of 
Samples(n=7) 
% Recovery SD RSD % 
1 98.42 0.70 0.71 
2 99.41 0.86 0.87 
3 98.85 0.19 0.19 
4 99.72 0.03 0.03 
5 100.70 0.10 0.10 
6 100.71 0.01 0.01 
7 98.25 0.14 0.15 
Mean recovery =99.44% RSD = 0.29% 
 
 
3.3.8 Limit of detection (LOD) and limit of quantification (LOQ) 
The limit of quantification (LOQ) and limit of detection (LOD) were calculated for salbutamol 
sulphate.  Three calibration runs were performed in triplicate and calibration curves were 
constructed using the least square method. The relative residual standard deviation of the y 
intercepts (δ) and the slope of the regression lines (S) was calculated from the calibration 





Limit of detection (LOD) is the lowest limit of the analyte that can be detected above the base 
line noise; typically, three times the noise level S/N =3.3. LOQ is defined as the lowest amount 
of the analyte which can be quantified accurately above the baseline noise i.e S/N=10.  
In the current study, LOD and LOQ were calculated using the relative standard deviation 
obtained from the calibration curve. The LOD and LOQ for salbutamol sulphate found to be 



























































Study of aerosolisation performance of Untreated Lactose 
and Processed Spray-Dried Lactose formulations using 
Salbutamol Sulphate as a model drug aerosolized from a 
MacHalerÒ into an Andersen Cascade Impactor (ACI) 
and Next Generation Impactor (NGI) at two inhalation 
flow rates (60 and 90 L/min) and at inhaled volumes 1 litre 









The aim of this chapter was to engineer a new lactose carrier, namely Processed Spray-dried 
Lactose (PSDL) for dry powder inhalation aerosol using solid-state crystallization of spray 
dried Lactohale. Commercial Lactohale was used as a control in this study and was fractioned 
so that its size range (63-90 µm) matched that of PSDL. Both lactose carriers namely Lactohale 
and PSDL were characterized using scanning electron microscopy, differential scanning 
calorimetry and X-ray powder diffraction. Each of these carriers was then blended separately 
with micronized salbutamol sulphate in a drug to carrier ratio of 1:67.5 (w/w). The 
homogeneity of each formulation was assessed by measuring drug content uniformity of SS 
using a validated HPLC method. The SS drug deposition profiles were determined using an 
Andersen Cascade Impactor and Next Generation Impactor after aerosolisation at different 
maximum inhalation flow rates (MIFs: 60 and 90 L/min) and inhaled volumes (Vin: 1 L and 




Most dry powder formulations comprise lactose as a coarse carrier. α-lactose monohydrate has 
been used most commonly and it is usually fractionated to 63-90 µm (Timsina et al., 1994). 
The carrier particles are usually large particles with a good flow to ensure a proper filling of 
the powder formulation containing a consistent dose of the API into the dose cavity (i.e., 
capsule, blister compartment) or DPI reservoir, but also emitting a consistent dose during 
inhalation and to provide efficient emptying of the device using patient inhalation maneuver.  
When the patient inhales, the drug particles must be detached from the carrier and be dispersed 
into the airstream to be able to reach the lungs. The drug particles are generally present in low 
concentration, with a drug to carrier ratio of 1:67.5 w/w  
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The large carrier particles provide good flow to the powder formulation leading to an 
improvement in drug consistency when filling capsules and aerosolisation from an inhaler 
device (S.P Newman, 2002). The carrier is an important component in DPI formulations and 
any changes in the morphological features of the carrier particles such as particle size (Larhrib 
et al., 1999; Zeng et al., 2001a), particle surface roughness, particle shape (Larhrib et al., 2003; 
Larhrib et al., 1999; Zeng et al., 2000), crystallinity (Kawashima et al., 1998b; Zeng et al., 
2001b) can have an impact on drug deposition. Several studies have reported an increase in the 
respirable dose of SS when delivered from DPI formulations comprising engineered lactose 
particles. For example, smoothing out the carrier surface irregularities by means of 
crystallization from solutions (Larhrib et al., 2003; Zeng et al., 2000) has resulted in an 
improvement in the amount of respirable fraction of SS. Particle smoothness was found to be 
a crucial factor in a study where two lactose grades of distinct morphological features, 
anhydrous and granulated lactose, were formulated with budesonide. The formulation with 
anhydrous lactose which had a smooth surface, gave a better drug delivery than the granulated 
lactose which had a rough surface (Heng et al., 2000). 
A study of five different grades of lactose for use as a carrier for SS in DPI formulations showed 
that the grade of lactose had a great effect on the performance of the DPI formulation and drug 
delivery in-vitro. Anhydrous lactose provided more effective drug delivery when compared to 
the other grades of lactose (Larhrib et al., 1999). Kaialy et al. (2011) reported that SS 
formulated with recrystallized needle-shaped mannitol gave a fine particle fraction of 46% in 
comparison to commercial mannitol formulation. The addition of fine lactose particles to fill 
the active sites on the surfaces of coarse lactose particles has been shown to improve the 
dispersion and de-aggregation of SS (Zeng et al., 1998). 
Current methods of engineering DPI carrier particles such as lactose (Zeng et al., 2000) or 
mannitol (Kaialy et al., 2011) use crystallization/precipitation from solution followed by 
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harvesting the crystals and drying. Crystallization from solution is unpredictable, firstly 
crystals may or may not form depending on the additives used, the nature of solvent(s) present 
in the crystallization medium, the size and shape of the crystallization vessel, stirring rate, 
stirring element and the temperature. Secondly the crystal shape, size and surface texture could 
not be predicted prior starting the crystallization process; furthermore, the harvested crystals 
are usually not uniform, product loss during the multistage processing sequence and batch to 
batch variation are not unusual causing problems in downstream processing and product 
uniformity.  Crystallization from solution remains the process of choice for particles formation 
but has limited scope in particle engineering and design. Therefore, there is a need to provide 
a reliable crystallization method to form crystals with the desired shape, particle size, surface 
texture and crystallinity. All of which have been shown to affect the powder flow, drug content 
uniformity, physicochemical stability and drug deposition.  
Spherical shape is desirable in many pharmaceutical solid dosage forms such as tablets, 
capsules, enteric coated granules/ pellets. Particles with spherical shape were useful in 
producing good flow, thus providing consistent filling of die cavity of the tableting machine 
and hence consistent dosing, in addition to reproducible drug release from pellets due to the 
uniformity of shape of the spherical particles. There are techniques available for producing 
spherical shaped particles such as spray drying, but the latter produces highly cohesive powder 
with some amorphous content hindering the stability and performance of the pharmaceutical 
product. The aim of this chapter was to overcome the above challenges by producing crystalline 
spherical shaped carrier lactose particles using a solid-state crystallization of spray dried 
lactose. The characterization of the engineered carrier and drug deposition will be carried out 
as discussed in the aim of the study. 
The standard pharmacopoeial in-vitro methods for determining the aerosol aerodynamic 
particle size distribution from a DPI suggest using multistage cascade impactors such as the 
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ACI and NGI. These methods involve simulating a maximum inhalation flow rate (MIF) 
equivalent to a pressure drop of 4 kPa and an inhaled volume (Vin) of 4 L using a vacuum 
pump to emit a dose and collect it into the impactors (Council of Europe, 2014; United States 
Pharmacopeia, 2014). Humans are not able to replicate the square wave profile generated by a 
vacuum pump and the majority of patients are not able to achieve the pharmacopoeia 
recommended inhaled volume of 4 L (Chrystyn et al., 2015), thus making the in-vitro and in-
vivo correlation between the impactor and clinical study difficult to achieve. Therefore, it is 
more appropriate to use an inhalation flow rate and volume when using an inertial impactor 
that a patient can achieve when using his inhaler device in real life. MacHaler® is a low 
resistance device with a specific resistance similar to the Onbrez Breezhaler® and many COPD 
patients were able to achieve a high inhalation flow from the latter and for this reason we 
carried out the SS deposition study using 60 and 90 L/min. ACI and NGI are routinely used for 
testing DPIs, the difference in their internal dead volumes ACI (1.155 L); NGI (2.025 L) can 
impact on the fractioning of the aerosol bolus emitted from an inhaler. The inhaled volume we 
choose for this work were 1 L and 2 L because the clinical study showed that 2 L is achievable 
by most of the asthmatic and COPD patients. This volume may be sufficient to pull the aerosol 
bolus to distal stages of the ACI and may not be sufficient for the NGI. Therefore, an 
investigation on the impact of the inhaled volume at 60 and 90 L/min on SS drug deposition 
from Lactohale® and engineered carrier will be carried out using ACI and NGI. 







4.2 Material and Methods  
 
4.2.1 Chemicals and solvents  
Salbutamol Sulphate was obtained from GSK (UK). Hexane sulfonic acid; glacial acetic acid; 
methanol (HPLC grade) and absolute ethanol were purchased from Fischer Scientific (UK). 
Lactose was obtained from DFE Pharma (UK).  The water was ultra-purified. 
 
4.2.2 Production of spray-dried particles  
Microparticles of lactohale were prepared by spray drying. A pre-calculated amount of 
lactohale was solubilized in water to obtain lactose concentration of 10% (w/v). Then the 
solution was spray dried using a laboratory scale spray dryer (Labplant SD-06, UK) with the 
following conditions: inlet temperature at 180 °C, solution feed rate at 4 rpm. The product was 
collected from the collecting chamber and transferred into a glass jar before storage in a 
desiccator before use. 
 
4.2.3 Preparation of Processed Spray dried Lactohale 
100 ml of absolute ethanol (Fisher, UK) was poured into a 600mL glass beaker and allowed to 
boil using a hot plate. This work was carried out in the fume-hood. 10g of spray-dried lactose 
particles were introduced to the boiling solvent under stirring for 30 secs at 250 rpm. The 
beaker was then removed and the content was passed through 500µm sieve into a collecting 
pan. The 500µm sieve was used to remove large agglomerates. The suspension recovered in 
the collecting pan was dispersed using a cool air generated by a hair drier. The cool air was 
preferred to the hot air in order not to affect the physicochemical stability of the particles such 
as polymorphic transformation, etc. This step was followed by drying in a ventilated oven at 
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45°C for 48 hours. The particles were easily removed from the collecting pan and stored in a 
clean glass jar until required. 
 
4.2.4 Preparation of coarse Lactohale 
The 63-90µm particle size fraction of lactohale was obtained by sieving. Approximately 50g 
of Lactohale was passed through a test sieve with an aperture width of 90 µm (Endecotts, UK) 
for 10 mins and the sieved powder fraction was then passed through a 63µm sieve for another 
10 mins. The powder was then collected from the 63µm sieve and stored in a sealed jar until 
required for further use. 
 
4.2.5 Characterisation of particle shape and size using scanning electron microscopy 
(SEM) 
SEM was used to investigate the particle size, shape and surface structure of the lactose carriers 
used in the formulations. The lactose particles were mounted on an aluminium stub on which 
a double-sided carbon adhesive tape (Agar Scientific, UK) was first placed and after removing 
the protective covering, a few particles were scattered on the tape. The particles were then 
coated with gold for one minute using a Quorum SC7620 ion sputter coater (Quorum 
Technologies Ltd., UK) under vacuum of 0.09 mbar and a current of 40mA. Images were then 
obtained by a Jeol 6060LV SM scanning electron microscope (JEOL, Japan). 
 
4.2.6 Characterisation of Salbutamol Sulphate and lactose carriers using thermal 
analysis techniques 
Differential scanning calorimetry (DSC) was used to determine the crystal form of SS and 
lactose carriers. The experiment was carried out using a Mettler TA 4000 (Mettler, Toledo). 
Approximately 5mg of each sample was weighed into an aluminium pan (40µl) (Mettler AT 
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260 delta range weighing balance) and the lid was crimped into place. The samples were then 
heated from 25 to 250ºC at a heating rate of 10ºC per minute. The DSC was continuously 
flushed with nitrogen at a flow rate of 50ml/min. 
Thermal gravimetric analysis (TGA) was carried out using a Mettler TA 4000 thermal analysis 
system, with a TG 50 thermo-balance. The sample of SS (10mg) was weighed into an 
aluminium crucible and placed into the furnace. The sample was heated from 25 to 250 ºC at a 
heating rate of 10 ºC min-1. The weight change with temperature was recorded and analysed 
with Mettler GraphWare software. 
 
4.2.7 Solid State Characterization of both lactose carriers using X-Ray Powder 
Diffraction (XRPD) 
Single crystal XRD data was used to assess the crystallinity of lactose crystals. In this work, 
the surface forces can be predicted based on such data. Powder X-ray diffraction patterns were 
recorded after samples were spread uniformly over the sample holder using a  D8 Advance 
powder X-Ray diffractometer with Cu Kαl radiation of λ = 1.54Å. (Bruker AXS ). The voltage 
and current applied were 40 kV and 40 mA respectively. The sample powder was packed into 
the rotation sample holder and scanned in the 2θ range 5° to 40°. Lactose particles’ 
morphologies were identified by comparing the characteristic 2θ peaks (“fingerprints”) of the 
XRD pattern. 
 
4.2.8 Blending lactose carrier particles with Salbutamol Sulphate 
Salbutamol Sulphate was mixed separately with lactohale and processed spray dried lactose in 
a ratio of 1:67.5, w/w in accordance with the ratio employed in the commercial ‘Ventolin®’ 
formulations. Thus, salbutamol sulphate was weighed into a 15 mL vial which was followed 
by the addition of one spatula full of lactohale crystals. The powder blend was mixed manually 
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with a spatula. More lactose particles (similar to the amount of the blend) were added to the 
vial and the blend was mixed manually. This process was repeated until all the lactose (2.70 g) 
had been added into the salbutamol sulphate/lactose blend to obtain a ratio of drug to carrier of 
1:67.5, w/w. The same process was done with salbutamol sulphate and processed spray dried 
lactose. The stoppered vials were then placed in a Turbula mixer and mixed for 30 min. Finally, 
the samples were stored in a vacuum desiccator over silica gel until required. 
Hard gelatine capsules (size 3) were filled with 27.4mg (corresponding to the mass of the 
powder blend needed for the filling of 100 capsules) of the powder mixture so that each of the 
capsules contained 400µg salbutamol sulphate. The filling of capsules was completed 
manually. 
 
4.2.9 Measurement of the homogeneity of the mixtures 
Nine samples were taken randomly from each blend. The sample (approximately 27.4 mg) was 
weighed accurately and the amount of salbutamol sulphate was measured by HPLC. The 
coefficient of variation in the drug content was used to evaluate the homogeneity of the 
mixtures. 
 
4.2.10  HPLC analysis of Salbutamol Sulphate 
A mixture of methanol: 10mM of hexane sulfonic acid was used as the mobile phase in the 
ratio of 30:70 v/v. Hexane sulfonic acid was used as an ion pairing agent to mask the ionized 
secondary amine group and to improve the retention of salbutamol sulphate on the stationary 
phase of the HPLC column.  




4.2.11 Deposition test of Salbutamol sulphate 
Salbutamol Sulphate was emitted from MacHaler device  using an Andersen Cascade Impactor 
(see Section 3.2.2 for set-up and method) 
 
 
4.3.  Results and discussion 
 
4.3.1 Morphological characterization of SS and lactose particles by SEM 
Filling of DPI capsules and deposition of the drug in the lung is influenced by the quality of 
the carrier particles used in DPI formulations. Lactose is widely used for inhalation due to its 
safety, good physico-chemical stability, it acts as a marker after the aerosolisation of the dose 
that it has been taken by the patient and as lactose is a disaccharide it leaves a sweet taste in 
the mouth. Lactose is widely used as an excipient in solid dosage forms (capsules, tablets). It 
is widely recognized and accepted by all regulatory authorities as being safe and ideal to be 
used as a carrier for DPIs. In most DPI formulations, the lactose carrier is the most important 
in term of quantity and drug to carrier ratio of 1:67.5 is been typical. According to a large 
number of studies mentioned in the introduction part of this chapter, any changes in the lactose 
morphological features can have an effect on drug deposition performance from DPIs (Kaialy 
et al., 2011). 
Lactose is available in various grades, particles sizes, shapes, polymorphic forms and surface 
properties and batch to batch variation is not unusual. Drug deposition from DPIs is generally 
considered poor with about 12–40% of the emitted dose is delivered to the lungs and 20–25% 
of the drug remains within the device (Labiris & Dolovich, 2003). A lot of effort has been 
made by researchers to manipulate lactose carrier, drug particles or the formulation as a 
whole to improve drug delivery to the lungs.  
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Such modifications include: altering carrier particle shape through crystallisation of lactose 
from solution to form needle-shaped lactose (Larhrib et al., 2003); smoothing out lactose 
surface irregularities by crystallising lactose in the presence of Carbopol gel (Zeng et al., 2000); 
adding a ternary agent to the formulation to cover the active sites of lactose (Colombo et al., 
2012; Grosvenor & Staniforth, 1996; Tee et al., 2000; Zeng et al., 1998) such ternary 
components include fine lactose, magnesium stereate, L-leucine.  
It is known that the attractive forces between drug and carrier particles can be influenced by 
shape, size of the carrier, surface texture and crystallinity (Mullins et al., 1992; Crowder et al., 
2001). 
Scanning electron micrographs of micronized salbutamol sulphate particles and Lactohale, 
spray-dried lactose (SDL) and PSDL are shown in Figure 4.1. 
 
 




   
                (b) Lactohale 
    
     (c) Spray-dried Lactohale 
   
(d) Processed Spray-dried Lactohale 
Figure 4.1. Scanning electron micrographs of SS (a); Lactohale (b); spray dried lactose(c) 
and processed spray dried Lactohale (d) 
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From the visual examination of the SE micrographs, SS was observed to be elongated with a 
size range between 1 to 5 µm as shown from the scale bar on the SS micrograph (Figure 4.1(a)). 
SS was donated by GSK Ware, UK and has a Volumetric Median Diameter (VMD) value of 
2.4 µm suggesting its suitability for inhalation.  
Lactohale showed a tomahawk shape with some surface roughness (Figure 4.1(b)) and this is 
in accordance with the literature (Larhrib et al., 1999). On the other hand, the spray-dried 
Lactohale particles are spherical with a smooth and fractured surface as shown in Figure 4.1(c).  
 
Spray drying is a single-step process used to yield dry and potentially respirable dry powder 
formulations suitable for inhalation. It offers control over parameters such as particle size and 
morphology, and also provides the choice of incorporating additives in one particle. In spray 
drying, many parameters can be adjusted to design powders suitable for effective delivery to 
the lungs. This process usually provides uniform particles with a geometric mean particle size 
below 10 µm. However, the main problem of spray-drying is the formation of amorphous 
material due to the rapid transition from liquid to solid state. Although the particles are of 
suitable size for inhalation, they are usually cohesive and difficult to disperse into individual 
particles making them to deposit in the upper airways or to stick to the wall of the inhaler 
device. These drawbacks can have a negative impact on the usability of spray-drying as a main 
process of forming particles for inhalation. In this study, we took on board some of the 
advantages of spray-drying such as the spherical shape and the hollowness of the particles 
which have been shown to enhance drug deposition to the lungs (Hassan & Lau, 2010b) and 
we tried to convert the disadvantages of the particles formed by this process into more useful 
particles by reducing the cohesiveness, improving their stability and flowability by processing 
the spray dried particles.  
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The method to produce the processed spray-dried particles is detailed in Section 4.2.3 and the 
resulting particles are shown in SE micrographs in Figure 4.1(d).  
It is clear that the particles have increased in size reaching about 80 µm without deviating from 
spherical shape. Ethanol acted as an inflating agent promoting an increase in the lactose particle 
size. A possible explanation is that the spray-dried lactose particles are polydisperse with some 
very small particles (Figure 4.1(c)) and amorphous as shown from X-ray powder diffraction 
scan (Fig 4.2(a) and 4.2(b)). Although the solubility of lactose in ethanol is limited (0.0111 g 
at 40 °C and 0.027 g at 60 °C per 100 g solution), the small size lactose with high amorphous 
content, in the presence of heat, may have promoted the dissolution of some particles totally 
or partially, thus increasing the concentration of lactose solution into the crystallisation 
medium (ethanol). Therefore, the dissolved lactose can be easily transferred under the influence 
of stirring and heat to the undissolved particles which act as a nucleus for crystal growth. The 
engineered lactose is spherical in shape and crystalline. These properties are desirable to 
produce a stable performant solid dosage form. With regards to inhalation, the engineered 
particles may contribute to improved flow of the DPI formulation and to a better drug delivery 
consistency. 
Larger carrier particles are usually used to improve dosing accuracy and to minimise the dose 
variability observed with drug formulations and making manufacturing operations easier to 
handle. (Hamishehkar, 2012). 
The surface properties of the carrier particle can play an important role, as there should be 
sufficient adhesive forces to hold the drug particles to the surface of the carrier particle during 
formulation, but that force of adhesion should be low enough to enable the dispersion of the 
drug in the respiratory tract (Zeng et al., 2000; Zhou et al., 2012). The rough surface of the 
PSDL particles (Figure 4.1(d)) will contribute to the stability of the powder blend against 
segregation. 
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Differences can be observed between the surface textures of all lactose grades. Spray dried 
lactose exhibited a smooth surface compared to the processed spray dried lactose which 
appeared to show a rougher surface texture. The literature provides contradictory data on the 
effect of surface roughness and the aerosolisation performance of DPI formulations. For 
example, Kaialy et al showed that a better DPI performance was observed when the 
formulation contained more irregular particles with rougher surfaces, as the carrier particles 
exhibited smaller adhesion forces with salbutamol sulphate, as opposed to commercial lactose 
particles. (Kaialy et al., 2011). In contrast, Flament et al., demonstrated that the rougher the 
lactose particles, the lower the FPF as rough particles have more contacts points with the drug, 
thus allowing a greater adherence of the terbutaline sulphate to the carrier particles (Flament 
et al., 2004). 
In a general aspect, the engineering process provided a method of producing suitable sized 
carrier particles, with a rougher surface while retaining the spherical shape of the spray-dried 
material which could potentially enhance drug deposition into deep lungs. 
 
4.3.2 Characterization of the polymorphic forms of SS and lactose particles by thermal 
analysis 
 





Figure 4.2b. X-Ray Diffraction pattern of Salbutamol Sulphate 
Figure 4.2. Thermal analysis on Salbutamol sulphate: Differential Scanning Calorimetry 
thermogram of Salbutamol Sulphate (4.2a), X-Ray Diffraction pattern of Salbutamol Sulphate 
(4.2b) 
 
On heating the sample (Figure 4.2a), no events occurred until around 153°C after which an 
endothermic peak was seen to start. This sharp peak had an extrapolated onset temperature of 
189.15 ± 0.13 °C. The endothermic transition peaked at 196.67 ± 0.25 °C. This transition 
corresponds to the melting of Salbutamol Sulphate (Corrigan et al., 2006; Kauppinen et al., 
2010). The offset of this initial endothermic peak overlapped with a broader endothermic event 
which in turn overlapped with a third endothermic event. These latter two endothermic events 
had peak temperatures at around 265 °C and 289 °C, respectively. However, a study carried 
out by Larhrib et al. (2003) suggested that the transition that was thought to correspond to 
melting of SS showed no transition from solid to liquid when SS sample was heated and 
observed under optical microscopy. The transition was suggested to correspond to the 










0 10 20 30 40 50
103  
was carried out on SS to provide a visual representation of the effect of heating the sample and 
these are represented at 10°C intervals from 100°C to 200°C in the pictures below. A final 
picture of the residue is also shown (Fig. 4.3).  
  
   
   
   
Figure 4.3. Hot stage microscopy of Salbutamol sulphate heated from 0 °C 
 to 300°C 
This study confirms that the sharp endothermic transition observed initially in the DSC 
thermogram at around 200 °C does not correspond to melting. Several studies indicated that 
SS melts at around 200°C but hot stage microscopy confirmed that no melting was observed 
but rather SS decomposed at higher temperatures. 
104  
It can be seen that there is no apparent change (from solid to liquid) in the appearance of the 
sample during heating until around 140°C when there is a slight yellowing of the sample. On 
further heating, the extent of discolouration continues until a mid-brown residue is seen at 
around 200°C. No molten phase indicating a melting reaction was observed throughout the 
heating cycle. Above 200°C, the decomposition reaction continued until a black carbonaceous 









Figure 4.7: X-Ray Diffraction patterns of untreated lactose (UL), spray-dried lactose (SDL) 
and processed spray-dried lactose (PSDL) 
 
Lactohale displayed DSC thermogram (Figure 4.4) which is representative of α-lactose 
monohydrate. This was justified by the presence of two typical endothermic transitions (Xian 
Ming Zeng, Pandhal, et al., 2000) 
The first endothermic peak of the Lactohale DSC thermogram (Figure 4.4) at around 148ºC 
corresponds to the loss of water of crystallisation whereas the second endothermic transition 
starting at around 200ºC is due to the melting of α-lactose monohydrate followed by its 
decomposition. A slight deflection from the baseline was observed at around 190 ºC reflecting 
the small amount of amorphous content in the sample. Lactohale exhibited an X-ray Diffraction 
pattern (Figure 4.7) comparable to α-lactose monohydrate (Sebhatu et al., 1994). The presence 
of α-lactose monohydrate was supported by the presence of a peak at a diffraction angle of 
around 13º. 
 
Spray-dried lactose exhibited a deflection of the baseline below 100 ºC suggesting that some 
amount of free water (surface water) was present in the sample. A small endothermic transition 

























size of this transition was much smaller compared to the one in Lactohale sample suggesting 
that the drying phase during the spray-drying process removed most of the water of 
crystallisation, thus rendering the material anhydrous (due to the presence only of small amount 
of water of crystallisation). This transition was followed by an exothermic transition at around 
180ºC which is representative of amorphous content. This non-crystalline portion is 
responsible for the improved compressibility of spray-dried lactose (José et al., 2000). The 
endothermic transition occurring at around 210ºC corresponded to the melting of a-lactose. 
The exothermic transition present in DSC thermogram is in agreement with the XRD data 
suggesting that spray-dried lactose is amorphous. The XRD pattern showed a dispersive scatter 
of X-rays confirming that the material was amorphous.  
 
The processed spray-dried lactose thermogram (Figure 4.6) indicated that the material was 
completely anhydrous. The peak at 210 ºC suggested that the material was a-anhydrous 
lactose. The engineering process helped repair the defects present in the spray-dried lactose. 
One of the advantages resulting from this process was that the product was made to be more 
stable due to its crystallinity being restored. The XRD pattern in Figure 4.7 shows the evidence 
of crystalline peaks. There was a difference in peak intensity between the untreated lactose and 
the processed spray-dried lactose which might reveal a difference in degree of crystallinity. 
The relative degree of crystallinity of different samples of the same crystal form is said to be 
proportional to the ratio of the peak intensity (Zeng et al., 2000). 
The obvious higher peak intensity for untreated lactose could be attributed to a higher 





4.3.3 Homogeneity of the blends 
 
Table 4.1. Drug content uniformity and coefficient of variation (%CV) of SS formulations 
containing either Lactohale or PSDL  
 
Both formulations showed a low coefficient of variation, which were found to be less than 5%. 
This indicates that processing, formulating and order mixing of the binary blend formulation 




4.3.4 MacHaler® resistance to airflow 
 
 
The relationship between pressure drop and flow rate is shown in Figure 4.8. It can be observed 
that this relationship is not linear. The relationship between pressure drop and flow rate can be 
made linear by plotting D𝑃 against flow rate (Figure 4.9). 
 
Table 2. Drug content uniformity and coefficient of variation (%CV) 




 SS- Lactohale 405.32 6.45 1.59 




Figure 4.8 MacHaler® resistance to airflow 
 
 
 Figure 4.9 Relationship between pressure drop and flow rate of MacHaler® 
  
The intrinsic resistance can be determined from the slope of the equation (Dal Negro, 2015). 
The pressure drops at different inhaled flow rates were measured for MacHaler device (Figure 
4.9). DPI devices are categorised into four groups based on their resistance (Dal Negro, 2015). 
Patients with airflow limitation can still achieve a high flow with a low resistance device 
(Buttini et al., 2016). Azouz and Chrystyn (2012) demonstrated that an inhaler device with a 





































high resistance and low flow rate. It is clear that turbulent energy is more related to IFR for the 
MacHaler. Thus, dose delivery would be more dependent on the inspiratory flow. Sufficient 
inspiratory flow should be produced by the patient in order to release the powder and 
deaggregate the dose to generate respirable particles. The relationship between the pressure 
drop and the flow rate is not linear. To attain 4KPa pressure drop across the MacHaler, an 
inhalation flow of 102L/min was required (Figure I). The results suggested that MacHaler is a 
low resistance device and this is in agreement with the published data (Dal Negro, 2015; Laube 
et al., 2011). Therefore, patients can achieve a high inhalation flow from this device. 
Figure 4.8 also showed that inhalation flow below 60 L/min caused only a little change in the 
pressure drop, hence turbulent energy. Above 60 L/min, a small change in the IFR caused a 
significant increase in pressure drop, thus 60 L/min can be considered as a threshold inhalation 
flow to successfully operate this device, suggesting that higher turbulence energy would be 
expected to occur inside the device above that flow rate. That is why flow rates of 60 and 90 






4.3.5 Aerodynamic properties for both formulations: 
Table 4.2. aerodynamic dose emission characteristics obtained from Lactohale-SS 




Figure 4.10 Amounts of SS found in each part of the ACI at 60 L/min, 90 L/min and 1 and 
2L for Lactohale-SS formulation  
Table 4.3 aerodynamic dose emission characteristics obtained from Lactohale-SS 

































Figure 4.11 Amounts of SS found in each part of the NGI at 60 L/min, 90 L/min and 1 and 
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Figure 4.12 Amounts of SS found in each part of the ACI at 60 L/min, 90 L/min and 1 and 
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Figure 4.13 Amounts of SS found in each part of the NGI at 60 L/min, 90 L/min and 1 and 
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4.3.5.1 Comparison between ACI and NGI data with Lactohale-SS formulation  
The aerodynamic dose emission results of SS with Lactohale formulations from ACI and NGI 
are summarised in Tables 4.2 and Table 4.3 and Figures 4.10 and 4.11. For both ACI and NGI, 
as the inhalation flow increased from 60 to 90 L/min, FPD increased significantly (p<0.05) 
while MMAD decreased (p<0.05). Also, irrespective of the inhalation flow for both impactors, 
as the inhaled volume (Vin) increased from 1 to 2 L, the EFPD increased significantly (p<0.05) 
resulting from an increase in the TED and an increased in the aerosol dispersion as suggested 
by the low MMAD values. 
MMAD values ranged from 5.4 and 4.6 for 1L at 60 and 90 L/min respectively for NGI, 
implying that 1L was not sufficient enough to de-aggregate and disperse the drug particles.  
When increasing the Vin to 2L, at both flow rates a significant decrease in MMAD was 
observed (p<0.05) with MMAD values of 2.7 to 1.8 at 60 and 90L/min, respectively with ACI 
and 3.0 to 3.7 at 60 and 90 L/min respectively with NGI, suggesting that the patient should 
inhale for a longer time for more drug particles to be dispersed thus, drug agglomerates were 
broken into fine particles and reach lower stages of the lungs. 
An increase in the inhalation volume promoted capsule and device emptying as shown from 
the decrease in the residual amount (RA) with increasing inhaled volume. This is in agreement 
with the TaskForce report statement (Laube et al., 2011). Furthermore, the increasing the 
inhaled volume would provide the dose emitted from the device with a longer time of flight to 
allow further drug detachment from the surface of the carrier but also dispersion of drug 
aggregates which may have contributed to the EFPD and reduction in MMAD. This result is 
in line with the literature which showed that dose emission from blisters and reservoir-based 
devices can occur at the start of the inhalation manoeuvre, whereas capsule-based devices such 
as MacHaler, require longer inhalation times to empty the capsule and the device (Abadelah et 
al., 2017) 
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LPM is superior or equal to 50% of the nominal dose (Tables 4.2 and 4.3) and was independent 
of the inhaled volume, this is in agreement with the studies carried out by Mohammed et al. 
(2012) and Abadelah et al. (2017).  
Above the threshold in inhalation flow 60 L/min, little change was observed in TED when the 
inhalation flow rate increased from 60 to 90 L/min suggesting that TED reached its maximum 
value at 60 L/min.  
Patients with low lung capacity may need to inhale twice to empty the capsule and device 
(Chrystyn et al., 2015; Laube et al., 2011). It is interesting to note that the highest TED values 
irrespective of the impactor was obtained at the highest inhaled volume coupled with the 
highest inhalation flow rate (90 L/min; 2 L) suggesting that a forceful inhalation coupled with 
deep breath are helpful in maximizing drug delivery to the lungs, as shown from the highest 
FPD values. 
PIF and Vin are important parameters in the patient inhalation manoeuvre. It is clear from this 
study that by coupling a high inhalation flow rate with a high inhalation volume, drug delivery 
to the lungs is maximised as shown from FPD values. 
The amount of drug lost during washing was negligible, almost all the drug was recovered as 
shown by the TRD values. 
 
4.3.5.2 Comparison between ACI and NGI data with PSDL-SS formulation  
The aerodynamic dose emission results of SS with PSDL formulations from ACI and NGI 
summarised in Tables 4.4 and 4.5 and Figures 4.12 and 4.13 respectively. The results showed 
a similar trend to Lactohale formulations deposition data. When using ACI, a significant 
increase (p<0.05) in TED, FPD and FPF was observed as the inhalation flow increased from 
60 to 90 L/min at 1L and 2L while MMAD decreased (p<0.05). Also, irrespective of the 
inhalation flow with both impactors, as the Vin increased from 1 to 2 L, the EFPD increased 
116  
significantly (p<0.05). 
 When using NGI less SS was found in the lowest stages in comparison to the ACI as shown 
in Figures 4.12 and 4.13. ACI and NGI have dissimilar internal dead volumes which are 1.150L 
and 2.025L respectively. When an inhaled volume of 1L was used with the NGI less SS was 
retrieved in the distal stages as shown in Figure 4.13 in comparison to the ACI (Figure 4.12). 
The results suggest that an inhaled volume of 1L was not sufficient to pull the aerosol to deep 
stages of the NGI. These results are in agreement with Mohammed et al. (2012) study which 
showed that 1L was not generating sufficient turbulent airflow within the device to de-
aggregate the powder and to overcome the dead volume of NGI.  
At 60 L/min, there was a significant increase in TED when Vin was increased from 1 to 2L. At 
90 L/min, no significant change was observed for TED when increasing the Vin from 1 to 2 L 
(Table 4.5). The result show that for this type of device, an increase in Vin is important, as there 
is an improvement in FPD and an increase in drug dispersion as suggested by a reduction in 
MMAD (Table 4.5), indicating further de-agglomeration had taken place.  
The total residual amount (TRA) significantly reduced (P<0.05) with increasing Vin suggesting 
that less drug impacted in the upper stages. From this observation, Vin plays an important role 
in maximizing drug delivery in-vitro. 
 
4.3.5.3 Comparison between Lactohale and PSDL  
The emitted dose consistency was calculated as the difference in the emitted dose between high 
volume (2 L) and low volume (1 L). With ACI for example, the difference in the emitted dose 
between 1 L and 2 L inhalation volumes for Lactohale was 13 ±0.18 µg at 60L/min and this 
difference increased to 17 ±0.17 µg at 90 L/min. For engineered lactose, the difference in the 
emitted dose between 1 L and 2 L inhaled volumes was 7 ±0.41 µg and 4 ±0.04 µg for 60 
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L/min and 90 L/min respectively. Thus, engineered lactose showed more consistency in the 
emitted dose compared to Lactohale. This probably was attributed to the difference in the 
morphological features between Lactohale and engineered lactose. The spherical shape and 
uniformity of size of engineered lactose might have contributed to the reproducibility of the 
dose released from the inhaler. With NGI, the variability between low and high inhalation 
volumes for engineered lactose became even smaller (2 ±0.22 µg) and this was observed when 
high inhalation flow rate was used (90 L/min). Although the difference in the emitted dose was 
not significant between 1 L and 2 L inhaled volumes (355.68 ±2.96 µg and 357.58 ±3.18 µg 
respectively) at 90 L/min, there was a huge and significant increase in the FPD from 75.83 
±1.15 µg to 128.05 ±1.63 µg, suggesting that the inhaled volume has contributed to drug 
detachment from the surface of the carrier and pulling the detached aerosol to the deepest stages 
of the impactor. 
Irrespective of the impactors, both Lactohale and engineered lactose showed an increase in the 
FPD with the inhalation flow rate (Tables 4.2, 4.3, 4.4 and 4.5). MacHaler® is a passive device 
relying on an inspiratory effort to deaggregate powder into particles small enough to reach the 
deepest stages of the impactors. DPIs have different resistances so the respiratory flow needed 
to create the pressure drop necessary for optimal delivery differ among DPI devices. For 
example, MacHaler® has a lower resistance than Turbohaler®, Easyhaler® and Handihaler® 
which are 0.110, 0.155 and 0.158 cmH2O)0.5 L/min respectively.  
Engineered lactose benefited more from the increase in the inhaled volume than Lactohale, as 
shown from the difference in the FPD between 1 L and 2 L (Tables 4.2, 4.3, 4.4, 4.5). 
Engineered lactose is hollow and spherical in shape (Figure 4.1.c) and by increasing the 
inhalation volume this may have provided this lactose with a longer time of flight allowing 
drug particles to reach the distal part of the impactors. 
118  
By combining a forceful inhalation with a prolonged inhalation time (inhaled volume) this does 
not only allow an increase in the turbulent energy inside the device but also to provide carrier 
and drug particles with sufficient time of flight to produce drug particles small enough to reach 
the lungs, as shown from the FPD and MMAD values. 
Irrespective of the IFR and Vin for both lactose and impactors the GSD values were higher 
than 1.2 suggesting the polydispersity of the aerosols. 
 
4.4 Conclusion 
This section of work investigated the effect of the lactose carrier particle shape and surface 
smoothness on the deposition of micronized salbutamol sulphate.  The effect of the main 
inhalation manoeuver parameters such as the inhalation flow rate and inhaled volume were also 
investigated. Engineered lactose particles resulting from solid state crystallization were 
produced to have a spherical shape with rougher surface as opposed to the control Lactohale 
which was tomahawk shape and smooth.  
The engineered lactose produced a higher and reproducible salbutamol sulphate emission and 
fine particle dose after aerosolisation via a MacHaler® tested in both ACI and NGI. It was 
concluded that choosing carefully the carrier can enhance the potential inhalable fraction of 
drug from dry powder inhalers, as suggested by the different deposition profiles obtained by 
the two different lactose carrier particles. 
Inhalation flow rate effect has been confirmed in the literature but little has been said with 
regards to the inhaled volume. This study showed that the inhaled volume is equally important 
as IFR with regard to dose emission, de-aggregation of the powder formulation and in 
producing respirable particles for deep lung penetration. 
The results obtained suggested that drug delivery to the lungs can be optimized by using a 
forceful inhalation in combination with a prolonged inhalation time. 
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Inhalation peak flow vary from patient to patient but the threshold inhalation flow as well as 
the inhalation time should be mentioned in the patient information leaflet to ensure that drug 
delivery to the lungs is maximised for the patient. 
This study demonstrated evidence of incomplete mass transfer through NGI at a volume (1 L) 
inferior than the internal dead volume (2.025 L) in contrast to the consistent behaviour of the 
ACI where the mass transfer had taken place normally even when volume (1 L) which is 
slightly lower than the internal volume (1.150 L) was used. 
The effects of factors such additives in DPI formulation on drug delivery from DPIs require 


























The impact of ternary components on the dose emission 




















Most commercialised DPI products are commonly formulated using a single excipient 
platform based on a micronised drug substance with an aerodynamic particle diameter of 1 to 
5µm and a single excipient which is generally a-lactose monohydrate. Lactose acts as a bulking 
agent, thus improving handling, dispensing and metering of the drug. Lactose carrier forms the 
large proportion of DPI formulation, therefore any subtle changes in the carrier particles 
morphological features such as particle size, shape and surface texture will affect the powder 
flowability, dosing accuracy and aerodynamic dose emission characteristics of the inhaled 
aerosol (Larhrib et al., 2003; Larhrib et al., 1999). Therefore, careful selection of lactose carrier 
with the desired morphological features is a crucial determinant for the overall performance of 
DPIs.  
Attempts were made to improve the dispersibility of cohesive drug particles by adding 
additives that modify the interparticle forces. This technique has been used by several 
researchers to improve drug dispersion during aerosolisation in DPI formulation without 
altering the particle size of the coarse carrier, for example, the mixing of fine carrier particles 
with a coarse carrier enhanced drug deposition of Salmeterol Xinafoate (Islam et al., 2004), 
salbutamol sulphate (Tee et al., 2000), and Beclomethasone Dipropionate (Zeng et al., 2000) 
in the corresponding DPI formulation powder blends. The fine carrier may be a different 
material from that which comprises the coarse carrier particles. Reducing sugars (glucose) and 
non-reducing sugars (mannitol and sorbitol) were used to facilitate DPI aerosolisation (Steckel 
& Bolzen, 2004; Tee et al., 2000; Zeng et al., 1998; Zhou et al., 2013). In addition, other ternary 
components have been also included to enhance DPI performance such as L-leucine ( Chew et 
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al., 2005) and Magnesium Stearate (Begat et al., 2004; Grosvenor & Staniforth, 1996; Islam, 
et al., 2004a; Kumon et al., 2006; Young et al., 2005). Magnesium Stearate was effective in 
improving flowability and dispersibility of powder blends (Zhou et al., 2010). Most ternary 
components used so far such as L-leucine, fine sugars and Magnesium Stearate (Hazare & 
Menon, 2009) are fine powders that can reach the lungs when inhaling the formulation, 
furthermore they are exogenous to the lungs and can be harmful. Parlati et al., (2009) prepared 
drug solutions with sodium stearate for spray drying and observed micelle formation when this 
excipient was added in amounts >1%. Amount slightly over >1% exceed the Critical Micelle 
Concentration (CMC) for this salt, this might happen locally in the lungs with Magnesium 
Stearate when it exceeds its CMC. The risks of such nanoparticles micelles are still widely 
unknown. Other researchers opted for the modification of lactose carrier morphological 
features by modifying lactose surface using crystallization from solution with or without 
additives such as carbopol (Larhrib et al., 2003; Zeng et al., 2000). The shape modification of 
lactose was also considered as an option to improve drug deposition by engineering elongated 
lactose in the form of needle shaped particles (Larhrib et al., 2003). 
Drug deposition was improved compared to commercial lactose but drug content uniformity 
was poor due to poor flow of needle lactose. Co-crystallisation of lactose-mannitol was also 
considered as an approach to enhance inhalation performance of DPI formulations (Kaialy et 
al., 2012). Crystallisation from solution has many deficiencies including little control of 
particle size, shape and surface morphologies. Good fluidity is one of the main requirements 
for commercial production of a particulate solid into tablet or inhaled solid dosage forms.  
Spray drying technique is one of the methods to prepare spherical particles. This 
process produces particles with narrow size distribution and is also easy to scale-up for 
commercial production (Pilcer et al., 2012). However, there is still one major disadvantage for 
spray-drying, such as, production of amorphous material which is physically unstable and the 
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transformation of amorphous powder to crystalline is a quick process especially in high 
humidity condition. To improve the spray dried powder characteristics, we processed spray 
dried lactose particles in the presence of hot ethanol to produce crystalline spherical large 
particles.  
 Surface modifiers (such as polyvinylpyrrolidone (PVP), cellulose derivatives, lecithin) 
can be added in DPI formulations after spray-drying particles to prevent agglomeration of the 
particles. PVP is a hydrophilic non-ionic polymer that has been extensively used in the 
formulation of pharmaceuticals. The predominant use of PVP is as a binder in the production 
of granules and tablets, however it is also used as a polymer coating for granules and tablets, 
as solubiliser in oral and parenteral formulations and a viscosity modifying agent in topical 
formulations (Thakur et al., 2016). It has excellent aqueous solubility but is also freely soluble 
in alcoholic solvents such as ethanol (S. A. Jones, Martin, & Brown, 2004). PVP and NaCl are 
known to be safe and widely used in various pharmaceutical applications: NaCl is used as a 
nasal spray, as ophthalmic solutions, in osmotic pumps, in control release. 
The inhalation device and the formulation together constitute the DPI. It is important 
to consider the compatibility between the formulation and the device when developing 
inhalation products in order to achieve good pharmaceutical performance and to improve 
patient compliance. DPIs usually rely on the patient’s inspiration to deliver the drug, however, 
this can become an issue for the patient if the activation of the DPI is flow-rate dependent. For 
example, a study showed that increasing the flow rate from 30 to 60 L/min led to almost double 
the emitted dose and fine particle mass with Turbuhaler® (Bagherisadeghi et al., 2015). The 
literature acknowledges the importance of the acceleration of the flow and the pressure change 
with regards to the de-aggregation of the DPI formulation because the drug is mostly emitted 
in the first part of an inhalation (Azouz et al., 2015). Manufacturers do not report the threshold 
at which the inhaler device will be the most efficient, this would make it easier for GPs to 
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assess whether patients will be able to use a certain device or not. On the other hand, the 
importance of the inhalation volume has not been clearly reported in the literature. The 
inhalation volume has to be sufficient enough for the dose to be emptied from the device and 
also for the drug particles to reach the airways. The volume required varies with different DPI 
inhalers: some need higher volumes to empty the dose than others. This is due to the difference 
in the design of the devices: the inhalation channel in each device has a different length and 
volume. The inhaled volume required for low resistance devices tend to be higher (Azouz et 
al., 2015), therefore it would be expected for MacHaler® to require a high inhalation volume 
for maximum delivery of the dose.  
The recommended method to obtain the aerodynamic characteristics of the emitted dose 
is to perform measurements using a pressure drop of 4 kPa and an inhaled volume of 4 L 
(United States Pharmacopeia, 2014; European Pharmacopeia, 2013). It has been reported in 
the literature that capsule-based DPI inhalers require 4 L to totally empty the dose (Amirav, 
Newhouse, & Mansour, 2005; Azouz et al., 2015). This volume is unrealistic from a clinical 
point of view as some studies have shown that most of the patients were not able to achieve 
more than 2L (Azouz & Chrystyn, 2012; Buttini et al., 2016). The inhalation manoeuvres when 
patients use DPIs are different depending on the patient: the inhalation characteristics of 
children with asthma are lower than those of adults and a bit lower than those of COPD patients. 
The sampling volume may rise issues to whether we are using ACI or NGI because of their 
difference in internal dead volume: 1.155 L and 2.025 L respectively (Copley et al., 2005). The 
sampling time should be sufficient enough to overcome the internal dead volume of the 
impactor and enable most of the dose to be emitted from the device and capsule. This is why 





The aim of this chapter was to co-spray dry lactose with additives namely, either Sodium 
Chloride (NaCl) or Polyvinylpyrrolidone (PVP) to produce small spherical amorphous 
particles. Processing said-spherical particles in the presence of hot ethanol that acts as both as 
an inflating agent to produce large crystalline spherical particles but also as a surface texture 
modifying agent, the engineered particles were named Processed Spray Dried Lactose (PSDL). 
The second aim was to characterize the particles using various techniques such as scanning 
electron microscopy, X-Ray Powder Diffraction and Differential Scanning Calorimetry. The 
third aim was to formulate separately each lactose carrier (sieved lactose (63-90 µm), PSDL-
PVP and PSDL-NaCl) with a model drug micronised Salbutamol Sulphate with a volume mean 
diameter of 2.4 µm (GSK, Ware, UK). Andersen Cascade Impactor and Next Generation 
Impactor have different internal dead volumes of 1.150 L and 2.025 L respectively, therefore, 
NGI may require larger sampling time than ACI and this may affect the aerosol distribution 
within the impactors. The fourth and the last aim of this chapter was to investigate the 
deposition of SS profile from a MacHaler® with each carrier using two inertial impactors (NGI 












5.2.1 Chemicals and solvents  
 
Salbutamol Sulphate was obtained from GSK (UK). Hexane sulfonic acid; glacial acetic acid; 
methanol (HPLC grade) and absolute ethanol were purchased from Fischer Scientific (UK). 
Lactose was obtained from DFE Pharma (UK).  The water was ultra-purified. 
 
5.2.2 Production of spray-dried particles  
Microparticles of Lactohale and PVP or NaCl were prepared by co-spray drying. Pre-calculated 
amount of Lactohale was solubilised in water to obtain lactose concentration of 10% (w/v). 1% 
of PVP or NaCl w/w was added.  Then the solution was spray dried using a laboratory scale 
spray dryer (Labplant SD-06, UK) with the following conditions: inlet temperature at 180 °C, 
solution feed rate at 4 rpm. The product was collected from the collecting chamber and 
transferred into a glass jar before stored in desiccator before use. 
 
      5.2.3 Preparation of Processed Spray dried lactohale 
Spray-dried particles were then further processed to obtain Processed Spray dried particles (See 
Section 4.2.3 for method) 
 
     5.2.4 Preparation of coarse lactohale 
Lactohale was used as a control. The particle size range was 63-90µm (See section 4.2.4 for 
method)  
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       5.2.5 Characterisation of particle shape and size using scanning electron microscopy 
(SEM) 
The shape, size and surface texture of Lactohale and PSDL particles were assessed using 
Scanning Electron Microscopy (See Section 4.2.5 for method). 
 
      5.2.6 Characterisation of lactose carriers using differential scanning calorimetry 
Differential Scanning Calorimetry (DSC) was used to determine the crystal form of PSDL-
PVP and PSDL-NaCl lactose carriers. The experiment was carried out using a Mettler TA 4000  
(Mettler, Toledo). Approximately 5mg of each sample was weighed into an aluminium pan 
(40µl) (Mettler AT 260 delta range weighing balance) and the lid was crimped into place. The 
samples were then heated from 25 to 250ºC at a heating rate of 10ºC per minute. The DSC was 
continuously flushed with nitrogen at a flow rate of 50ml/min. 
 
5.2.7 Solid State Characterization of lactose carriers using X-Ray Powder 
Diffraction (XRPD) 
The crystallinity of the carrier particles was assessed using X-Ray diffraction (See section 4.2.7 
for method). 
 
5.2.8 Blending lactose carrier particles with salbutamol sulphate 
Salbutamol sulphate was mixed separately with PSDL-PVP and PSDL-NaCl in a ratio of 
1:67.5, w/w in accordance with the ratio employed in the commercial ‘Ventolin®’ formulations. 
Thus, salbutamol sulphate was weighed into a 15 ml vial which was followed by the addition 
of one spatula full of PSDL-PVP crystals. The powder blend was mixed manually with a 
spatula. More lactose particles (similar to the amount of the blend) were added to the vial and 
the blend was mixed manually. This process was repeated until all the PSDL-PVP particles 
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(2.70 g) had been added into the salbutamol sulphate/lactose blend to obtain a ratio of drug to 
carrier of 1:67.5, w/w. The same process was done with salbutamol sulphate and PSDL-NaCl. 
The stoppered vials were then placed in a Turbula mixer and mixed for 30 min. Finally, the 
samples were stored in a vacuum desiccator over silica gel until required. 
Hard gelatine capsules (size 3) were filled with 27.4 mg of the powder mixture so that each 
capsule contained 400 µg salbutamol sulphate. The filling of capsules was completed manually. 
5.2.9 Measurement of the homogeneity of the mixtures 
Nine samples were taken randomly from each blend. The sample (approximately 27.4 mg) was 
weighed accurately and the amount of salbutamol sulphate was measured by HPLC. The 

















5.3 Results and discussion: 
5.3.1 Particle shape and surface texture of lactose 
 
        




         
Fig 5.1 (B) PSDL-NaCl                          Fig 5.1 (C) PSDL-NaCl  
Figure 5.1 Scanning Electron Microscopy images of (A) Spray Dried Lactohale with NaCl, 





      5.2(A) SDL-PVP              
 
     
5.2(B) PSDL-PVP-         5.2(C)- PSDL-PVP  
 
Figure 5.2 Scanning Electron Microscopy Images of (A) Spray Dried Lactohale with PVP, 
(B-C) close views of PSDL-PVP 
 
Solid phase crystallisation of co-spray dried lactose-NaCl and lactose-PVP with ethanol 
produced particles with larger size without changing their spherical shape. Before 
crystallisation, spray-dried particles were less than 10 µm (Figures 5.1A and 5.2A) with a 
smooth surface. Crystallisation of particles in the presence of ethanol produced large particles 
with different surface roughness, depending on the additive. 
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PSDL-NaCl (Figure 5.1C) appeared to be rougher than PSDL-PVP (Figure 5.2C). Thus, the 
increase in the particle size with the change in surface texture indicates that lactose particles 
have undergone some crystallization during the treatment with ethanol. On contact with 
ethanol, some of the lactose molecules may have dissolved in the ethanol until a saturated 
solution was formed. Such an ethanolic solution will contain some lactose, although lactose is 
practically insoluble in ethanol. The solubility could have been enhanced by the presence of 
amorphous regions in the spray-dried lactose particles, as shown in X-ray diffraction pattern 
(Figures 5.6 and 5.8). 
The dissolved lactose molecules can then be transferred onto the surface of lactose inducing 
crystal growth, encouraging particle size increase and correcting surface defects produced 
during spray-drying. 
Regions with higher energy such as amorphous regions are more likely to dissolve than those 
with low energy, thus some of the amorphous regions will diminish or disappear giving place 
to the formation of crystalline regions (Figures 5.7 and 5.9). 
This process of crystallisation used in this thesis is reliable as the particles produced are 
spherical, irrespective of the type of additive and its solubility in the non-solvent. Surface 
textures can be modified to produce particles of different surface rugosity and different degrees 









5.3.2 Characterization of lactose particles by DSC and XRPD 
 
 
Figure 5.4. DSC thermograph of PSDL-NaCl 
 
 
Figure 5.5. DSC thermograph of PSDL-PVP 
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Figure 5.6. X-Ray diffraction pattern of SDL-NaCl 
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Figure 5.8. X-Ray diffraction pattern of SDL-PVP 
      
Figure 5.9. X-Ray diffraction pattern of PSDL-PVP 
 
SDL thermogram exhibited three endothermic transitions and an exothermic one. The first 
transition was a large broad endothermic transition that corresponds to the loss of free water 
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transition at around 120 °C corresponds to the loss of bound water. A strong exothermic 
transition peaking at around 180 °C suggested the presence of amorphous lactose in the sample, 
this transition was followed by a sharp endothermic transition corresponding to the melting of 
α-lactose peaking at around 210 °C. 
SDL-PVP showed a similar trend to SDL. 
On the other hand, PSDL only displayed one endothermic transition at around 210 °C which 
corresponded to the melting of α-lactose.  
PSDL-PVP thermogram (Figure 5.5) showed three endothermic transitions. The first one 
occurred at about 135°C followed by two other endothermic transitions around 220°C and 
230°C. The first small endothermic transition corresponds to the loss of bound water, the 
second transition corresponds to the melting of α-lactose whereas the third endothermic 
transition corresponds to the melting of β-lactose. 
SDL with or without PVP produced amorphous material with α-lactose form dominating. 
However, there is a great difference between PSDL and PSDL-PVP. Only the α- form was 
apparent in PSDL and both α and β were present in PSDL-PVP (Figure 5.5) with proportions 
of β form dominating the most. 
Both SDL-NaCl (Figure 5.3) and PSDL-NaCl crystallise (Figure 5.4) in α- form. PSDL-NaCl 
produced a sharper melting peak compared to SDL-NaCl. 
The recrystallisation process used in this study enabled the removal of any free water and any 
amorphous content as suggested by the loss of the exothermic transition that occurred around 






5.3.3 Aerodynamic dose emission results  
Table 5.1. SS dose emissions from NGI at 60 L/min at 1L and 2L for SS-PSDL-NaCl and 
SS-PSDL-PVP from MacHaler®. 
 
 
Table 5.2. SS dose emissions from ACI at 60 L/min at 1L and 2L for SS-PSDL-NaCl and 
SS-PSDL-PVP from MacHaler®. 
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Impact of the inhaled volume: 
The inhaled volume is a crucial parameter as it can govern the quality of the emitted 
dose (Abadelah et al., 2018). Inconsistent emitted dose can affect the clinical response (too 
much drug can cause toxic effects and not enough dose can cause suboptimal treatment) and 
side effects (Abdelrahim et al., 2010). For dose emission testing, it is recommended by the 
Pharmacopoeia to use a Vin of 4 L, however most patients with asthma or COPD are usually 
able to inhale at around 2L  (Abadelah et al., 2017) and some patients (children and very severe-
case patients) are only able to generate even lower volumes. Additionally, depending on the 
inhaler device used, dose emission can occur either at the beginning of the inhalation 
manoeuver (for devices with reservoir or blister based device) or occurs during a more 
prolonged inspiration (single-dose capsule based devices) (Chrystyn, 2009; Laube et al., 2011).  
The aerodynamic characteristics of the emitted dose of SS from MacHaler® was 
measured at two inhalation volumes 1 litre and 2 litres using both NGI and ACI Tables 5.1 and 
5.2 for both formulations PSDL-NaCl and PSDL-PVP.  NGI results (Table 5.1) showed that 
increasing the Vin from 1 L to 2 L resulted in a significant decrease (p<0.05) in the amount of 
SS in the inhaler device, MP, pre-separator, USP throat and stage 1 whilst the amount of SS in 
stages 2 to 6 has significantly increased. Consequently, resulting in a decrease in the RA left 
in the inhaler device and an increase in the aerodynamic characteristics of inhaled SS such as 
TED, FPD, %FPF and EFPD but it should be noted that the MMAD has significantly decreased 
(Table 5.1) with increasing the inhaled volume. MacHaler® is a low resistance based device 
and would require a prolonged inhalation time to empty most of the capsule as shown from the 
results of the RA left in the inhaler at 1 L and 2 L inhaled volume for both formulations.  The 
TED has also significantly increased with the inhaled volume which is in agreement with the 
literature Chrystyn, 2009; Laube et al., 2011, Azouz et al., 2015; Abdelrahim et al., 2010; 
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Abadelah et al., 2018). Thus, patients with who are unable to generate sufficient inhaled 
volume are encouraged to inhale more than once from the inhaler to empty the capsule.  
It is generally, recognised that dose emission characteristics from breath activated 
devices such MacHaler® are associated with inhalation flow rate dependency, the present 
results suggest that MacHaler® depends also on the inhaled volume. An increase in the inhaled 
volume from 1 L to 2 L has led to a better device and capsule emptying as shown from the 
decrease in the total residual amount (TRA). Of the TED, only a fraction of the drug should 
reach the distal parts of the impactor as a FPD containing particles of clinical relevance smaller 
than 5 µm and the great majority would deposit as LPM and/or in the proximal stages of the 
impactor. In real life, the drug particles depositing as LPM are swallowed and do not reach the 
lungs and providing no therapeutic benefits. Our results showed that a great portion of LPM 
was converted into FPD smaller than 5 µm when the inhaled volume was increased from 1 L 
to 2 L (Tables 5.1 and 5.2). MacHaler was capable of producing particles with an MMAD 
smaller than 5 µm (Tables 5.1 and 5.2). An MMAD < 5 µm is considered to be necessary for 
sufficient airway deposition (Abadelah et al., 2017). The results shown in Tables 5.1 and 5.2 
suggest that inhaled formulation from a MacHaler® should reach the lungs using the present 
conditions (60 L/min and at least 1 L inhaled volume).  An increase in the inhaled volume 
would have provided particles with sufficient time of flight causing further de-aggregation and 
dispersion of drug particles in the emitted dose as demonstrated by the shift towards much 
smaller particles as shown from the MMAD and EFPD (Tables 5.1 and 5.2). 
 
Impact of formulation: 
Dry powder formulations have attracted interest in the last decade due to their several 
advantages over other pulmonary drug delivery platforms. The main goal is to achieve dosing 
accuracy, minimising dose variability and high pulmonary drug deposition. The carrier is an 
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important component in the DPI formulation and the ratio of drug to carrier (1:67.5%) w/w 
being typical according to Ventolin formulation and this ratio of drug to carrier was used by 
several authors as a reference in formulating DPIs (Larhrib et al., 2003; Larhrib et al., 1999; X 
Zeng et al., 2001a). Since lactose forms the major proportion in the DPI formulation, any 
changes in the physico-chemical properties of the carrier can affect the drug deposition profile 
(Larhrib, Martin, Marriott, et al., 2003). Unsatisfactory drug detachment from the surface of 
the carrier due to strong inter-particulate forces between drug and carrier may be one of the 
main reasons of inefficient drug delivery encountered with most DPIs ( Zeng et al., 2001a). 
Adjusted balance between adhesive and cohesive forces to provide sufficient adhesion of drug 
to carrier producing a long lasting and stable mix with good drug content uniformity and no 
segregation yet allows for an easy drug detachment from the surface of the carrier during the 
inhalation manoeuvre. It has been stated that the efficiency of a DPI formulation is extremely 
dependent on the carrier characteristics and the selection of the carrier is a determinant factor 
of the overall DPI performance (Pilcer et al., 2012). 
It can be seen that the DPI formulations PSDL-NaCl and PSDL-PVP differ in their SS 
drug deposition profiles (Tables 5.1 and 5.2) when aerosolised under the same conditions. The 
TRD of SS from all PSDL formulations were in the range of 347.21 ± 3.15 µg to 405.28 ± 2.97 
µg (Tables 5.1 and 5.2), these values fall within the acceptable range of 75%-125% of the 
nominal dose (USP 29, 2006). The satisfactory TRD values for both PSDL indicate that the 
overall procedures of mixing, sampling, capsule filling, aerosolisation, washing and analysing 
the drug were accurate and reproducible. At any inhaled volume and irrespective of the 
impactor used, the TED of SS for PSDL-NaCl were significantly higher (p<0.05) than PSDL-
PVP (Tables 5.1 and 5.2). When using the same device, such as the case in this study, TED is 
mainly governed by powder flow. PSDL-NaCl and PSDL-PVP are both spherical in shape but 
they differ in their surface texture (Figures 5.1C and 5.2C) with PSDL-NaCl rougher and 
140  
appears to be more porous than PSDL-PVP. This may have imported some aerodynamicity to 
the particles compared to non-porous particles, facilitating particle emptying from the device 
and capsule. The TRA was more or less the same especially with the ACI.   
To achieve both a good device and capsule emptying, high drug emission and high drug 
deposition, the surface characteristics of the carrier is important. Higher TRD and TED for 
PSDL-NaCl compared to PSDL-PVP indicates that higher amounts of SS is delivered from 
PSDL-NaCl formulation, thus more drug is expected to be available to the patient when 
inhaling through the DPI and deposit in the lungs. Percent recovery varied from 86.8 to 101.3% 
for all formulation suggesting that some drug was lost during the washing procedure but was 
not substantial and acceptable as discussed above in the TRD. 
Both in-vitro and in-vivo deposition studies show that delivered drug fractions in the required 
aerodynamic size fraction from capsule based DPIs with adhesive mixtures are quite low as 
shown in Figure 5.10. 
 
Figure 5.10. In-vitro %FPF of label claim from different DPIs tested at using a next 
generation impactor (with permission from DeBoer et al. (2016)).  
The poor performance of DPIs especially capsule based devices was attributed to the strong 
inter-particulate forces in the adhesive mixtures and to inefficient dispersion of the powder 
formulation by the inhaler device. Formulation powder blends containing PSDL as a carrier 
performed better than most of commercially available DPIs shown in the Figure 5.10. This 
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indicates that employing engineered lactose in DPI formulations instead of commercially 
available lactose carrier would result in a high amount of drug reaching the lungs as shown 
from the %FPF (Tables 5.1 and 5.2). 
Comparing PSDL-NaCl with PSDL-PVP, it is clear that PSDL-NaCl performed better than 
PSDL-PVP as a carrier. Irrespective of the impactor used, the FPD of PSDL-NaCl were greater 
than PSDL-PVP especially at 1 L inhaled volume (Table 5.1 and 5.2) and the difference in 
FPD becomes even smaller by increasing the inhaled volume to 2 L. Several factors may have 
accounted for this, the TED is significantly increased (p<0.05) at 2L so more drug was emitted 
from the inhaler device (Table 1 and 2), secondly the dose emitted from the inhaler was further 
de-aggregated and dispersed in the airstream by prolonging the time of flight of drug particles 
as shown from the MMAD values which were further reduced at 2 L inhaled volume. The 
number of particles smaller than <5 µm as well as the EFPD <3 µm showed a significant 
increase (p<0.05) with inhaled volumes. 
The improved SS drug deposition from PSDL-NaCl can be attributed to the surface texture 
of the PSDL. The solubility of NaCl is much less than that of PVP in ethanol, therefore ethanol 
may have washed away all PVP or great portion of it from the surface of lactose, whereas, the 
poor solubility of NaCl in ethanol has led to the formation of microscopic spikes on the surface 
of spray dried lactose giving some roughness and porosity to lactose particles. Unlike clefts 
and crevices, these microscopic projections did not accommodate the drug particles and instead 
enhanced drug detachment from the lactose surface and improved inhalation efficiency. 
 
Comparison of the impactor used: 
The cascade impactors are designed to operate at a constant flow rate (Mitchell and Nagel, 
2003) and an inhaled volume of 4 L of air is drawn through the DPI to aerosolise the 
formulation. The 4 L inhaled volume should be sufficient to allow the aerosol cloud to reach 
142  
the distal regions of the impactor, thus permitting a complete size fractionation from which the 
aerodynamic particle size distribution can be determined. Both ACI and NGI are used for 
assessing the aerosol performance in-vitro, however, they both differ in their internal dead 
volumes, the latter being 1.155 L for the ACI and 2.025 L for the NGI. The 4 L recommended 
by the Pharmacopoeia exceeds the internal volumes of both impactors, thus allowing sufficient 
time for assessing the DPI performance without bias with either impactor.  
From a clinical point of view, patients with lung impairment as well as geriatric and 
paediatric patients with significantly weaker inspiration may however struggle to achieve the 
4 L inhaled volume recommended by Pharmacopoeia.  Therefore, our study was undertaken to 
compare the ACI performance with NGI in assessing the aerosol performance from SS DPI 
formulations containing PSDL-NaCl and PSDL-PVP using an inhalation flow of 60 L/min and 
an inhaled volume of 1 L and 2L. The experiments were performed with a MacHaler® having 
a low resistance (0.0189 kPa 0.5 L/min) and the inhalation duration is calculated from the 
determined flow rate and the specified inhaled volume for aerosol aerodynamic characteristics 
determination. The flow rate was set to 60 L/min, sampling time was 1 second and 2 seconds 
for 2 L and 4 L inhaled volumes respectively. The effects of changing inhaled volume on % 





Figure 5.11. The %FPF of SS as a function of inhaled volume for PSDL-PVP using NGI 
and ACI. 
 
Figure 5.12. The %FPF of SS as a function of inhaled volume for PSDL-NaCl using NGI 
and ACI. 
 
NGI showed a significant decrease (p<0.05) in the %FPF for both PSDL-PVP and PSDL- 
NaCl when the inhaled volume was reduced to 1 L (Figures 5.11 and 5.12). The 2 L sampling 
































sampling inhaled volume of 1 L is about 50% of the dead internal volume of the NGI would 
therefore not have allowed sufficient time for the aerosolised powder formulation to reach the 
distal regions of the impactor. This explanation is further supported by the marked and 
significant decrease of EFPD (< 3µm) (Figures 5.13 and 5.14) and the corresponding increase 
in the mass of the unsized drug captured in the induction port and the pre-separator of the 
impactor (LPM) when the inhaled volume was reduced to 1 L (Figures 5.15 and 5.16), 
suggesting premature and substantial drug deposition of the emitted dose in the induction port 
and pre-separator of the NGI.  
 
 
Figure 5.13. The EFPD (< 3 µm) of SS as a function of inhaled volume for PSDL-PVP 





















Figure 5.14. The EFPD (< 3 µm) of SS as a function of inhaled volume for PSDL-NaCl 
using NGI and ACI. 
 
 




































Figure 5.16. The LPM of SS as a function of inhaled volume for PSDL-NaCl using NGI 
and ACI. 
 
It is also interesting to note the shift towards a reduction in the SS particles deposition with 
reducing inhaled volume from 2L to 1L for all collection cups beyond stage 1 for PSDL-PVP 
and stage 3 for PSDL-NaCl as shown in Figure 5.17 and Figure 5.18, respectively.  This is 
consistent with the above explanation of %FPF and EFPD suggesting that less aerosol reached 
the distal stages of the NGI when the IV was reduced from 2 L to 1 L. There was also a 
noticeable increase in the SS deposition in the pre-separator for both formulations when the 



















Figure 5.17. Deposition profile of SS from a MacHaler® as a function of inhaled volume 




Figure 5.18. Deposition profile of SS from a MacHaler® as a function of inhaled volume 
after actuation at 60 L/min into an NGI of the DPI formulation containing PSDL-NaCl 
carrier. 
 
The effect of reducing the inhaled volume from 2 L to 1 L for the NGI was accompanied 
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2.80 ± 0.10 µm to 4 ± 0.12 µm for PSDL-PVP and from 2.85 ± 0.06 µm 3.90 ± 0.08 µm for 
PSDL-NaCl (Table 5.1).  The NGI was more sensitive to change in the inhaled volume than 
the PSDL-NaCl (Table 5.1).  The NGI was more sensitive to change in the inhaled volume than 
the ACI as shown in Tables 5.1 and 5.2. The comparison of ACI and NGI was very important 
in-vitro as to ensure the suitability for ACI or NGI for further study. NGI has a higher dead 
volume (2.025 L) and some patients might not be able to achieve volumes of 2 L or above 
(especially when using patient inhalation profiles for COPD patients). Sufficient volume of air 
has to be drawn through the CI (typically 4 L) so that the finest suspended particles have 
sufficient time to pass through the entire system and be fractionated. The minimum volume is 
based on the magnitude of the internal dead volume of the impactor. Recent studies 
(Mohammed et al., 2012) have demonstrated that decreasing the sample volume when using 
the NGI at 60 L/min resulted in a lower FPF value which indicated that the finer particles had 
not enough time to get to the distal stages of the impactor. However, the ACI did not appear to 
be as sensitive, this is believed to be because of a maldistribution of the flow through the ACI 
(Mitchell et al., 2013).  That is why in the next chapters of this work, it was preferred to use 
the ACI which has a lower internal dead volume (1.050 L) and patients could easily achieve 
that volume. Regulatory authorities accept both ACI and NGI however, the data in-vitro might 










The solid phase crystallisation process applied in this work has many advantages compared to 
crystallisation from solution. The shape, size and surface texture cannot be predicted prior 
crystallisation when crystallising from a saturated solution on the other hand the physico-
chemical properties of the additive used in the crystallization medium may slow, inhibit or 
promote crystallization. In addition to the stirring speed, the solvent and its volume, shape of 
the crystallization vessel, temperature can impact on the morphological features of the crystal 
formed. 
The Salbutamol Sulphate dose emissions from the capsule-based MacHaler® device for both 
formulations PSDL-NaCl and PSDL-PVP demonstrated inhalation volume-dependent dose 
emissions. The aerodynamic characteristics of Salbutamol sulphate showed MacHaler® was 
effective in producing respirable particles with an MMAD (<5 µm) irrespective of the 
formulation used, but the mass fraction of particles with an aerodynamic diameter less than 
3 µm was more noticeable at 2 L.  
Finally, the results confirm the recommendation of using a prolonged inhalation time when 























The effect of the carrier morphology and mixing 
time on blend uniformity and drug adhesion in Dry 












Approximately 300 million people worldwide are suffering from asthma and almost 
240 million people are affected by COPD. More than half of the patients opt for the use of dry 
powder inhalers as part of their treatment. DPI devices have shown over the years to deliver 
reliable drug dose to the patient, with constant evolution in their designs focusing on patient 
compliance, low cost and ease of use.  
 From a formulation point of view, DPIs are capable of delivering small and large 
dosage for a wide range of molecules from traditional asthma drugs, antibiotics to proteins and 
oligonucleotides. In particular, delivering biological therapeutics deeper into the lungs for 
systemic delivery offers the most propitious inhalation therapy platform. Drugs for inhalation 
are often cohesive, due to the high specific surface area (surface area-to-mass ratio) of micron-
sized drug particles. Thus, the DPI must be formulated appropriately such that the particles of 
active ingredient can be easily detached from the surface of the carrier and become easily 
dispersed into respirable particles upon inhalation. In most DPIs, micron sized drug particles 
(1-5µm) are adhered to large carrier particles such as lactose via an order mix (Hersey, 1979).  
The energy of powder dispersion is usually derived from the inhalation effort applied 
by the patient. Powders for pulmonary delivery are often cohesive, due to the high specific 
surface area (surface area-to-mass ratio) of micron-sized particles. Thus, the powders must be 
formulated appropriately to firstly facilitate drug detachment from the carrier surface and 
secondly dispersion of drug particles into single particles suitable for deep lung penetration. 
The extent of drug detachment from the surface of the large carrier is largely dependent upon 
the interaction between the two components. Stronger adhesion results in lower amounts of 
drug detaching from carrier particles and is the major cause of low delivery efficiency of drugs 
from most DPIs.  Adhesion forces are mainly composed of van der Waal’s and electrostatic 
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forces (Zimon, 1982).  The adhesives forces between fine particles and coarser carrier particles 
must be strong enough to ensure a good blend homogeneity but on the other hand, the adhesive 
forces should be weak enough to allow drug detachment from the carrier during the inhalation 
manoeuvre to allow the drug to enter the lungs.  Pharmaceutical powders show a tendency to 
gain electrical charges during handling, processing (e.g., mixing, milling, spray drying, 
sieving), transfer of materials from one location to another (Bailey, 1993).  All these processes 
involve high shear forces and can generate electrostatic charges on the powder blends. The 
impact of these electrical charges on powders in pharmaceutical product development is not 
fully understood and remains quite unexplored. Drug particles and pharmaceutical excipients 
can be categorised as electropositive, electronegative or neutral depending on how the powder 
particles charge. Fig .6.1 shows the examples of commonly used pharmaceutical materials and 










Contact electrification occurs when two different materials make contact and then separate, 
resulting in a transfer of charge between them (Harper, 1967). Contact electrification is similar 
to, but distinct to triboelectrification, which occurs when two materials collide or are rubbed 
together, causing a transfer of charge leading up to a build-up of static charge (Dechene & 
Newton, 1987; Yu & Watson, 2001).  The induced charges on the powders may have an effect 
on the flow behaviour, capsule fill uniformity, drug content uniformity and drug-carrier 
detachment on actuation (Yu et al.2008). 
It is known that tribo-charging (or contact charging) of adhesive mixtures in 
pharmaceutical processes, such as sieving, mixing, compression, is influenced by several 
factors such as particle shape (Murtomaa et al., 2004), particle size, electrical properties of 
each component of the formulation, surface properties of the particles such as surface 
roughness (Karner et al., 2014), specific surface area, contact area and frequency, purity of the 
surface and atmospheric conditions (Bailey, 1993; Byron et al., 1995; Kulvanich & Stewart, 
1987). Triboelectrification remains a complex phenomenon, as not all materials are sensitive 
to electrostatic charging at atmospheric conditions and also because triboelectrification can 
only be characterised if the true area of contact is known (Bailey, 1993). The true area of 
contact is influenced by the surface roughness of the particles as well as the contact pressure 
between the particles. Researchers have attempted to modify the contact area between particles 
by altering the surface roughness of carrier particles in order to reduce tribo-electric charging. 
Such modifications can be achieved by crystallising lactose particles to produce different 
surface roughness (Nokhodchi & Martin, 2015). Most pharmaceutical substances are organic 
materials which behave as insulators under ambient conditions. When two dissimilar particles 
make contact, a transfer of electrons occurs between the particles in contact due to the 
difference in their effective work functions (as to equalize the Fermi level energies). The work 
function of a particle is defined as the difference in the energy state between a reference 
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material and the outermost electrons (or Fermi level) of the particle. This difference between 
work functions produce electrostatic charges and it is this adhesion energy, along with electric 
forces (Van der Waals forces, Coulomb interactions and surface tension interactions) which 
must be overcome to ensure free movement of particles in pharmaceutical powders.  
In order to obtain a high mixing homogeneity and stable DPI formulations, it is crucial 
that the drug particles are able to attach to the carrier particle surface during contact. During 
mixing of DPI formulation, particles make repeated contacts with different surfaces, such as 
the surface of other components in the DPI formulation and the metallic or glass surfaces of 
the handling and processing equipment. After each contact, the powder particles charge either 
positively or negatively. The charging behaviour of the particles is highly dependent on the 
charges present on the particles. Such charged particles are subject to high adhesive forces and 
drug particles may adhere strongly to the carrier surface, thus compromising drug-carrier 
particle separation on actuation (Karner et al., 2014). The charges of powder can also affect 
powder flow and dose uniformity. Karner and Urbantez (2013) have reviewed many factors 
affecting the magnitude and polarity of particle charges which include particle size and shape, 
surface roughness, relative humidity and energy of contact.  In general, drug particles tend to 
demonstrate higher levels of charge than excipients (Šupuk et al., 2012). To overcome the high 
adhesive forces, the addition of antistatic agents can be used to make the surface of the material 
slightly conductive (Simpkin et al., 1999). Another approach is, when formulating DPI 
products, the careful selection of the carrier based on the electrical properties of individual 
components in the DPI formulation so that the final formulation can exhibit neutral charge 





6.1.2 Aim  
This chapter was designed to investigate the effects of mixing time on the homogeneity of the 
blend, the dispersion performance of DPI formulations and on the electrostatic charges 
generated during the mixing process of the pharmaceutical materials. Furthermore, it was 
studied if the surface texture of different lactose carriers (smooth Lactohale and rough PSDL 
particles) have an effect on the following parameters: the de-agglomeration of the drug during 
mixing, the effect of drug-carrier adhesion forces and tribo-electrification of lactose carrier and 
drug particles during formulation. For this purpose, the formulations used in this chapter were 
made with different types of drugs (hydrophobic and hydrophilic) and lactose carriers having 
different surface roughness (sieved commercial Lactohale and two types of Processed Spray 
Dried Lactohale (PSDL) with different surface roughness). Each drug: Salbutamol Sulphate, 
Fluticasone Propionate or Beclomethasone Dipropionate, was separately mixed for different 
periods of time with Lactohale or PSDL in a Turbula mixer. The resulting formulations were 
checked for drug content uniformity. Various analytical techniques were used to characterise 
the particles. Scanning Electron Microscopy was used to assess the morphological 
characteristics of the particles qualitatively. XRD was used to assess the crystallinity of the 
materials. The tribo-electrification arising during the mixing of each formulation component 
of the DPI was investigated by measuring the net charges of the different lactose carriers as 
well as the charges of the different drugs using tribo-electrification method detailed in Section 
6.2.3.10 of Chapter 6. The dose emission characteristics of each drug from all DPI formulations 
was determined by aerosolising each formulation from the BreezeHaler® into an Andersen 
cascade impactor (ACI) at an inhalation flow rate corresponding to a pressure drop of 4 kPa at 






v a-lactose monohydrate (Lactohale™, DFE Pharma UK) 
v Salbutamol Sulphate with a VMD of approx. 4.2 µm (GSK, Ware, UK) 
v Fluticasone propionate with a VMD of approx. 4.2 µm (GSK, Ware, UK) 
v Beclomethasone Dipropionate with a VMD of approx. 4.2 µm (GSK, Ware, UK) 
v Absolute ethanol (Fisher Scientific Ltd, UK)  
v Ultra-purified water apparatus (Fisher Scientific Ltd, UK)  
 
6.2.2 General laboratory apparatus and equipment 
v 500 µm, 125µm, 90 µm and 63 µm sieves with collecting pans (Endecott, UK) 
v Hot plate (Cole-Parmer®, UK) 
v 20 ml clear glass vials (Sigma Aldrich, UK) 
v Volumetric flasks, glass beakers (Fischer Scientific Ltd, UK) 
v SD-06 Spray dryer (Labplant, UK) 
v Hair dryer (Revlon, UK) 
v Ventilated oven (Memmert, Germany) 
v Ultrawave U300 benchtop bath (Ultrawave Scienitifc Laboratory Supplies Ltd, UK) 
v Turbula mixer T2F (Willy A. Bachofen AG Maschinenfabrik, Switzerland) 
v Tribo-Electric Charging Device (Šupuk et al., 2009) 
v Scanning Electron Microscope (Jeol, Japan) 
v Differential Scanning Calorimeter (Mettler Toledo, UK) 
v X-Ray Powder Diffractometer (Bruker AXS, UK) 
v High Performance Liquid Chromatography (Shimadzu, UK) 
v Onbreez BreezHaler® device (Novartis Pharmaceuticals UK Ltd) 
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v Hard gelatine capsules, size 3 (Capsugel, France) 
v Andersen Cascade Impactor (Copley, UK) 
 
6.2.3 Methods  
 
6.2.3.1 Preparation of lactohale carrier 
Lactohale was sieved to obtain relatively narrow size distribution (63-90µm) to match 
approximately the particle size of PSDL. About 50g of Lactohale was poured into a 90µm sieve 
which was placed upon a 63 µm sieve. Lactose is known to be brittle, as a result the powder 
was sieved manually and slowly for about 30 minutes so as to limit particle abrasion, breakage 
and tribo-charging which can occur during conventional mechanical sieving. The powder was 
then collected in a sealed glass jar and stored in a desiccator over silica gel until required for 
further investigation. 
 
6.2.3.2 Production of spray-dried particles 
 Microparticles of Lactohale were prepared by spray drying. Pre-determined amount of 
Lactohale was solubilised in ultra-pure water to obtain 10% w/v lactose solution. This lactose 
solution was spray-dried using a laboratory scale spray dryer (SD-06 spray-drier, Labplant, 
UK). The following conditions were used from spray-drying: inlet temperature of 180°C, outlet 
temperature of 102°C, solution feed rate to 4rpm (2ml/min), pressure: (3 bar), 0.5mm nozzle. 
Following spray-drying, the product was recovered from the collecting jar and transferred into 






6.2.3.3 Production of Processed Spray dried lactohale    
100 ml of absolute ethanol (Fisher, UK) was poured into a 600mL glass beaker and transferred 
to the fumehood, where ethanol was allowed to boil using a hot plate (Cole-Parmer®, UK).  A 
pre-determined quantity of spray-dried lactose particles (about 10 g) was introduced to the 
boiling solvent for 10 secs while stirring the lactose suspension at 250 rpm. The beaker was 
then removed from the hot plate using special laboratory gloves (Delta Plus Grey Cut Resistant 
Polyethylene-coated cut resistant gloves, RS, UK). The lactose suspension was poured through 
500µm sieve into a collecting pan to remove any lumps. The recovered processed spray-dried 
lactose suspension was dispersed using a cool air generated by a hair drier to avoid  
polymorphic transformation which can be caused by hot air generated by the hair drier. This 
step was followed by drying in a ventilated oven at 45°C for 48 hours (Memmert, Germany). 
The particles were easily removed from the collecting pan as a free-flowing powder and 
allowed to cool to room temperature for 1 hour before transferring into a clean sealed glass jar 
and stored in a desiccator over the silica gel until required. The particles resulting from this 
batch were named PSDL10.  
The same process was repeated for a second batch however, the spray-dried particles were left 
on contact with boiling ethanol for a longer time (30 s). The particles resulting from this batch 
were named PSDL30. 
 
6.2.3.4 Preparation of powder blends  
 Each drug (SS, FP and BDP, Glaxo Smithkline, Ware, UK) 40 ± 1.45 mg was mixed separately 
with 2.7 g Lactohale and PSDL in a ratio of 1:67.5 w/w, in accordance with the ratio employed 
in the commercial ‘Ventolin®’ formulation so that each capsule contains 400 ± 14.5 µg and 27 
mg lactose. Thus, each drug with a volume mean diameter of 2.4 µm , was weighed into a 20ml 
159  
glass vial to which was added approximately an equivalent amount of lactose carrier either 
lactohale or PSDL and blended manually using microspatula. Then more lactose carrier was 
added similar to the amount of the blend contained in the glass vial and mixed manually using 
the same microspatula. This process was repeated until all the lactose (2.70 g) had been added 
into the drug/lactose blend to obtain a ratio of drug to carrier of 1:67.5, w/w. The same process 
was applied to all formulations irrespective of the drug or carrier. The stoppered vials were 
then placed in a Turbula mixer and mixed for 5 mins, 10 mins, 15 mins and 30 mins. Finally, 
the samples were stored at room temperature (25 ± 2 ºC) in a vacuum desiccator over silica gel 
until required for further investigation. 
Hard gelatine capsules (size 3) were filled with exactly 27.4 ±0.5 mg of the powder mixture so 
that each capsule contained 400 ± 14.5µg of the drug. The filling of capsules was completed 
manually. 
 
6.2.3.5 Measurement of the homogeneity of the mixtures 
 After each mixing time in the Turbula mixer, the drug content uniformity of SS, FP and BDP 
were determined by taking randomly 10 aliquots of approximately 27.4 mg each (3 from the 
top, 3 from the middle, 3 from the bottom and one from anywhere in the blend), Each aliquot 
was poured into a 100ml volumetric flak and made up to the volume with the HPLC washing 
solution acetonitrile: water (75:25 v/v). Each solution was assayed for the drug content using 
a validated HPLC method illustrated in Chapter 3; Section 3.4. The average mean recovery 
related to the nominal dose were calculated and the percentage coefficient of variation (% CV) 




6.2.3.6 Characterisation of particle shape and size using Scanning Electron Microscopy 
(SEM) 
 SEM was used to assess the lactose carriers (lactohale and PSDL) morphological features: 
particle size, shape and surface structure. Double-sided carbon adhesive tape (Agar Scientific, 
UK) was placed on an aluminium stub and after stripping off the upper side of the adhesive, a 
small amount of lactose particles was firstly dispersed on a glass microscope slide to ensure 
uniform particle dispersion before mounting them on the adhesive stub. The particles were then 
coated with approximately 15 to 20 nm gold for one minute using a ion sputter coater (Quorum 
Technologies Ltd., UK) under vacuum of 0.09 mbar and a current of 40mA. Micrograph 
Images were produced by scanning fields, selected randomly at several magnifications with a 
Jeol 6060LV SM Scanning Electron Microscope (JEOL, Japan). 
 
6.2.3.7 Characterisation of lactose carriers using differential scanning calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) was used to determine the crystal form of lactose 
carriers. The experiment was carried out using a Mettler TA 4000 (Mettler, Toledo). 
Approximately 5 mg of each sample was weighed into an aluminium pan (40µl) (Mettler AT 
260 delta range weighing balance) and the lid was crimped into place and the lid of the DSC 
pans reference and sample were pierced with 0.1 mm needle before transferring to measuring 
cell. Introducing the pin hole will avoid the increase in the vapour pressure in the sample which 
can be caused by gas or vapour evolved from the sample. The samples were then heated from 
25 to 250ºC at a heating rate of 10ºC per minute. The DSC was continuously flushed with 




6.2.3.8 Solid State Characterization of lactohale and PSDL using X-Ray Powder 
Diffraction (XRPD) 
 X-Ray powder diffraction was used to assess the crystallinity of lactose crystals. 
Powder X-ray diffraction patterns were recorded after samples were spread uniformly over the 
sample holder using a  D8 Advance powder X-Ray diffractometer with Cu Kαl radiation of λ = 
1.54Å. (Bruker AXS ). The voltage and current applied were 40 kV and 40 mA, respectively. 
The sample powder was packed into the rotation sample holder and scanned in the 2θ range 5° 
to 40°. Lactose particles’ crystallinity were identified by comparing the characteristic 2θ peaks 
(“fingerprints”) of the XRD pattern. 
 
6.2.3.9 Drug quantification using HPLC method 
SS was analysed by HPLC method described in Chapter 3 section 3.4. FP and BDP were 
analysed using HPLC method containing the mobile phase of acetonitrile and water (75: 25) 
v/v. The flow rate of the mobile phase was 1 ml min-1 and UV detection of BDP and FP was at 
230 nm. The HPLC runs for both BDP and FP were run at room temperature but the pressure 
remained the same at 1050 psi. The Shimadzu HPLC system comprised a liquid chromatograph 
(LC-20AT), an auto sampler (SIL-20A), a column oven (CTO-10ASVP), a UV-VIS detector 
(SPD-20A) and an Ascentis RP-Amide column (25 cm x 4.6 mm, 5 µm). The injection volume 
of the sample was 20 µl. The retention times for FP and BDP were 2.8 and 6.5 minutes, 
respectively. 
 
6.2.3.10 Measurement of Triboelectric charges 
The tribo-electric charge to mass ratio (Q/M) of the DPI formulation was determined using an 
electrostatic charge measurement apparatus comprising a Faraday cup, an electrometer and a 
shaking machine (Šupuk et al., 2009). The Faraday cup consists of two concentric cups made 
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of a conducting material. The concentring cups differ in size: the outer cup is larger than the 
inner cup which acts as an electrical shield to prevent impacts of external electric fields. The 
inner cup was connected to an electrometer (Keithley, model 6514, UK), as shown in Fig. 6.2, 
as per the method described by Secker and Chubb, 1984.  
 Each weighed DPI powder (approximately 0.1 g for each run, n=3) was placed in a Retsch 
stainless steel cylindrical container (10 ml) before being shaken in a horizontal direction using 
a shaking machine (Retsch MM 400) for 2 minutes at a vibration frequency of 20 Hertz. The 
measurements were repeated three times. The powder sample was then poured into the Faraday 
cup. The net charge (C) present on the powder particles were measured on the electrometer. 
The mean charge per mass of powder was obtained from three replicate measurements.  
The mean charge values were presented as nano-coulombs (nC) and the mean charge to mass 
ratio (Q/M) of each powder was calculated by dividing the final charge with the final mass of 
the respective powder and was presented as nanoCoulombs/gram (nC/g). The same procedure 
was followed for all DPI formulations.  
The Retsch shaking cylindrical stainless steel container was cleaned thoroughly after each 
measurement with isopropyl alcohol to ensure the removal of any residual particles and 
impurities susceptible to invalidate the results.  The experiment method was carried in a 
controlled environment with an ambient temperature of 20-23 °C and relative humidity (RH) 

































6.3 Results and discussion  
 
6.3.1 Morphological characterisation of lactose carrier particles by SEM 
 
       
6.3a-General view of Lactohale            6.3b- Close view of Lactohale 
 








     
6.4a-General view of Spray Dried Lactohale         6.4b- Close view of Spray Dried Lactohale 
 




        
6.5a-General view of PSDL10            6.5b- Close view of PSDL10 
 
Figure 6.5. SEM micrographs of PSDL10 (General view and close view) 
 
 
                         
6.6a-General view of PSDL30            6.6b- Close view of PSDL30         
 
Figure.6.6 SEM micrographs of PSDL30 (General view and close view) 
 
 
One of the problems that the development of DPIs faces is that drugs that are fine 
enough to deposit in the lung are very difficult to handle, measure and meter on their own. 
Consequently, such drugs have to go through an adhesion or aggregation process, which 
usually involves binding or adhering the drug to lactose carrier. As the material passes through 
the device during inhalation manoeuver, a proportion of the drug de-aggregates to create 
respirable particles. This proportion is typically quite low for BreezHaler®, around 30 % of 
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label claim (De Boer, 2016) with a significant oropharyngeal deposition of the drug because 
most of the drug remains associated with large carrier particles. The de-aggregation process is 
generated by the patient inspiration. 
 The performance of DPI formulations is highly governed by the drug-carrier adhesion 
forces. High adhesive forces between drug and carrier particles can hinder drug detachment 
when the drug is aerosolized, leading to poor drug dispersion (Begat et al., 2004). The literature 
provides contradictory data on the effect of surface roughness and the aerosolisation 
performance of DPI formulations. For example, Kaialy et al showed that a better DPI 
performance was observed when the formulation contained more irregular particles with 
rougher surfaces, as the carrier particles exhibited smaller adhesion forces with salbutamol 
sulphate, as opposed to commercial lactose particles.(Kaialy et al., 2012). In contrast, Flament 
et al., demonstrated that the rougher the lactose particles, the lower the FPF as rough particles 
have more contacts points with the drug, thus allowing a greater adherence of the terbutaline 
sulphate to the carrier particles (Flament et al., 2004).  
Good adherence of the drug to the carrier usually result in a good homogeneity of the 
blend, but can lead to less drug de-aggregation from the carrier during aerosolisation.  
The morphological features of the particles are also known to influence the aerosol 
performance. A study by Zellnitz et al. showed that glass beads with rougher surfaces exhibited 
a higher FPF. This study is in contradiction with the studies from Flament and Kaialy 
mentioned above. All these studies show in fact that in order to have a higher dose of the drug 





  Solid state crystallisation of the spray-dried lactose particles resulted in the formation 
of spherical particles with a rough surface (Figures.6.5 and 6.6) as opposed to Lactohale 
particles that had a tomahawk shape with a smoother surface (Figure. 6.3). The PDSL particles 
can be produced with different surface rugosity without altering size and shape of the particles. 
The time of exposure of spray-dried particles (Figure 6.4) to hot ethanol was a critical factor 
in altering surface rugosity as shown in SE micrographs (Figures 6.5 and 6.6). We processed 
spray dried lactose particles using two exposure times:10 seconds and 30 seconds to produce 
PSDL10 and PSDL30 respectively. The longer the exposure time to ethanol the rougher the 
particles. Therefore, PSDL30 was rougher and more porous than PSDL10. The performance of 
DPIs is greatly influenced by the physical properties of the carrier, particularly their particle 
size, morphology/shape and surface roughness. Because these factors are interdependent, it is 
difficult to completely understand how they individually influence DPI performance (Peng et 
al., 2016). Solid-state crystallisation, has been shown to produce spherical particles with any 
desired size, therefore the impact of particle size on the aerosol performance can be investigated 
independently without interference from any other morphological features such as shape and 
surface roughness. The surface roughness can be adjusted using different exposure times to 
ethanol to produce particles with desired surface rugosity without affecting their shape or size. 
Thus, the impact of surface rugosity on the aerosol performance can also be studied 
interdependently from any other morphological features such as the shape and size.  
Solid state crystallisation was attempted at room temperature under stirring but there was no 
change in the particles growth, the particles collapsed when left for long forming a slurry. 
Increasing the temperature is expected to enhance the solubility of lactose especially very fine 
particles and amorphous regions within lactose, thus reducing the supersaturation of lactose in 
the crystallisation medium. Initially, spray dried particles (10g) were introduced in the 
crystallisation medium and using a solvent in which the solubility of lactose is not substantially 
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affected to maintain the supersaturation of lactose in the crystallisation medium. Undissolved 
lactose would act as a seed for crystal growth. It is important to note that the temperature 
reduces the viscosity of the crystallisation medium, thus facilitating the transfer of the dissolved 
lactose solution onto the lactose seeds for crystal growth. Increasing the time from 10 secs to 
30 secs affected surface texture of the particles forming rough porous spherical particles.  
Pharmaceutical powders are generally divided into three categories; plastic, elastic and brittle. 
Lactose is known to be brittle as shown from its high mean yield pressure derived from Heckel 
plot (Heckel, 1961; Roberts and Rowe, 1985).  During crystal growth, the hollow volume of 
PSDL increases and reaches a maximum volume after which the particles burst to form needles. 
The increase in the hollow volume is dictated by the plasto-elasticity of the material. As the 
growth of the particles progress, the porous structure of the particles facilitates permeation of 
the solvent inside the hollow space, thus causing an increase in the vapour pressure caused by 
the evaporation of the solvent. The vapour pressure built inside the hollow space of the particle 
exerts a radial stress on the shell as shown in the schematic Figure 6.7.  If the radial stress 
exceeds certain limit, the particle will either expand by plastic or elastic deformation or burst 
if fragmenting. Lactose is a fragmenting material and increasing the exposure time of the 
particles to the solvents beyond 30 secs caused them to burst as they could not withstand the 
radial stress applied from inside the particles. The vapour pressure increases in a radial 







Figure 6.7. Schematic figure representing the direction of the radial stress occurring in a 
spherical particle as the vapour pressure inside increases. 
 
Both ethanol and heat acted together as inflating and blowing agents to increase the size of the 
particles but also to modify the particle surface texture to produce light porous particles. The 
PSDL carrier is hollow and porous, therefore lighter than Lactohale and it is expected that 
PSDL particles would have a longer time of flight when inhaled in a DPI to allow more time 















6.3.2 Crystallinity of the lactose particles by XRPD: 
X-ray diffractograms of lactohale, spray-dried lactose, PSDL10 and PSDL30 were recorded and 
displayed in figures 6.8, 6.9, 6.10 and 6.11 respectively. 
 
Figure .6.8 XRD pattern of Lactose monohydrate 
 









Figure. 6.11 XRD pattern of PSDL30 
 
X-Ray powder diffraction is considered to be the most accurate method for the study 
of crystalline structures (Doff, Brownen, & Corrigan, 1986; Hancock & Zografi, 1997). This 
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technique is widely used to study the changes in the crystalline states. The reflections of the 
diffractograms were presented as peaks deviating from the baseline. Crystallinity of materials 
can be assessed by presuming that broad peaks come from amorphous phase and sharp peaks 
arise from crystal phase.  
Lactohale was found to be crystalline with diffraction peaks at 12°; 16° and 19° (Figure 6.8) 
representative of the crystalline form of a-lactose monohydrate (Gombas et al., 2002). The 
principle of spray drying is to disperse drug or excipient solution into very small droplets by 
the atomizer, then rapidly evaporate the solvent in a hot dry medium like hot air to obtain dry 
product of powder. This process produces product with narrow particle size distribution, and 
also is relatively easy to scale up for commercial production (Pilcer et al., 2012). Spray-drying 
lactose rendered lactose amorphous as suggested by the broad diffuse peaks (Figure 6.9). 
Spray-drying is known to produce predominantly amorphous material because the transition 
between the liquid and solid phase is instantaneous, in other words, the rapid drying of the 
lactose solute droplet did not allow sufficient time for lactose to form a crystalline structure,  
this is one of the drawbacks of spray drying because the amorphous particles tend to be highly 
cohesive (Young et al., 2007), have a poor flow  and thermodynamically unstable (Shen et al., 
2010). In order to improve the handling, metering and flow of DPI drugs, coarse carrier 
particles are generally used, however spray-dried lactose particles produced are small (Figure 
6.4), thus not large enough to be used as carrier particles in DPI formulations. The only 
advantage of using spray drying in our study was to produce hollow spherical particles, which 
are considered effective in DPI formulations. This is why a processing method was developed 
to restore the crystallinity of the particles and to modify their surface texture without affecting 
their spherical shape. Processing the spray-dried particles in the presence of ethanol restored 
the crystallinity to lactose particles to form crystalline PSDL particles (Figures. 6.10 and 6.11). 
The relative degree of crystallinity of different samples of the same crystal form is usually 
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proportional to the ratio of the peak intensity (Zeng et al., 2000). It is interesting to note that 
higher peak intensities were observed on PSDL30 diffractogram (Figure 6.11) suggesting that 
PSDL30 was more crystalline than PSDL10. It is clear that prolonging the exposure time to 
ethanol has an impact on the crystallinity of the PSDL particles, since it has been reported that 
the increase in temperature has a linear relationship with the degree of crystallinity of lactose 
particles (Young et al., 2007).  
Operation processes such as sieving, milling, mixing spray-drying and transfer of 
powder involve frequent interactions between each component of the powder formulation, i.e. 
the active ingredient and the excipient. Since triboelectrification is a contact phenomenon and 
pharmaceutical substances are known to gain charges during all the different steps involved in 
the preparation of dosage forms. The acquired charges associated with DPIs have been 
recognised to have a significant impact in adhesion/cohesion (Hiestand, 1966). When the 
patient inhales through a device, the DPI powder blend is fluidized and dispersed; drug 
particles separate from the surface of the carrier particles and charges are usually exchanged 
during this process resulting in net particles charges on the particles, which may affect their 
trajectories and deposition. It is worth mentioning that studies have established a correlation 
between crystallinity and tribo-charging of particles. Wong et al. (2014) found that SS 
crystalline particles acquired more charging during tumbling than amorphous SS. The 
arrangement of SS molecules in the crystal lattice was responsible for the polarity of the charge 
and the charging. This knowledge should be taken into consideration when optimising 
formulations for DPIs as the degree of crystallinity has an effect on the electrostatic charges 





6.3.3 Impact of mixing time on drug content uniformity of SS, FP, BDP in formulations 
containing either lactohale or PSDL as a carrier 
 
 
Table 6.1 Content uniformity of SS, FP and BDP with Lactohale at different mixing times: 5, 







Table 6.2 Content uniformity of SS, FP and BDP with PSDL30 at different mixing times: 5, 





Table 6.3 Content uniformity of SS, FP and BDP with PSDL10 at different mixing times: 5, 




amount(SD) %CV amount(SD) %CV amount	(SD) %CV
5mins 396.78(24.73) 6.23 412.86	(6.57) 1.59 404.48	(4.23) 1.04
10mins 359.54(15.83) 4.4 406.67	(5.79) 1.42 409.85	(25.53) 6.23
15mins 399(13.65) 3.42 414.27(7.31) 1.76 408.66	(37.95) 9.29




amount(SD) %CV amount(SD) %CV amount	(SD) %CV
425.1(15.36) 3.61 407.51	(5.20) 1.28 414.64	(14.79) 3.57
412.37(10.32) 2.5 416.92	(8.36) 2 404.80	(9.57) 2.36
404.45(9.87) 2.44 412.32(9.13) 2.21 408.31	(20.61) 5.05




amount(SD) %CV amount(SD) %CV amount	(SD) %CV
404.76(11.56) 2.85 409.67	(3.40) 0.83 408.81	(14.56) 3.32
405.21(8.63) 2.13 398.16(6.11) 1.53 413.64	(11.91) 2.88
416.29(15.43) 3.71 398.79(6.24) 1.56 403.42	(11.12) 2.75





Various physico-chemical properties of drug substances are affected by their particle 
size distribution and shapes and it is also known to formulation scientists that very fine 
pharmaceutical materials such as fine drug particles used for inhalation are difficult to handle. 
There is a large difference in size between the active component and excipient such as lactose 
used for inhalation; segregation by percolation can occur, making mixing difficult. The most 
appropriate mixing method commonly used for DPIs is order mixing to allow fine drug 
particles to adhere to large carrier particles (63-90 µm) to minimise de-mixing. Not only 
particle size, but also particle shape and surface texture can influence the flow and mixing 
efficiency of powder formulations. Adequate distribution of the drug must be demonstrated 
within the powder blend and also in the final dosage form. The FDA guidelines state that the 
USP criteria for content uniformity is 85-115% (Berman et al., 1995), but the industry standard 
for content uniformity is 90-110% (Muselík et al., 2014). 
In this chapter, the homogeneity of the blends was assessed using the %CV calculated for each 
powder blend containing either SS, FP or BDP, which should be less than 5 % (Kaialy, 2016; 
Larhrib et al., 2003; Zeng et al., 2001a). Homogeneity of the blend is crucial in ensuring that 
the strength of the drug in the DPI formulation is within the acceptable limits and also gives an 
indication of the quality of the blend (Williams et al., 2002).  
Blend uniformity as demonstrated using procedures described in the parenteral drug 
association (PDA, 1997). 10 aliquots of 27.4 ± 1mg each were selected from three different 
depths (3 from the top, 3 from the middle and 3 from the bottom of the blender) and the 10th 
pulled sample was chosen randomly from the blender. The adequacy of the mix is demonstrated 
if the mean is between 90-110% of target and %CV is less than 5% (Kaialy et al., 2012; Larhrib 
et al., 2003; Zeng et al., 2001a). 
Blending uniformity of the binary mixtures varied significantly (p<0.05) with mixing 
times, drug types and the type of carrier (Tables 6.1 and 6.2). The mean drug contents varied 
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between 359.54 ± 15.83 µg and 416.92 ± 8.36 µg for all batches, which are within the 
acceptable limit of 90-110% of the target weight. However, some mixing times showed a % 
CV less than 5%. Of the three drugs investigated, SS produced the poorest drug content 
uniformity with prolonging the mixing time, especially with Lactohale as shown from the 
highest %CV values exceeding 9% (Table 6.1). A short mixing time of 5 minutes provided a 
better repartition of SS particles on the surface of Lactohale as shown from the low %CV of 
0.31%. The morphological features of particles are known to affect the blend uniformity 
(Venables & Wells, 2001). Carrier particles with high elongation ratio are disadvantageous in 
DPI dose metering and processing at handling scale due to their poor flowability (Kaialy et al., 
2011; Larhrib et al., 2003).  
 
Furthermore, smooth carrier particles have a low loading capacity which can promote drug 
segregation especially for high dose drugs. Lactohale has an elongated shape with a smooth 
surface (Figure 6.3), these morphological features may have affected both the adhesion of drug 
to the carrier and the flow of powder inside the Turbula mixer, facilitating segregation between 
drug and carrier particles by prolonging the mixing time.    
Both BDP and FP are hydrophobic and showed a similar variability in drug content with 
prolonged mixing time, as quantified by %CV (Table 6.1), therefore achieved better blend 
uniformity with Lactohale than hydrophilic SS. SS mixes and de-mixes rapidly and this is 
shown also with PSDL (Table 6.2), although the %CV observed with PSDL was smaller than 
with Lactohale (Table 6.2). Hydrophobic drugs such as BDP and FP are highly cohesive and 
require longer time of mixing and high shear forces to break up drug aggregates before 
distributing uniformly on the lactose carrier. Thus, hydrophobic drugs can benefit from 
prolonged mixing times to provide good content uniformity than hydrophilic drugs such as SS 
with either Lactohale or PSDL. 
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 Pollen shaped carrier particles have low density, therefore they are expected to adhere to the  
drug for a longer period of time and increase drug deposition in the lungs (Hassan & Lau, 2011; 
Larhrib et al., 2003). According to Hassan et al. (2011), the use of pollen-shaped carrier 
particles in formulations resulted in increased FPF.  
PSDL was produced to provide pollen-like particles to improve drug content uniformity and to 
facilitate aerosolisation of drug particles. PSDL particles are spherical in shape with rough 
surface and gave the highest homogeneity with a very low coefficient of variation than 



















6.3.4 Impact of mixing process on tribo-charging behaviours of both SS, FP, BDP 




Table 6.4. The average final charge to mass ratios of the formulations after tribo-
electrification 
Formulation Average final charge: mass ratio (nC g-1) 
Lactohale -15.38 ±17.89 
PSDL30 5.39 ± 1.23 
PSDL10 1.06 ± 2.43 
  
SS 102.79 ± 24.67 
FP -34.52 ± 6.59 
BDP -378.77 ± 80.25 
  
Lactohale-SS -25.68 ± 2.60 
PSDL30-SS -19.39 ± 4.88 
PSDL10-SS 1.75 ± 2.02 
  
Lactohale-FP -4.51 ± 0.53 
PSDL30-FP -10.93 ± 4.29 
PSDL10-FP 2.01 ± 6.40 
  
Lactohale-BDP -13.35± 3.96 
PSDL30-BDP -8.49 ± 3.14 
PSDL10-BDP 3.91± 4.27 
  
 
In DPI formulations, electrostatic forces have a great impact on the adhesion between 
drug and carrier particles, consequently affecting the detachment and deposition of drug 
particles (Staniforth, 1995;Bailey, 1993) 
All the individual components that make up the DPI formulation (Carter et al., 1998) and the 
formulation physicochemical properties (Peart, 1996) will have an effect on the charging 
behaviour of the powder formulation. 
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Pharmaceutical processing of materials into dosage forms is usually a multi-step 
process e.g. sieving, milling, spray-drying, mixing, transfer of the powder blend, compaction 
(Lachman & Lin, 1968). DPI formulations inevitably undergo tribo-charging during frequent 
particle-particle physical contacts, particle contacts with the surfaces of the inhaler device, and 
high impact velocities during their use.  
 Triboelectrification occurs when particles surfaces’ make contact and they gain 
electrical charges during this multi-step process. The accumulated charges on the particles 
surface result in ‘de-mixing’ which can compromise the flowability of powder blends. In order 
to investigate the effect of triboelectrification during the mixing process of DPI formulations, 
lactose carriers with different surface morphologies were used: Lactohale, PSDL10 and PSDL30. 
The different components used in the formulations were assessed for electrical 
properties using a Faraday cup coupled to an electrometer and the results are summarised in 
Table 6.4. The specific charge (nC/g) was obtained for each component. The tabulated results 
are represented as a mean and standard deviation of three replicate readings.  
Particles that are less than 5µm have large specific surface area and therefore tend to 
charge very high (Tsai et al., 2006; Grosvenor and Staniforth, 1996). Usually, drugs are known 
to display higher levels of charge than excipients (Šupuk et al., 2012). 
Table 6.4 indicates that different materials have different charging behaviours. The 
results show that lactose monohydrate showed a specific charge of -15.38 C g-1 whereas 
PSDL30 and PSDL10 were positively charged with a specific charge of 5.39 C g-1 and 1.06 C g-
1 respectively. Our XRPD data showed that Lactohale is more crystalline than PSDL10 (Figures 
6.8, 6.10 and 6.11). These results are in agreement with Weng et al. study (2014) and Carter et 
al. (1998) study which showed that amorphous lactose (such as spray dried lactose) exhibited 
lower electrostatic charges than crystalline lactose (Carter et al., 1998). This was further 
confirmed with a study by Murtomaa et al. (2002) which also noticed that the specific charge 
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of lactose decreases as a function of the amorphous content. To correlate this to our study, the 
data shows that PSDL30 charged slightly higher than PSDL10 (5.39 nC/g and 1.06 nC/g 
respectively). XRD patterns of both PSDL10 and PSDL30 (Figs. 6.10 and 6.11) showed that 
PSDL10 was less crystalline and indeed more amorphous than PSDL30 which explained why 
PSDL30 was more charged than PSDL10. Weng et al. (2014) found that crystalline SS acquired 
more charging during tumbling than amorphous SS. The arrangement of SS molecules in the 
crystal lattice was responsible for the polarity of the charge and the charging.  
The crystallinity of particles can affect how the charge is distributed on the surface of 
the particles. For example, electrical charges may distribute much quicker for amorphous 
particles than for crystalline particles. This is due to the mobility of the molecules that can be 
hindered in crystalline particles due to their crystal lattice. Similarly, charge distribution occurs 
more evenly on the surface of spherical amorphous particles, whereas the charges on crystalline 
irregular particles may be mostly distributed on the tips and edges (Figure 2.11) (Zeng et al., 
2001a; 2001b).  
Since charging behaviour is a surface phenomenon, this will eventually influence the 
interactions between drugs and carrier particles and could inherently influence adhesion and 
agglomeration of particles as well as in-vitro drug deposition (Bennett et al., 1999).  
Another possible explanation for this difference in charge could be the specific surface area of 
the particles. Although in this study no experiment was carried out to measure the specific 
surface area of the particles, it is known from the literature that particles of the same size range 
but with different surface textures have different surface areas: for example, particles with a 
rougher surface will result in a larger specific surface area. Such particles will be able to take 
up more tribo-charges until their surface is charge saturated (Karner & Urbanetz, 2013) as 
opposed to smooth particles. As shown in Table 6.3, Lactohale alone or in the formulation with 
SS, FP or BDP always exhibited negative charge. The electronegative charge on Lactohale 
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increased even more when formulated with SS particles, the charge increased from -15.38 nC/g 
for Lactohale alone to -25.68 nC/g when formulated with SS. The addition of SS to the carrier 
particles charged the formulation more negatively, this could be due to de-mixing of the blend, 
which was supported by drug content uniformity data showing an increase in the %CV with 
increasing mixing time.  
The triboelectrification data also showed that SS remains adhered to the wall of the container, 
suggesting de-mixing. A similar phenomenon was observed for PSDL30 where the addition of 
a drug seems to increase the negative charge of the blend (Table 6.3). A different phenomenon 
was observed with PSDL10, where not significant change was observed in the charges 
generated whether PSDL10 was alone or in a formulation (Table 6.3). PSDL10 was the least 
crystalline carrier and acquired the least charge, on the other hand, more crystalline particles 
gained more charges. i.e. were more susceptible to exchange charges which could be attributed 
to a higher difference in work function between Lactohale, PSDL30 and the container. 
PSDL30 was positively charged when on its own but acquired even more negative charge when 
in a powder formulation irrespective of the drug SS, FP or BDP (Table 6.3). It is interesting to 
note that PSDL30 with SS blend was the most negatively charged (Table 6.3). This was also 
reflected in the amount of SS recovered from the walls in PSDL30 formulation (Table 6.4). 
Although PSDL30 acquired charge, the amount of drug recovered off the wall for PSDL30-SS 
formulation was only 9% of the blend. Spherical particles have less contact area with adhering 
surface compared to elongated particles. Lactohale is tomahawk shape and is elongated, 
therefore it is expected to adhere more in comparison to spherical particles such as PSDL. The 
data showed that different grades of lactose exhibit different charging behaviours either alone 
or with different drugs in formulations. Staniforth et al. (1982) showed that contact 
electrification can be used to develop charges on the surfaces of drug and excipients particles. 
Such charges can be optimised to render more stable mixes and reduce the tendency of powder 
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blends to segregate. It is interesting to note that the results obtained in this study showed that 
PSDL10 appeared to have less variation in the charging behaviour of the powder blend, which 
indicates that the morphological features of PSDL10 could potentially be beneficial in DPI 
formulations as an antistatic effect was observed with this type of carrier and a more stable mix 
was observed. Anti-static agents can work by reducing the friction between particles or increase 
the conduction of particle surfaces. 
Therefore, it is possible to select carefully components so that the DPI formulation is not prone 
to high charging.  
 
6.3.5 Assessment of deaggregation of drug particles by measuring drug amounts 





Table 6.5. The average drug content of SS, FP and BDP recovered from the wall of the 
stainless-steel shaker after tribo-charging measurements (n=3) 
 




SS-L 1051.31 13.86 71.9 ±0.95 
SS-PSDL30 135.21 1.27 9.26 ±0.09 
SS-PSDL10 28.56 0.43 1.96 ± 0.03 
   
BDP-L 11.9 2.06 0.8± 0.14 
BDP-PSDL30 1.95 0.26 0.13±0.01 
BDP-PSDL10 24.93 0.42 1.71 ±0.02 
   
FP-L 8.83 2.94 0.6± 0.2 
FP-PSDL30 0.81 0.06 0.05 ±0.0 






A strong correlation was found in the present work as Lactohale-SS with high level of net 
charge required longer mixing time to achieve a good drug content uniformity due to 
segregation (Supuk et al., 2011), (as shown from %CV within SS-L DPI formulation). This 
also correlated to the amount adhered to the surface of the stainless-steel container which 
showed that 71% was adhered to the wall of the stainless-steel shaker (Table 6.5). 
 
Table 6.4 shows the different amounts of drug recovered from the walls of the shaking 
container after tribo-electrification for all DPI formulation, using HPLC. The results showed a 
high amount of SS drug was recovered after shaking the formulation containing SS and 
Lactohale with an average value of 1051.3 ± 13.86 µg corresponding to almost 72% of SS 
recovered from the wall of the shaker. However, the SS amount recovered when shaking with 
the PSDL30 formulation was significantly lower (p<0.05) with an average value of 135.2 ±1.27 
µg and even lower (p<0.05) for PSDL10 formulation with an average of 28.56 ±0.43 µg. 
PSDL10 has a spherical shape and is the least crystalline and exhibited less variations in its 
charging behaviours, also the amount of SS found on the walls when formulated with PSDL10 
was only less than 2% (Table 6.5). This data confirms the tribo-electrification results 
suggesting that SS de-mixes rapidly in Lactohale formulation, this was also observed in the 
drug content uniformity results (Tables 6.1 and 6.2). In comparison, the average BDP content 
recovered from the walls was the lowest with the PSDL30 formulation which was 1.95 ±0.26 
µg. The same trend was perpetuated with FP (Table 6.4). BDP and FP are both hydrophobic 
drugs and the impact of the carrier has less effect, this is also shown from the drug content 
uniformity data (Table 6.1 and Table 6.2). The drug particles found adhered to the wall of the 
shaker could be either the drug alone or the drug attached to the carrier. In the case of Lactohale, 
it is more likely that large portion of the drug could adhere alone to the shaker given its 
tendency to de-mixing. From the drug content uniformity data (Table 6.1), it was observed that 
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de-mixing is easily occurring with SS, on the other hand, Lactohale is crystalline, highly 
charged and is prone to adhere to the wall of the shaker. From Table 6.4, the high recovery of 
the drug from the wall of the container may suggest that high amount of the drug and high 
amount of the carrier are adhering to the wall, not as a blend but separated from each other.  
The drug amounts found on the shaker wall are drug particles that remained attached to the 
surface of the lactose monohydrate carrier particles, in comparison to PSDL carriers which 
possess crevices on the surface in which the drug particles can embed within, as well as a lower 
ability for PSDL on its own to adhere to the walls which in turn reduces the amount of drug 
left within the shaker after inducing to the motion. 
This results from the difference in the surface morphologies and different degrees of 
crystallinities of the carriers. The surface of Lactohale is smooth whereas both PSDL10 and 
PSDL30 are rough (Fig 6.4, 6.5 and 6.6). When comparing Lactohale to PSDL particles, the 
irregularities present on the surface of PSDL particles allow a higher adhesion between drug 
and carrier particles as the drug particles got trapped in the crevices of the PSDL surfaces, 
resulting in a poor drug detachment from the PSDL carrier, as shown in Table 6.5 with the 
lower amounts of drugs recovered from the PSDL formulations, especially PSDL30 which has 
the roughest surface texture. Lactohale showed a better SS drug release from the carrier due to 
its smooth surface. Ganderton’s data (1992) supports this result, as he showed that reducing 
the roughness of particles allowed more drug deposition in the lower stages of the lungs. This 
result is in line with the drug content uniformity results of Lactose-SS formulation which 
showed that SS was prone to segregation with increasing the mixing time (Table 6.1). A 
homogeneous mix was rapidly achieved with SS, prolonging the mixing time had a negative 
impact on the homogeneity of the blend suggesting that there is a weak adhesion between SS 
and Lactohale particles.  
185  
The difference in the degree of crystallinity between all carriers played an important role in the 
different amounts of SS, FP and BDP being recovered from the formulations. Lactohale is the 
most crystalline and PSDL10 is more crystalline than PSDL30 (Figures 6.8, 6.10, 6.11), 
implying that both PSDL carrier particles have more amorphous contents than Lactohale. 
Amorphous materials have higher surface energies which facilitate the adhesion between drug 
and carriers but also prevents the detachment of the drug from the carrier (Saint-Lorant et al., 
2006). This justifies the low amounts of drugs retrieved from PSDL formulations. This finding 
is supported by Saint Lorant et al.’s study (2007) which showed that Lactopress SD 250 which 
was more amorphous than Pearlitol 100 SD, showed a poor drug deposition compared to 
Pearlitol 100 SD.  
The difference in the physicochemical properties of SS, FP and BDP also contributed to the 
differences seen in the blend uniformities. From the literature, SS and Lactose are known to be 
hydrophilic (Harjunen et al., 2003; Berard et al., 2002) whereas FP and BDP are more 
hydrophobic (Harjunen et al., 2003; Zeng et al., 2000). From the results in Table 6.5, it can be 
seen that the content uniformity for both FP and BDP were found to be less than that of SS this 
suggesting that both FP and BDP drug particles were adhering strongly to the carriers. This is 
in line with the drug content uniformity results which showed that of all three APIs, FP was 
the least affected by the mixing time as the %CV varied less with the mixing time (Table 6.1 
and 6.2), followed by BDP. Both these drugs are hydrophobic and showed a different degree 
of adhesion to the carrier compared to SS.  
The data with BDP and FP were found to be conflicting with the results obtained with SS 
regarding tribo-charging, drug content uniformity and deposition performance.  SS is a 
hydrophilic drug whereas BDP and FP are hydrophobic. The extend of de-agglomeration of 
the drug depends on the drug’s physicochemical properties (such as hydrophobicity) thus, a 
direct comparison between hydrophilic and hydrophobic drugs cannot be possible. The 
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literature showed that the cohesion-adhesion balance (CAB) of Fluticasone with a-lactose 
monohydrate is 0.22 (Jones et al., 2008; Hooton et al., 2006). It would be expected to have 
different CAB values depending on the drug used with a-lactose monohydrate. The CAB-value 
of FP was an indication of a great adhesion to Lactose. 
The coarse crystalline Lactohale carrier may have cause higher press-on forces, due to higher 
contact area, than PSDL spherical particles, leading to a stronger adhesion between BDP and 
FP with Lactohale than with spherical particles. Spherical particles would therefore exert less 
press-on forces than elongated particles.  
Both BDP and FP have high CAB-values, they tend to adhere strongly to the carrier. 
Additionally, the drug is more likely to be entrapped in the cavities or valleys of PSDL30 
surface, hindering drug detachment. The difference in deposition between PSDL30 and PSDL10 
is attributed to the difference in their surface topography. PSDL30 is rough and present cavities 
and valleys on its surface where the drug particles are likely to be entrapped, reducing drug 
detachment. 
PSDL10 presented nanoscale surface irregularities. This nanoscale topography may be 
favourable as it provides sufficient adhesion for the drug to the carrier, ensuring a uniform mix 

































2L 4L 2L 4L 2L 4 L
Deposition location
Mouthpiece (MP) 3.18 (0.24) 2.51 (0.36) 5.19 (0.81) 5.22 (0.29) 8.52 (1.65) 16.49 (2.56)
Induction Port (IP) 43.54 (0.46) 41.64 (2.71) 50.01 (1.32) 44.29 (2.90) 132.82 (3.26) 94.77 (2.69)




145.93 139.77 223.39 215.47 243.02 247.61
S-2A 6.17 (0.43) 8.03 (0.89) 7.33 (0.63) 9.32 (0.89) 5.12 (0.62) 8.26 (2.28)
S-1A 3.17 (0.18) 4.96 (0.27) 3.41 (0.99) 3.52 (0.93) 2.32 (0.25) 2.43 (2.65)
S-0 5.37 (0.18) 7.44 (0.27) 4.49 (0.92) 4.24 (0.86) 5.76 (0.45) 3.21 (1.72)
S1 16.35 (0.68) 13.31 (1.22) 12.39 (2.43) 12.53 (2.85) 10.17 (0.46) 14.63 (1.54)
S2 25.50 (0.50) 27.30 (1.41) 17.80 (1.96) 20.11 (4.63) 10.77 (0.05) 15.79 (0.18)
S3 57.76 (1.14) 58.54 (1.47) 36.26 (1.30) 43.70 (3.49) 23.49 (0.18) 28.23 (2.37)
S4 30.59 (1.90) 31.53 (1.91) 14.12 (0.74) 17.19 (3.79) 9.62 (1.00) 11.74 (1.38)
S5 4.85 (0.34) 5.17 (0.81) 1.49 (0.01) 1.75 (0.36) 1.16 (0.10) 3.99 (2.67)
Filter 12.95 (1.09) 9.57 (1.93) 0.74 (0.29) 0.70 (0.34) 0.55 (0.54) 1.79 (1.52)
Fine Particle Dose 




102.69 104.82 49.85 63.34 34.82 (0.8) 45.84 (0.7)
Fine Particle 
Fraction (FPF) 49.11 (2.45) 50.70 (3.05) 26.68 (1.40) 30.50 (2.52) 19.72 (1.4) 23.53 (1.1)
MMAD (um) 1.57 (0.06) 1.60 (0.00) 1.97 (0.06) 1.90 (0.00) 2.1 (0.1) 2.0 (0.1)
GSD 2.30 (0.10) 2.27 (0.06) 2.40 (0.10) 2.47 (0.06) 2.4 (0.0) 2.4 (0.0)
RA caps 10.22 (0.60) 8.22 (2.05) 1.9 (0.45) 1.25 (0.33) 18.66 (2.31) 10.85 (2.01)
RA dev 47.81 (3.72) 44.09 (2.21) 44.6 (2.61) 33.75 (2.24) 34.21 (1.36) 33.67 (1.17)
TRA 58.03 52.31 46.5 35 52.87 44.52
TED 308.66 (3.47) 309.22 (2.97) 321.43 (3.39) 328.52 (3.27) 312.00 (4.7) 337.04 (3.5)














Table 6.8. In vitro deposition results of BDP with Lactohale, PSDL10 and PSDL30 at 2L and 
4L. 
2L 4L 2L 4L 2L 4L
Deposition location
Mouthpiece (MP) 6.57 (0.31) 6.75 (0.78) 17.54 (2.29) 17.87 (0.97) 12.27 (0.78) 17.02 (0.48)
Induction Port (IP) 112.37 (7.61) 90.24 (3.49) 118.19 (3.79) 120.89 (4.74) 116.21 (3.36) 84.49 (2.28)




248.04 243.87 253.63 247.95 223.85 226.63
S-2A 8.79 (0.97) 8.52 (0.51) 6.81 (0,85) 9.32 (0.89) 7.66 (1.32) 8.82 (1.25)
S-1A 3.87 (0.38) 4.54 (0.37) 1.92 (0.21) 3.52 (0.93) 2.98 (0.98) 3.51 (1.12)
S-0 7.54 (0.59) 7.83 (0.39) 2.80 (0.25) 4.24 (0.86) 3.91 (1.45) 4.28 (1.62)
S1 17.43 (0.94) 16.86 (2.94) 7.08 (0.57) 12.53 (2.85) 8.01 (0.21) 16.19 (1.01)
S2 13.56 (0.88) 15.39 (1.43) 10.26 (0.75) 20.11 (1.63) 11.15 (0.20) 11.75 (0.24)
S3 22.19 (1.17) 23.40 (1.45) 23.90 (0.44) 43.70 (2.49) 28.31 (0.48) 29.66 (0.68)
S4 7.21 (0.21) 8.41 (1.14) 12.35 (0.44) 17.19 (1.79) 17.36 (1.01) 19.46 (1.69)
S5 1.28 (0.14) 1.12 (0.08) 1.78 (0.10) 1.75 (0.36) 2.90 (2.12) 2.31 (0.45)
Filter 0.94 (0.06) 2.46 (0.36) 1.14 (0.09) 0.70 (0.34) 1.89 (1.63) 0.95 (0.08)
Fine Particle Dose 




31.63 35.4 37.4 42.5 50.46 (0.7) 52.38 (0.62)
Fine Particle 
Fraction (FPF) 21.20 (0.56) 22.71 (1.61) 18.79 (0.50) 20.71 (0.13) 23.87 (0.8) 26.15 (1.2)
MMAD (um) 2.87 (0.12) 2.67 (0.06) 1.80 (0.00) 1.80 (0.00) 2.3 (0.1) 2.3 (0.12)
GSD 2.00 (0.00) 2.17(0.06) 2.77 (0.12) 2.93 (0.06) 2.4 (0.00) 2.5 (0.00)
RA caps 18.15 (3.15) 26.39 (2.43) 14.96 (0.28) 14.61 (1.80) 17.30 (1.29) 14.49 (2.89)
RA dev 35.47 (2.27) 33.39 (1.44) 47.29 (3.14) 44.24 (4.80) 49.08 (3.18) 11.89 (2.76)
TRA 53.62 59.78 62.25 58.85 66.38 26.38
TED 330.88 (3.64) 332.43 (2.52) 321.67 (2.01) 324.36 (1.76) 308.04 (2.1) 323.57 (2.3)







Impact of inhaled volume on the aerodynamic dose emission characteristics 
The effects of changing lactose carriers on aerodynamic characteristics for BDP, FP and SS 
are shown in Tables 6.6, 6.7 and 6.8 respectively.  
Tables 6.6, 6.7 and 6.8 summarise the parameters used to calculate the deposition profiles of 
SS, BDP and FP in an Andersen Cascade Impactor at 2 L and 4 L.  Table 6.6 showed that TED 
for SS varied between 308.66 ± 3.47 to 337.04 ± 3.3 µg, similarly for FP (Table 6.7) where the 
TED varied between 308.04 ± 2.1 to 332.43 ± 2.52 µg. Finally, TED for BDP (Table 6.8) 
2L 4L 2L 4L 2L 4L
Deposition location
Mouthpiece (MP) 9.36 (0.49) 12.90 (2.61) 4.64 (0.64) 6.49 (0.41) 17.36 (0.03) 17.74 (0.52)
Induction Port (IP) 92.78 (0.56) 53.41 (6.04) 98.12 (1.85) 100.85 (0.26) 131.95 (2.50) 96.53 (2.64)
Pre-separator (PS) 94.34 (5.26) 132.78 (7.06) 129.24 (1.51) 132.65 (5.51) 88.91 (2.84) 133.26 (3.92)
Large Particle Mass 
(LPM)= (MP+IP+PS) 196.48 199.09 232.00 239.9 238.22 247.53
S-2A 6.50 (1.21) 4.59 (1.28) 5.10 (0.20) 5.33 (0.28) 6.37 (0.97) 9.89 (0.87)
S-1A 2.94 (0.26) 3.93 (0.46) 2.67 (0.36) 2.97 (0.30) 2.89 (2.14) 3.99 (1.97)
S-0 4.48 (0.17) 2.67 (0.13) 5.25 (0.34) 6.28 (0.31) 4.23 (1.58) 5.06 (1.20)
S1 11.86 (0.52) 12.60 (0.54) 13.34 (1.37) 14.69 (0.34) 10.34 (0.64) 15.81 (0.16)
S2 12.79 (0.23) 13.65 (0.43) 9.56 (0.93) 11.30 (0.45) 13.26 (0.33) 14.35 (0.30)
S3 19.18 (2.50) 20.09 (1.27) 10.99 (1.81) 13.99 (0.47) 24.68 (1.46) 26.26 (0.75)
S4 5.52 (0.30) 6.57 (0.61) 3.74 (0.42) 4.01 (0.31) 8.44 (3.25) 13.59 (2.98)
S5 0.98 (0.48) 0.63 (0.04) 0.33 (0.06) 0.35 (0.08) 0.19 (2.40) 1.35 (2.90)
Filter 9.86 (0.53) 13.43 (2.71) 11.66 (2.41) 8.77 (1.00) 0.03 (3.98) 1.27 (3.69)
Fine Particle Dose 




33.5 40.73 26.73 27.11 33.35 (0.7) 42.38 (0.80)
Fine Particle 
Fraction (FPF) 23.39 (0.94) 25.12 (1.05) 18.63 (1.41) 19.29 (0.47) 19.82 (1.1) 22.77 (1.40)
MMAD (um) 2.23 (0.12) 1.93 (0.06) 2.70 (0.10) 2.67 (0.06) 1.7 (0.1) 2.3 (0.10)
GSD 2.37 (0.06) 2.27 (0.25) 1.93(0.00) 1.90 (0.02) 2.9 (0.00) 2.70 (0.90)
RA caps 25.23 (2.70) 15.29 (0.79) 18.24 (1.91) 29.44 (1.49) 8.03 (0.41) 15.04 (2.02)
RA dev 44.34 (1.24) 36.34 (2.44) 40.31 (1.25) 50.88 (2.39) 58.99 (2.79) 9.09 (3.56)
TRA 69.57 51.63 58.55 80.32 67.03 (0.7) 23.98 (0.90)
TED 270.32 (2.72) 277.27 (1.56) 294.67 (2.58) 307.69 (2.29) 308.66 (2.5) 340.72 (2.70)





varied between 201.88 ± 2.58 to 340.72 ± 2.70 µg. The extent of variation in dose emission 
was dependent on the active ingredient, the type of carrier and inhaled volume.   
In most cases, TED showed an increase with increasing Vin from 2 L to 4 L.  For capsule-
based DPIs it is recommended to make two separate inhalations for emptying the capsule from 
each dose, as one inhalation may not be sufficient to fully empty the capsule, especially for 
patients with low lung capacity as these patients are not capable of prolonging their inhalation 
time (Laube et al., 2011). This study showed that dose emission increased by increasing the 
Vin from 2 L to 4 L (Tables 6.6, 6.7 and 6.8) 
The TED significantly increased with Vin whilst the TRA, which was calculated as the sum of 
the amounts left in the capsule and device, decreased with increasing Vin from 2 L to 4 L. It is 
interesting to note that the amount left in the capsule was generally much lower than that of the 
device (Tables 6.6, 6.7 and 6.8). The shape of the inhaler device might account for the high 
residual amount left in the device as Onbrez BreezHaler® has a long inhalation channel (Figure 
2.4), which is the distance from the capsule chamber to the end of the mouthpiece. Once the 
capsule is emptied, the particles are more likely to adhere to the walls of the inhaler device 
before reaching the patient’s mouth.  
The FPD, i.e. particles having an aerodynamic diameter less than 5µm, significantly increased 
with increasing Vin from 2 L to 4 L (Tables 6.6, 6.7 and 6.8). A similar observation was noted 
with EFPD, i.e. particles having size less than 2 µm. Because TED increased with the Vin, it 
was expected that a greater portion of that emitted dose would have reached the distal stages 
of the impactor as shown in Tables 6.6, 6.7 and 6.8. Therefore, increasing the Vin would be 
beneficial for capsule-based devices, such as BreezHaler®. Not all patients can achieve a high 
Vin due to the restriction in their lung capacity, in such circumstances they should inhale twice 
from the same dose to ensure capsule emptying (Abadelah et al., 2017). 
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Impact of the carrier on the aerodynamics dose emission characteristics 
This part of the work aimed to study the physicochemical characteristics that influence the 
interactions between the drug and carrier particles and their effect on drug dispersion and 
deposition.  In this study, SS, FP and BDP were blended with either Lactohale or PSDL 
carriers. Drug deposition analysis was based on the influence of the operating conditions (e.g. 
mixing time, triboelectric forces), the morphological features of the carriers (shape, surface 
texture), the properties of the drugs (degree of hydrophobicity) and inhalation manoeuver 
parameter (inhalation volume). 
When developing DPI formulations, it is important to take into consideration two types of inter-
particulate interactions: drug-drug cohesive forces and drug-carrier adhesive forces (Peng et 
al., 2016). The performance of DPIs is fundamentally influenced by the drug-carrier adhesive 
forces since high drug adhesion to the carrier limits drug detachment during aerosolisation, 
thus decrease drug dispersion (Zellnitz et al.,  2013). The carrier is the major component in 
DPI formulations and it is critical to design a carrier with desired morphological features to 
provide sufficient adhesion with drug particles to form a stable mix with good drug content 
uniformity but also to allow drug detachment from its surface during the inhalation manoeuver.  
For these reasons, we designed two lactose carriers (PSDL30 and PSDL10), both spherical in 
shape but with different surface roughness. PSDL30 has a rougher surface than PSDL10 (as 
explained in section 6.3.1).  
Blades and knives in blenders help in introducing more shear force to break up agglomerates. 
Particles which have some projections and surface roughness are usually sharper than smooth 
surfaces and may help de-agglomerating cohesive powders (hydrophobic drug are cohesive 
and tend to agglomerate more). For cohesive powders, high shear mixing technology is 
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advised, scientists focus on the nature of the mixer (high shear mixer or low shear blender) but 
it is also important to take into account the properties of the particles. 
Inter-particles interactions are very important in DPI formulations as they govern drug 
dispersion from carrier particles to allow drug deposition in the lungs. The interactions are 
dependent on the physicochemical properties of all components in the DPI formulation. The 
manufacturing process is also a critical step as the blend homogeneity is important when 
considering the quality of the formulation (FDA, 1998).  
Capsule-based DPIs are generally limited by adhesion of the powder in the capsule and the 
device, which usually result in lower doses of the drug emitted (Vidgren et al., 1988).  
For the first determination with BDP, LPM was almost 50% of the total nominal dose, 
depositing in the MP, IP and PS. This observation is consistent with Mohamad et al. (2012) 
and Abadalah et al. (2017). The LPM remained almost equal or higher than 50% of the nominal 
dose irrespective of the Vin, as both volumes used in this work were higher than ACI’s internal 
dead volume (1.155 L), 2 L and 4 L Vins used in this work provided sufficient inhalation time 
for the aerosol to pass through the entire ACI system. 
Both MP and PS showed no trend with increasing Vin irrespective of the carrier and drugs used 
for all DPI formulations, whereas the amount of the IP generally showed a significant decrease 
with increasing Vin.  
35 to 63 % of the nominal dose was deposited as LPM. The lowest value was observed with 
Lactohale-SS formulation at a Vin of 4 L and the highest was observed for PSDL30-FP 
formulation at 2 L Vin. Up to 50% of the nominal dose was observed with ACI in several 
reports (Mohamad et al., 2012; Abadelah et al., 2017)  
The emission of drug particles from the capsule and the device at 4 L were significantly 
improved when using PSDL10 as a carrier as opposed to using Lactohale particles (Tables 6.6, 
6.7, 6.8). The PSDL10 particles were most effective at emitting the drug particles probably 
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because of their high surface area, which is expected for rough particles. This finding is in line 
with a study of Kawashima et al. 1998, who found that lactose particles with higher surface 
area achieved a higher drug emission and consequently less drug was found in the device and 
capsule (Kawashima et al., 1998a). Additionally, irrespective of the drug used, the total residual 
amount (in capsule + device) significantly (P<0.05) decreased at 4 L when using PSDL10. For 
this type of device, a deep and prolonged inhalation contributed to a reduction in the TRA.  
The inhalation volumes used in this study exceed the internal dead volume of the ACI, which 
is 1.155 L, to allow sufficient sampling time for the aerosol bolus transfer from the Breezhaler® 
device to the lowest stages of the ACI. The ACI data shows the importance of the inhalation 
volume on the aerodynamic characteristics of SS, FP and BDP emitted doses (Tables 6.6, 6.7, 
6.8). 
There was an opposite trend observed between hydrophilic drugs and hydrophobic drugs. This 
trend corroborates with the drug content uniformity results (Tables 6.1 and 6.2) and the drug 
amounts recovered from the walls of the shaker after the tribo-electrification measurements 
(Table 6.5) where high amounts of SS were recovered from the wall of the container with the 
SS formulation with Lactohale as opposed to SS-PSDL10 and SS-PSDL30. The drug content 
uniformity data showed that SS was prone to segregate from Lactohale with higher mixing 
times, i.e. more drug is detached from the smooth Lactohale carrier and available for 
deposition.  
In contrast, FP which was strongly adhered to the carrier (Table 6.4) was then allowed to be 
released from the PSDL carrier when a longer sampling time was generated. The rough surface 
of PSDL allowed a good blend homogeneity, and allowed hydrophobic drug particles to detach 




In this chapter, we discussed a new crystallisation technique from solid state to produce hollow 
spherical particles with defined surface texture. This crystallisation technique can be used to 
repair crystal defects and restore the crystallinity to form stable crystalline powder. 
Furthermore, the final particle size and shape of the particle can greatly depend on the plasto-
elasticity of the material composing the particle. Lactose carriers used in this study were 
characterised in terms of their physicochemical properties, morphological features and 
aerodynamic properties. Lactohale, PSDL10 and PSDL30 contrasted in their characteristics: 
carrier shape (tomahawk/spherical), surface texture (smooth/rough), surface net charges and 
polarities (positively and negatively charged) and degrees of crystallinity. 
In general, the results showed that the content uniformity is affected by the mixing time and is 
different for each type of drug and each carrier. This study made it possible to demonstrate that 
surface modification (surface roughness) of the carrier particles through solid phase 
crystallisation resulted in a dissimilar charging behaviour of the carriers during the mixing of 
the formulation as opposed to Lactohale. The carrier particles with less roughness charged 
significantly higher. This was attributed to the difference in contact area between drug and 
carrier particles as well as particles and the container wall.  
Despite Lactohale and PSDL’s respective formulations presenting good content uniformity, 
Lactohale may be considered as the most favourable carrier when used with hydrophilic drugs 
such as SS as a good content uniformity was achieved with only 5 min of mixing and high 
doses of SS were emitted and deposited from Lactohale-SS formulation. The amount of drug 
quantified from the wall of the shaker from tribo-charging analysis with Lactohale-SS 
formulation was a good indicator of the tendency for SS to segregate from the carrier easily, 
which was also confirmed by the result obtained with the increase of mixing time and the 
deposition data for SS-Lactohale formulations. The positive correlation between the different 
experiments undertaken in this study shows that there is a potential for tribo-electrification 
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study to be used as a screening tool for DPI formulations instead of using the Andersen Cascade 
impactor which would be beneficial for researchers as experiments with the ACI are more time 
consuming and expensive.  
 On the other hand, PSDL10 was considered to be most favourable for hydrophobic drugs where 
its moderate rough surface was ideal for the drug to adhere to and obtain a stable mix with very 
good content uniformity irrespective of the mixing time, but the adhesion was weak enough to 
allow the drug to detach from the carrier during aerosolisation and deposit in the deepest stages 
of the impactor.  
Further optimisation of the PSDL particles should be done and further in-vitro drug deposition 
studies should to be conducted with different combinations of drugs and different types of 
carriers in order to discover a better correlation between the tribo-electrification results and the 
dose emission experiments.  
Such results would allow a better selection of carriers and drugs when formulating DPI 
products as successful carrier selection is crucial in controlling the dose uniformity and the 
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DPIs are breath-actuated devices and the dose emission from such devices is dependent on 
different inspiratory parameters, namely maximum inspiratory flow (MIF), inhalation volume 
and acceleration rate (ACIM) at the start of the inhalation manoeuvre (Abadelah et al., 2017; 
Dal Negro, 2015; Olsson and Asking, 1994). 
 The patient inhalation manoeuvre parameters as well as the shape of inhalation profiles (IP)  
vary depending on the age of the patient, gender, body max index, the type and severity of the 
disease, as well as the lung geometry (Henry Chrystyn, 2009).These parameters account for 
the inter-patient variability, thus each patient would receive a different dose when inhaling 
through the same DPI inhaler device (Hickey et al., 1998; Pasquali et al., 2015; Buttini et al., 
2016).   
In order to measure the TED and FPD, standard pharmacopoeial methods are used (Council of 
Europe, 2014; United States Pharmacopeia, 2014). Humans are unable to replicate the square 
wave generated by a vacuum pump and most of the patients are not able to achieve the 
inhalation parameters recommended by the pharmacopoeia (Azouz et al., 2015). Recent 
methods developments by (Chrystyn et al., (2015) and Bagherisadeghi et al. (2017)) led to a 
method using a patient inhalation profile instead of the vacuum pump measure the TED. 
 
 
Onbrez Breezhaler® is a low resistance device (0.017 kPa0.5 L/min, Dal Negro, 2015) and a 
MIF of 107 L/min was required to achieve 4kPa pressure drop (Pavkov et al., 2010), patients 
inhaling through Breezhaler were able to achieve inspiratory parameters of MIF (88 L/min), 
Vin (2.7 L) and ACIM (5 L/s2).  The experimental set-up used in this study was similar to that 
used by Bagherisaghi et al., 2017. A mixing inlet was inserted between the pre-separator and 
the induction port, which allow a complementary air flow to be introduced through the side 
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arm of the mixing inlet (Figure 7.1). Therefore, the flow at the mouthpiece will be maintained 
at 0 L/min while keeping constant flow through the impactor (Experimental set-up in details, 
see Section 4.2.3). In DPI formulations, lactose monohydrate is the most commonly used 
carrier, several studies have shown that the aerodynamic characteristics and the surface 
morphology of the lactose particles used in the formulation can affect the overall dose emission 
from DPIs  (Flament et al., 2004; Martin et al., 2012; Kaialy et al., 2012; Kawashima et al., 
1998b; Peng et al., 2016; Pilcer et al., 2012; Zellnitz et al., 2015; Zhou et al., 2010). It was 
showed in the previous chapters that it was possible to engineer lactose carrier particles with 
or without generally recognised safe additives (GRAS) from spray dried lactose particles 
produced in-house and in the present chapter it was attempted to apply the same particle 
engineering technique but using commercially available spray dried lactose (Fisher Scientific 
Ltd, UK). The latter is commercially available and can be purchased in any batch size from 
lactose suppliers. Thus, by processing this lactose, a novel form of lactose may be obtained 
with improved surface morphological features different from the commercially available spray 
dried lactose and of any batch size. Our engineering technique as reported in the previous 
chapters (Chapter 4, Chapter 5 and Chapter 6) showed an improvement in the quality of lactose 
in terms of dose emission and crystallinity. These features are prerequisite for oral solid dosage 
forms whether, tablets, capsules, powder or dry powder inhalers. Engineered Spray Dried 
Lactose and Lactohale were separately formulated with SS using an order mix and proportion 
of lactose to drug. Drug content uniformity from each DPI formulation was assessed using 
%CV and deposition study was carried out ex-vivo using patient inhalation profiles generated 
in-vivo. Among 19 inhalation profiles, only those with the same Vin, ACIM but with different 
MIFs were selected so as to investigate the impact of the MIF alone on SS drug deposition ex-
vivo from both DPI formulations containing Lactohale and Engineered spray dried lactose 
(PSDLcom) as carriers. 
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7.2 Material and method  
 
7.2.1 Material 
A list of materials and general laboratory apparatus used for the determination of salbutamol 
dose emission characteristics using ex-vivo technique was illustrated in chapter 3 (section 3.1).  
 
7.2.2 Experimental Methods   
 
7.2.2.1 Preparation of PDSL particles 
The procedure for generating the PSDL particles used in this study was previously detailed in 
Chapter 4 (Section 4.2.3).  
 
7.2.2.2 Blending lactose carrier particles with salbutamol sulphate 
Salbutamol sulphate was mixed with the carrier particles using an order mix (See Section 4.2.8 
for method) 
7.2.2.3 Characterisation of particle shape and size using scanning electron microscopy 
(SEM) 









7.2.2.4 Breath simulator with ACI method set-up  
Figure 7.1 shows the experimental set-up of the breath simulator (BRS 3000) with ACI. The 
breath simulator warming profile was carried out (20 cycles) prior to the experiment run.The 
system warm- up procedure was recommended by the manufacturer (Copley et al., 2014). 
 
Figure 7.1 Schematic diagram of the methodology set-up (Adpated from Abadelah et al., 
2017) 
 
 The ACI and the vacuum pump were connected via a critical flow controller (TPK 2000, 
Copley Scientific Ltd, UK). Then, the breath simulator attached to the impactor using the 
mixing inlet side arm (Figure 7.1). The additional air cylinder was joined to the breath simulator 
using a regulatory flow valve. The vacuum pump was allowed to reach flow stability prior to 
starting the experiment by leaving it on for 20 minutes before the first determination. The 
airflow through the ACI was set according to the inhalation profile chosen and the flow from 
the vacuum pump was set while the regulatory flow valve remained closed. The flow meter 
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(DFM 2000, Copley Scientific Ltd, UK) was used to gauge the flow through the impactor (flow 
stability P3/P2 ≤ 0.5). When the required flow was achieved, the regulatory valve was then 
opened to allow the entry of the supplementary air through the mixing inlet side arm. It was 
important to monitor the flow meter screen to ensure that the incoming supplementary air is 
equal to that introduced by the vacuum pump, and the flow at the mouthpiece is 0 L/min. 
Then, the inhalation profiles were run using the breath simulator software. A constant flow rate 
was maintained through via the vacuum pump. For the inhalation profiles that are lower than 
60 L/min, an operating flow rate of 60 L/min was used and a flow rate of 90 L/min was used 
for inhalation profiles beyond 60 L/min.  ACI stages and collection plates were set-up 
depending on the flow rate (Discussed in Chapter 3- section 3.3). 
The salbutamol sulphate dose emission was performed by using three capsules for each 
inhalation profile as recommended by the patient information leaflet (PIL) of the Onbrez 
Breezhaler® (Novartis Pharmaceuticals Ltd, UK) and to ensure the reproducibility of the dose 
emission. After the aerosolisation of the three capsules, the residual amount left in the capsules 
and device was assessed.  
After aerosolising the dose and before starting the washing procedure, the mouthpiece and the 
mixing inlet side arm were sealed with parafilm to make sure that no drug loss occurred during 
while disassembling the set-up.  
The washing solution was methanol:water 70:30 % (v/v). Appropriate volumes were used to 
wash and recover the drug from each part of the set-up: the mouthpiece, the throat, the pre-
separator, the ACI stages, the capsule, the device and the filter. The recovered samples were 
then sonicated for 15 minutes to facilitate drug particle solubility. Finally, all samples were 
transferred and sealed into 2 mL HPLC amber vials by using a plastic syringe and 0.45 filter 
tips (Thermo Scientific Ltd, UK). The salbutamol sulphate amounts in each sample were then 
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quantified using a validated HPLC method (HPLC method validation discussed in Chapter 3 – 
Section 4).  
 
7.2.2.5 Data analysis  
The aerodynamic dose emission parameters were calculated using the Copley Inhaler Data 
Analysis Software (CITDAS version 2.0, Copley Scientific, UK) 
The total emitted dose (TED) was obtained by adding up the amounts of SS collected on the 
mouthpiece adapter, Alberta-idealised throat, mixing inlet, pre-separator, all the stages of the 
ACI and finally the filter. The fine particle dose (FPD) was the mass of drug with an 
aerodynamic particle diameter less than 5 µm, the extra-fine particle dose (EFPD) was the mass 
of drug with an aerodynamic particle diameter less than 3 µm. The fine particle fraction (FPF) 
was calculated as a percentage of the FPD divided by the TED. The mass median aerodynamic 
diameter (MMAD) was represented as the size corresponding to half of the sum of all the 
recovered amounts of drug deposited on the stages of the ACI.  
A validated HPLC method for the determination of Salbutamol in recovered samples was 
explained in detail in Chapter 3 (Section 3.4).  A one and two-way ANOVA were carried out 
to determine any significant differences in the FPD, TED, MMAD, EFPD. A p value of less 









7.3 Results and discussion  
7.3.1 Characterisation by SEM 
 
  





Fig. 7.2.3 Close view spherical lactose                Fig.7.2.4 Surface of spherical lactose  
 





   
Fig. 7.3.1 General view PSDL        Fig. 7.3.2 General view PSDL  
 
 
Fig. 7.3.3 Surface of PSDL  
 
Figure. 7.3. SE images of PSDL particles 
 
The mechanism of solid state crystallisation of Spray Dried Lactose particles was fully 
explained in the previous chapters (Chapter 4, Section 4.2.3) However, in this chapter we tried 
to expand our understanding on the reliability of our engineering technique using commercially 
available spray dried particles. In the previous chapters, we processed spray dried lactose 
produced from solution whereas in this current chapter we processed spray dried lactose 
produced from a suspension. By looking at the SE micrographs (Fig. 7.2.1 and 7.2.2), it is clear 
that the spherical spray dried lactose particles were produced by spray drying a lactose 
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suspension, the individual particles are glued together to form rough spherical particles (Figure 
7.2.3). The manufacturer did not mention whether a binder was included in the suspending 
medium or not. 
The SE micrographs displayed the morphological features of the original material (unprocessed 
commercial spherical lactose) and the processed spray dried lactose (PSDLcom). The images 
showed that the integrity of spherical particles was retained after processing the particles in hot 
ethanolic solution. By comparing Figure 7.2.1 before processing and Figure 7.3.1 after 
processing, the processing imparted to the particles new features making them rougher, as 
shown in Figure 7.3.2. The particles discussed in the previous chapter (Chapter 6, Figure 6.5 
and 6.6) have a different surface texture compared to the present particles (Figure 7.3.2). The 
former particles were initially produced from a spray dried solution forming a continuous shell 
(Chapter 6, Figure 6.4) whilst, the latter was initially spray dried from a suspension and 
discontinuities are apparent between particles as shown in Figure 7.2.3. During processing in 
hot ethanol, the crystal growth was somehow taking place on each single particle as observed 
in Figure 7.3.2 and 7.3. 3. This is due to the discontinuity presents between particles, the growth 
of the crystal was not able to close the gap between the particles to propagate to the 
neighbouring particles. It seems like the particles were growing independently of each other 
and upwards (Fig. 7.3.3). Thus, providing a high surface roughness (Figures 7.3.2 and 7.3.3) 
compared to those particles processed from spray dried lactose solution (Chapter 6, Figures 6.5 







7.3.2 Aerodynamic dose emission characteristics using in-vivo method  
 
 






















  35.9L/min   54.9L/min   70.8L/min   85.7L/min 
  mean SD   mean SD   mean SD   mean SD 
S-1 2.83 0.03 S-1 3.50 0.52 S-2A 6.53 0.78 S-2A 5.60 0.48 
S-0 3.95 0.50 S-0 4.35 0.64 S-1A 2.24 0.36 S-1A 2.97 0.28 
S1 7.65 0.84 S1 11.33 0.92 S-0 5.00 0.54 S-0 5.83 0.62 
S2 13.47 0.97 S2 13.73 0.87 S1 14.63 1.32 S1 14.36 1.25 
S3 35.88 2.14 S3 41.80 1.97 S2 19.46 0.98 S2 21.81 1.12 
S4 16.95 1.58 S4 19.22 1.20 S3 37.10 1.45 S3 47.53 1.62 
S5 2.47 0.64 S5 2.62 0.16 S4 14.66 0.21 S4 20.80 1.01 
S6 0.00 0.00 S6 0.39 0.00 S5 1.52 0.00 S5 2.49 0.24 
Filter 12.52 1.46 Filter 5.20 0.75 Filter 18.50 0.48 Filter 8.51 0.68 
throat 79.00 3.25 throat 88.62 2.98 throat 90.36 4.01 throat 95.33 3.69 
MI 12.38 2.40 MI 14.42 2.98 MI 14.57 2.12 MI 13.50 2.45 
PreSep 84.53 3.98 PreSep 78.09 3.69 PreSep 98.16 4.63 PreSep 97.50 4.29 
MP 3.29 0.41 MP 4.61 1.02 MP 3.87 1.29 MP 2.96 2.89 
Device 67.50 2.79 Device 63.34 3.56 Device 43.62 3.18 Device 32.49 2.76 
Cap 38.64 2.52 Cap 21.82 1.12 Cap 20.42 2.26 Cap 22.09 3.56 
  
TED  274.94 3.92 TED  287.90 2.97 TED  326.59 3.17 TED  339.19 2.85 
FPD 88.95 1.25 FPD 94.30 1.16 FPD 110.88 2.90 FPD 121.32 1.30 
%FPF 32.35 1.42 %FPF 32.75 1.83 %FPF 33.95 1.26 %FPF 35.77 1.98 
TRA 106.14 2.15 TRA 85.16 1.97 TRA 64.04 1.47 TRA 54.59 1.10 
TRD 381.07 3.75 TRD 373.06 3.38 TRD 390.63 2.89 TRD 393.77 2.78 
% 
Recovery  95.27   
% 
Recovery  93.27   
% 
Recovery  97.66   
% 
Recovery  98.44   
LPM 175.92 2.10 LPM 181.14 2.47 LPM 203.08 2.54 LPM 206.34 2.54 
EFPD (<3) 66.34 1.32 
EFPD 
(<3) 60.88 2.24 EFPD (<3) 87.30 1.13 EFPD (<3) 96.67 1.13 
MMAD 2.60 0.07 MMAD 2.70 0.18 MMAD 1.70 0.02 MMAD 1.70 0.02 
GSD 1.90 0.00 GSD 1.80 0.01 GSD 2.00 0.07 GSD 2.30 0.07 
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Table 7.2 Summary of SS deposition from PSDL-SS formulations at different MIF 
 
The in-vitro aerodynamic parameters and resulting particle size distributions from a DPI are 
usually measured using standard pharmacopeial methodology which is widely accepted by the 
regulatory authorities (Chrystyn, 2015; Council of Europe, 2014; USP 2014). The procedure 
involves generating a flow using a vacuum pump to simulate an inhalation profile through an 
inhaler to emit the dose and collect it in a cascade impactor. However, humans cannot replicate 
the square wave generated by a vacuum pump and majority of patients are unable to achieve 
the inhalation parameters recommended by the Pharmacopoeia (4 kPa pressure drop and 4L 
inhaled volume) (USP, 2014) when they inhale through Breezhaler® (Azouz et al., 2015). 
This becomes more challenging for paediatric patients whose lung capacities are usually less 
than that of an adult. Ex-vivo method with patient inhalation profiles was used in this chapter 
to replace the vacuum pump used with pharmacopeial methods. This would provide us with 
experimental aerodynamic parameters (TED, FPD and MMAD) being more realistic and closer 
to what patients would have achieved in real life. The Breezhaler® has a low resistance (0.017 
 
  35.9L/min   54.9L/min   70.8L/min   85.7L/min 
  mean SD   mean SD   mean SD   mean SD 
S-1 0.14 0.02 S-1 0.73 0.12 S-2A 1.96 0.23 S-2A 2.71 0.08 
S-0 0.58 0.07 S-0 0.35 0.07 S-1A 0.39 0.04 S-1A 0.99 0.05 
S1 2.89 0.13 S1 3.67 0.23 S-0 0.82 0.08 S-0 1.52 0.12 
S2 5.01 0.26 S2 6.33 0.41 S1 5.40 0.12 S1 7.38 0.34 
S3 17.96 1.07 S3 15.64 1.25 S2 9.21 0.35 S2 13.38 0.76 
S4 8.03 0.98 S4 5.72 0.75 S3 17.09 0.89 S3 26.38 0.98 
S5 0.00 0.00 S5 0.00 0.00 S4 5.01 0.21 S4 9.02 0.34 
S6 0.00 0.00 S6 0.00 0.00 S5 0.00 0.00 S5 0.66 0.04 
Filter 6.12 0.34 Filter 35.03 1.69 Filter 31.26 1.45 Filter 34.89 1.37 
throat 82.91 2.42 throat 61.17 1.89 throat 42.23 1.37 throat 59.22 1.34 
MI 9.60 0.99 MI 9.33 1.14 MI 5.89 0.78 MI 5.06 0.96 
PreSep 151.13 2.89 PreSep 170.21 2.23 PreSep 196.54 1.95 PreSep 160.44 2.14 
MP 2.97 0.42 MP 5.04 0.68 MP 7.99 1.04 MP 2.71 0.58 
Device 56.84 1.09 Device 38.71 1.32 Device 34.02 1.10 Device 32.83 1.52 
Cap 5.32 0.12 Cap 7.18 0.56 Cap 9.26 0.78 Cap 9.15 0.68 
  
TED  287.36 2.45 TED  313.22 2.74 TED  323.79 1.98 TED  324.37 2.32 
FPD 37.13 1.20 FPD 66.39 1.45 FPD 68.79 1.36 FPD 93.23 1.75 
%FPF 12.92 1.14 %FPF 21.20 1.25 %FPF 21.24 1.08 %FPF 28.74 1.17 
TRA 62.16 1.32 TRA 45.89 1.27 TRA 43.29 1.10 TRA 41.98 1.27 
TRD 349.53 3.12 TRD 359.12 2.96 TRD 367.07 2.81 TRD 366.35 3.13 
% 
Recovery  87.38   
% 
Recovery  89.78   
% 
Recovery  91.77   
% 
Recovery  91.59   
EFPD (<3) 28.60 1.64 
EFPD 
(<3) 34.12 1.41 
EFPD 
(<3) 62.42 1.85 
EFPD 
(<3) 79.11 1.34 
MMAD 2.50 0.12 MMAD 2.60 0.14 MMAD 0.90 0.07 MMAD 1.20 0.00 
GSD 1.50 0.02 GSD 1.50 0.00 GSD 1.20 0.00 GSD 1.20 0.00 
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kPa0.5 min/L) and the patient needs to exceed 100 L/min to generate the 4 kPa pressure drop in 
the device (Section 7.1).  
Drug de-aggregation, dispersion and emission relies highly on the patient’s inspiratory flow 
rate, the volume and the acceleration (how fast he inhales) (Abadelah et al., 2017; Chrystyn et 
al., 2015).  
The performance of salbutamol sulphate using a Breezhaler® was determined using real life 
recorded patients’ IPs. These profiles were generated in-vivo and were re-played ex-vivo using 
a breath simulator (BRS) to determine dose emission characteristics of SS.  
The results obtained from the ex-vivo deposition tests are shown in Fig. 7.4, 7.5, 7.6 are 
represented as total emitted dose, fine particle dose, extra fine particle dose of SS for both 
lactose formulations. 
The dose emission of Salbutamol from two different formulations using inhalation profiles 
were determined. The two formulations showed difference in the dose emission depending on 
the MIF.  
The results indicated that TED increased significantly (p< 0.05) with increasing the MIF of the 
inhalation profiles from 274.94 ± 3.92 µg to 339.19 ± 2.85 µg when SS-Lactohale was used 
(Table 7.1). A similar trend was observed with SS-PSDL formulation, where TED ranged from 
287 ± 2.45 µg to 324 ±2.32 µg with increasing the MIF (Table 7.2). FPD also improved as MIF 
increased with both formulations, however the values were significantly higher with SS-
Lactohale than SS-PSDL (Figure 7.5). On the other hand, MMAD showed a dissimilar trend 
as MMAD values decreased with increasing MIF with SS-Lactohale formulation, the MMAD 
obtained at 35.9L/min was 2.60 ± 0.07 and at 85.7L/min it was found to be 1.70 (Table 7.1 and 
7.2). The MMAD obtained with SS-PSDL formulation was 2.50 at 35.9 L/min and was 1.20 at 
85.7 L/min. 
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The dose emission from Lactohale was more flow-rate dependent than engineered particles, 
especially at low MIFs.  PSDLcom showed more flow rate dependency in the dose emission at 
low flow rates (Tables 1 and 2) whereas more dose emission in comparison to engineered 
lactose was observed only at high MIFs (i.e. 85.7 L/min). 
The difference in the particle shape between these carriers may have accounted for the 
difference in dose emission results for PSDL.  The high dose emission at low flow rate for 
PSDL may have been promoted by the spherical shape of the carrier particles, in comparison 
to elongated tomahawk shape Lactohale carrier particles. 
FPD was calculated as a percentage of the total delivered dose obtained from drug content 
uniformity (Table 7.1 and 7.2). FPD of SS from both carriers increased with increasing the 
MIF, suggesting a portion of the TED was delivered as a fine particle mass (<5µm) (Figure 
7.5).  
FPD was found to vary between approximately 9% to 30% depending on the flow rate and the 
type of carrier used (smooth or rough carrier) (Figure 7.5).  
Although TED was higher at low MIF (35.9 and 54.9 L/min) for PSDLcom, the corresponding 
FPD was found to be lower than for Lactohale. This probably was caused by the surface 
roughness of the PSDLcom particles (Figures 7.3.2 and 7.3.3), allowing less drug detachment 
from its rough surface. A great proportion (³ 50% of the total delivered dose) of SS was 
deposited prematurely as LPM (Table 7.2). The present study confirms the superiority for 
Lactohale for delivering SS in comparison to PSDL observed in the previous chapters (Chapter 
1, Chapter 3). Therefore, SS is better delivered from smooth surface than from rough carrier 
surface. The increase of LPM associated with the increase in MIF is typical for DPI devices 
especially those having a low resistance such as BreezHaler®. Most drug will impact in the 
oropharyngeal region due to an increase in the particle-particle momentum and the high MIF.  
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As previously mentioned, a carrier which performs better with one drug might not perform 
better with another drug, depending on the physicochemical characteristics of the drug, as 
shown with BDP and FP which performed better with a carrier (PSDL10) with moderate surface 
roughness (Chapter 3). Therefore, there is no ideal universal carrier that performs well with all 
drugs, which may explain why drug delivery to the lungs from DPIs is still low despite the 
effort made by DPI formulators and device engineers (<30% as confirmed by de Boer et al., 
2016). This novel finding would be useful for inhalation formulation scientists that moderate 
surface roughness may be useful more for hydrophobic drugs than hydrophilic drugs. The 
PSDLcom has excessively rough surface, which could further hinder drug deposition compared 
to PSDL10 (produced in Chapter 3) or Lactohale. 
A plot of the TED from the two formulations at different MIF is presented in Fig. 7.3. This plot 
suggests that as the MIF increased from 35.9 to 85.7 L/min, irrespective of the formulation 
used, SS was significantly (p<0.05) more emitted from the device. It is known that capsule-
based DPIs tend to retain drugs as residual amounts (in capsule and device) which could lead 
to less dose being emitted (Abadelah et al., 2018) 
It is interesting to note that less SS was retained in the device when PSDL formulation was 
used as opposed to lactose formulation.  
 Furthermore, irrespective of the formulation used, the incomplete dose emptying can be seen 
from the values of TRA retained in the capsule and device which appear to be higher at low 
MIF (35.9 and 54.9 L/min). Thus, inhaling forcefully would contribute to the reduction in the 
TRA.  
 
The results of the FPD as a function of the nominal dose at different MIFs for both formulations 
are shown in Fig. 7.4. The FPD significantly (p < 0.05) increased with the MIF irrespective of 
the formulation used.  
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The results suggest that SS-lactose dose emission characteristics showed very good results with 
maximum dose emitted from the device at 70.8 L/min and above. When low MIFs of 35.9 
L/min and 54.9 L/min were used, the turbulence energy generated inside the Breezhaler® was 
not enough to efficiently de-aggregate the dose, consequently less dose was emitted from the 
device. The formulation with untreated lactose showed a very good correlation with the MIF 
used in the dose emission characteristics. The Breezhaler® has been previously reported to 
show a flow-dependent dose emission for Indacaterol formulations (Pavkov et al., 2010), SS 
dose emission showed similar results with flow dependency of the formulation. There are three 
main reasons for successful dose emission: the inhaler device, the inhalation manoeuvre by the 
patient and finally the formulation with the active ingredient.  The above results showed high 
doses would reach the patient lungs when MIF of 60 L/min and above was used. 60 L/min 
could be considered as a threshold MIF to manoeuvre the Breezhaler®, this MIF can be easily 
achieved as this inhaler has a low resistance. These results are in line with Abadelah et al. 
(2018) study which also showed that the rate of increase in the FPD with BreezHaler® was 
higher when reaching 60 L/min. In our study, almost 30% fine particle dose was generated at 
high flow rate with untreated lactose formulation as opposed to almost 25% with PSDL 
formulation (Fig. 7.4), suggesting that the inter-particle forces were stronger between PSDL 
particles and SS particles than between untreated lactose and SS particles. These results are in 
line with the results found in Chapter 6 where SS was found to be more easily emitted from 
Lactohale smooth particles than from PSDL rough particles. One of the reasons was the 
physico-chemical properties of the drug, SS being hydrophilic, had a weaker adhesion force to 
the Lactohale particles than the PSDL particles.  
 
The results of the EFPD for both formulations with increasing MIFs are shown in Fig. 7.6. 
EFPD significantly increased (p<0.05) when increasing the MIFs. Irrespective of the 
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formulation used, the steepest increase in the EFPD was observed when MIF value was above 
60 L/min. The increase in EFPD was combined with a significant (p < 0.05) decrease in the 
MMAD (Table 7.1 and 7.2) when the MIF value above 60 L/min was used. High values of 
EFPD would correspond to higher amounts of drug deposited in the peripheral airways in the 
lungs, which is favourable in treating COPD patients (Grasmeijer & De Boer, 2014). High 
MIFs generated higher turbulence energy inside the device to be able to de-aggregate the 
particles, thus favouring drug particles detachment from the carrier particles, particle 
dispersion and allowed single drug particles to reach the deepest regions of the impactor.  
When PSDL-SS was used, MMAD was low and more drug was recovered in the filter (Table 
7.2), suggesting that in real life use, the patient might get more therapeutic effect despite less 
dose emitted compared to untreated lactose formulations data. 
A possible reason for that could be that in constricted airways, particles within the range of 
2µm (1-3µm) have more tendency to produce vaso-relaxation effect and better asthma and 
COPD management (Heyder, 2004; Morén, 1987). An MMAD of less than 5 µm is thought to 
be required to achieve an efficient deposition of the drug in the airways (Roche et al., 2013). 
7.4 Conclusion 
The dose emission study of SS from the capsule-based Breezhaler® appeared to show 
inhalation flow-dependency, irrespective of the formulation used. The aerodynamic 
characteristics of SS from the lactose-SS formulation showed that using a carrier with a smooth 
surface when using a hydrophilic drug such as SS was effective in producing respirable 
particles with a low MMAD (less than 5µm) irrespective of the MIF used. This chapter also 
showed the importance of the MIF to maximise the fraction of SS particles less than 3µm 
(EFPD). The results showed that the increase in EFPD was more noticeable above 54.9 L/min. 
These results confirm the recommendation of using a forceful inhalation when using Onbrez 
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Breezhaler®. This chapter showed that the solid phase crystallisation method was promising 
and successful in achieving spherical particles with rough surface, however the method needs  
to be further optimised to achieve the right degree of rugosity depending on the API used to 
achieve optimum adhesion forces between the particles. Using ex-vivo study as opposed to 
Pharmacopoeial method provided us with more accurate results that reflect more realistically 







































8.1 General conclusions 
Drug delivery to the lungs via dry powder inhalers (DPIs) is becoming increasingly popular. 
The most important component of the DPI formulation is the carrier particle, as the ratio of 
drug to carrier is usually 1:67.5, thus any changes in the physicochemical properties of the 
carrier will have a great impact on the formulation and lung deposition. Carrier particles should 
have a number of key physicochemical properties to obtain both a successful formulation and 
an efficient delivery of the drug to the lungs. Lactose is most commonly used in DPI 
formulations, it should be of a suitable particle size to be used as carriers, the particles should 
also be crystalline to allow the formulation to be stable during shelf life and also to ensure the 
reproducibility of the particle morphology. The overall objective of this thesis was to produce 
a carrier particle with suitable properties to be used in DPI formulations. Hence, this thesis was 
more focused on the formulation development of DPIs.  
 
The use of commercially available lactose in DPI formulations poses many challenges in 
dispersing the drug from the lactose carrier surface. The latter only allows 20-30% of the total 
dose to reach the lungs. Such low efficiency of current DPIs emphasises the need for DPI 
formulations to be optimised. The most common technique used to modify the morphological 
features of lactose particles is crystallisation from solutions. However, this technique has many 
disadvantages that limit the opportunity to optimise and control the physicochemical properties 
of the engineered particles. The final product is usually complex and unpredictable as inter- 
and intra-batch variations are likely to occur. Also, this technique requires the use of toxic 
solvents (e.g. hexane, chloroform) which are not environmental-friendly. Therefore, it would 
be preferable to develop a crystallisation method that controls particle size, shape, crystallinity 
and surface texture of the carrier particle so that desirable features are obtained.  
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Many studies in the literature suggest the use of spherical shaped particles as an alternative to 
the traditional irregular lactose. Spherical carriers have been shown to improve drug deposition 
to the lungs. This is why, this project suggested the use of spherical engineered lactose particles 
to be used as carriers in DPI formulations.  
 
The first step in this project was to engineer the lactose particles (PSDL) from commercially 
available Lactohale®, characterise them with various analytical techniques then formulate both 
Lactohale and PSDL with Salbutamol Sulphate and finally assess their performance in DPI 
formulations.  
The engineering process involved few steps: the first step was to spray dry lactose particles to 
obtain spherical particles. The spherical particles were then introduced to the inflating agent 
(ethanol), when the particles came in contact with the inflating agent, the amorphous regions 
on the surface of the spray-dried particles partially dissolved, allowing ethanol to form pores 
and permeate into the hollow space of the particles. As the vapour pressure of the inflating 
agent increased, the pressure inside the particles increased, inflating the particles until it 
reached a certain point. The engineering process allowed the particles to have increased in size 
reaching more than 80 µm without deviating from the spherical shape. Ethanol acted as an 
inflating agent promoting an increase in the lactose particle size. The engineering process also 
allowed to modify the surface of the particles to engineer rough surfaces. The rough surface of 
the PSDL particles contributed to the stability of the powder blend against segregation. 
The engineered lactose was found to be crystalline as opposed to the spray-dried lactose which 
was amorphous. The engineering process helped repairing the defects present in the spray-
dried lactose. One of the advantages resulting from this process was that the product was made 
to be more stable due to its crystallinity being restored. 
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Spherical shape, rough surface and crystalline particle are desirable features in order to produce 
a stable and performant solid dosage form. With regards to inhalation, the engineered particles 
contributed to a better dose emission of the DPI formulation and to a better drug delivery 
consistency. 
In a general aspect, the engineering process provided a reliable method of producing suitable 
sized carrier particles, with a rougher surface while retaining the spherical shape of the spray-
dried material which could potentially enhance drug deposition into deep lungs. 
 
When comparing the deposition profiles of both DPI formulations, there was less drug (SS) 
dispersed from PSDL formulation in comparison to Lactohale®. This was because the 
adhesion forces between PSDL and SS were stronger than the forces between Lactohale and 
SS.  
The deposition studies were performed with a MacHaler® device, the results showed that this 
device has a threshold at 60L/min. Above the threshold, a little change has been observed in 
TED when the inhalation flow rate increased from 60 to 90 L/min suggesting that TED reached 
its maximum value at 60 L/min. Both ACI and NGI were compared in this study and it is 
interesting to note that the highest TED values irrespective of the impactor were obtained at 
the highest inhaled volume coupled with the highest inhalation flow rate (90L/min; 2 L) 
suggesting that a forceful inhalation coupled with deep breath are helpful in maximizing drug 
delivery to the lungs, as shown from the highest FPD values. 
The results suggest that an inhaled volume of 1L was not sufficient to pull the aerosol to deep 
stages of the NGI. These results are in agreement with Mohammed et al. (2012) study which 
showed that 1L was not generating sufficient turbulent airflow within the device to de-
aggregate the powder and to overcome the dead volume of NGI. PSDL showed more 
consistency in the emitted dose compared to Lactohale. The spherical shape and uniformity of 
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size of engineered lactose might have contributed to the reproducibility of the dose released 
from the inhaler. Engineered lactose benefited more from the increase in the inhaled volume 
than Lactohale, as shown from the difference in the FPD between 1 L and 2 L. Engineered 
lactose is hollow and spherical in shape and by increasing the inhalation volume this may have 
provided this lactose with a longer time of flight allowing drug particles to reach the distal part 
of the impactors. By combining a forceful inhalation with a prolonged inhalation time (inhaled 
volume) this does not only allow an increase in the turbulent energy inside the device but also 
to provide carrier and drug particles with sufficient time of flight to produce drug particles 
small enough to reach the lungs, as shown from the FPD and MMAD values obtained.  
The engineered lactose produced a more reproducible Salbutamol Sulphate emission and Fine 
Particle Dose after aerosolisation via a MacHaler® tested in both ACI and NGI. 
This study showed that Vin is equally important as MIF with regard to dose emission, de-
aggregation of the powder formulation and in producing respirable particles for deep lung 
penetration. 
The results obtained suggested that drug delivery to the lungs can be optimised by using a 
forceful inhalation in combination with a prolonged inhalation time. 
Inhalation peak flow vary from patient to patient but the threshold inhalation flow as well as 
the inhalation time should be mentioned in the patient information leaflet to ensure that drug 
delivery to the lungs is maximised for the patient. 
This study demonstrated evidence of incomplete mass transfer through NGI at a volume (1 L) 
inferior than the internal dead volume (2.025 L) in contrast to the consistent behaviour of the 
ACI where the mass transfer had taken place normally even when volume (1 L) which is 
slightly lower than the internal volume (1.150 L) was used. 
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Secondly this project investigated the effect of incorporating a ternary component to the 
formulation and assess the effect they have on the surface properties of the resulting particles. 
The effect of Vin and the difference between the two impactors (ACI and NGI) was further 
studied in this chapter. NaCl and PVP were used for this purpose. 
Solid-phase crystallisation of co-spray dried lactose-NaCl and lactose-PVP with ethanol 
produced particles with larger size compared to the spray-dried particles, without changing 
their spherical shape. PSDL-NaCl appeared to have a rougher surface than PSDL-PVP. This 
method showed that the surface roughness can be adjusted, depending on the solubility of the 
additive to ethanol. This method also affected the polymorphic forms of lactose by producing 
either α or α-β mixtures.  
This process of crystallization is reliable as the particles produced are spherical, irrespective of 
the type of additive and its solubility in the non-solvent. Surface textures can be modified to 
produce particles of different surface rugosity and different degrees of crystallinity, depending 
the solubility and the time of exposure to the crystallization medium. 
Formulation powder blends containing PSDL as a carrier performed better than most of 
commercially available DPIs at higher volumes, as suggested by the %FPF obtained >30%, in 
comparison to the %FPF of commercial DPIs. This indicates that employing engineered lactose 
in DPI formulations instead of commercially available lactose carrier would result in a high 
amount of drug reaching the lungs. The improved SS drug deposition from PSDL-NaCl can be 
attributed to the surface texture of the PSDL. The solubility of NaCl is much less than that of 
PVP in ethanol, therefore ethanol may have washed away all PVP or great portion of it from 
the surface of lactose, whereas, the poor solubility of NaCl in ethanol has led to the formation 
of microscopic spikes on the surface of spray dried lactose giving some roughness and porosity 
to lactose particles. Unlike clefts and crevices, these microscopic projections did not 
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accommodate the drug particles and instead enhanced drug detachment from the lactose surface 
and improved inhalation efficiency. 
The NGI was more sensitive to change in the inhaled volume than the ACI as the latter did not 
appear to be as sensitive, this is believed to be because of a maldistribution of the flow through 
the ACI 
 
Thirdly, a comprehensive investigation on some of the process parameters (e.g. processing 
time, mixing time, triboelectrification, use of hydrophobic/hydrophilic drugs) was done. 
Determining the degree of adhesive forces of the carrier helped correlate the aerosolisation 
results with the morphological features, especially the surface roughness of the carrier.  
The PDSL particles could be produced with different surface rugosity without altering size and 
shape of the particles. The time of exposure of spray-dried particles to hot ethanol was a critical 
factor in altering surface rugosity: the longer the particles were in contact with ethanol, the 
rougher they were.  
Lactohale, PSDL10 and PSDL30 contrasted in their characteristics: carrier shape 
(tomahawk/spherical), surface texture (smooth/rough), surface net charges and polarities 
(positively and negatively charged) and degrees of crystallinity. 
The data showed that different grades of lactose exhibit different charging behaviours either 
alone or with different drugs in formulations. 
PSDL10 appeared to have less variation in the charging behaviour of the powder blend, which 
indicates that the morphological features of PSDL10 could potentially be beneficial in DPI 
formulations as an antistatic effect was observed with this type of carrier and a more stable mix 
was observed. 
In general, the results showed that the content uniformity is affected by the mixing time and is 
different for each type of drug and each carrier.  
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Despite Lactohale and PSDL’s respective formulations presenting good content uniformity, 
Lactohale may be considered as the most favourable carrier when used with hydrophilic drugs 
such as SS as a good content uniformity was achieved with only 5 mins of mixing and high 
doses of SS were emitted and deposited from Lactohale-SS formulation. 
On the other hand, PSDL was considered to be most favourable for hydrophobic drugs where 
its rough surface was ideal for the drug to adhere to and obtain a stable mix with very good 
content uniformity irrespective of the mixing time, but the adhesion was weak enough to allow 
the drug to detach from the carrier during aerosolisation and deposit in the deepest stages of 
the impactor.  
In the last part of the study, we wanted to ensure that the engineering method was reliable in 
retaining the spherical shape of the particles while modifying their surface texture, 
commercially available spray-dried lactose (which was spherical) was processed to obtain 
rough particles. It is interesting to note that the commercial available lactose used was initially 
spray-dried from a suspension, in comparison to the PSDL particles engineered in Chapter 4, 
5 and 6 which were spray-dried from a solution. The results showed that processing lactose 
particles obtained from a spray-dried suspension resulted in much rougher particles than when 
processed from spray-dried solution. These results suggest that the surface roughness of the 
particle can be adjusted by either spray drying from a lactose solution or a suspension. 
With regards to SS, there was no improvement in drug dispersion when using PSDLcom, 
however the results showed that more drug was emitted from the device at low MIFs 
(<60L/min) with PSDL formulations, this was due to the spherical shape of the PSDLcom 
particles, allowing a better flow of the powder formulation out of the device. The last part of 
the study showed that there is no ideal universal carrier that performs well with all drugs, which 
may explain why drug delivery to the lungs from DPIs is still low despite the effort made by 
DPI formulators and device engineers (<30%). As previously mentioned, a carrier which 
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performs better with one drug might not perform better with another drug, depending on the 
physicochemical characteristics of the drug, as shown with BDP and FP which performed 
better with a carrier with moderate surface roughness (Chapter 6). SS was shown to be better 
delivered from smooth surface than from rough carrier surface. (Chapter 6 and Chapter 7). 
 
8.2 Future work 
 
• Further tuning of the engineering method should be done, i.e. use of different inflating 
agents, different contact times with the crystallisation medium to be able to achieve 
different particle sizes. 
• Use of different starting material with different plasto-elasticity to produce novel 
particle shapes (e.g. use of a material that is both fragmentating and plastic could form 
unsymmetrical particles which are not yet in the literature). Scientists have been 
crystallising using various material but there has been no mention about the plasto-
elasticity of the material which play an important role in the inflating mechanism in the 
crystallisation process. 
• Use of different additives (with different solubility to the crystallisation medium) to 
establish a better correlation between the physicochemical properties of the additive 
and the surface roughness of the carrier particles. 
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